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Abstract 
 
 
 
The high incidence of gastrointestinal cancers in the general population and the 
presence of premalignant dysplastic precursor lesions in the gastrointestinal tract make 
the gastrointestinal tract an ideal environment to study cancer clonality and clonal 
expansion.  
 
Background:  
Intestinal metaplastic (IM) glands in the human stomach are clonal, contain multiple 
stem cells and spread by fission. This mechanism of gland fission causes field 
cancerisation. We hypothesised that gastric adenocarcinoma (GA) progresses through 
a series of genetic events arising from a founder mutation. A process analogous to 
niche succession may also take place in the normal oesophagus. We hypothesise that 
oesophageal squamous cell cancer occurs by a process of field cancerisation of the 
oesophagus. RHBDF2 has been identified as the gene responsible for tylosis with 
oesophageal carcinoma (TOC). We hypothesise that RHBDF2 germline gain of 
function mutations might be lost during tumour progression in TOC and this might 
affect iRhom2 localisation in the cell. 
 
Methods and results:  
A cohort of 23 patients with dysplasia and a cohort of 51 GA patients were screened 
for genes accounting for 75% of all somatic mutations previously reported in GA. 
Only 13% of dysplastic patients and 31.4% of GA patients had mutations. Three 
dysplastic patients and six GA patients were analysed by microdissection. Small 
gastric cancer foci in a cohort of hereditary diffuse gastric cancer (HDGC) patients 
(n=5) were also screened by laser-capture microdissection (LCM) for mutations in 
TP53. A cohort of 30 patients was screened for common mutations in OSCC and for 
RHBDF2 mutations. 36.36% of the patients presented mutations. Three patients with 
mutations were randomly selected and areas of oesophageal squamous cell dysplasia 
and OSCC were analysed by LCM. Three TOC patients were also analysed by LCM 
and immunohistochemistry was performed for iRhom2 and ADAM17. 
 
Conclusions:  
The usual mutational events established for GA development during the metaplasia-
dysplasia-carcinoma sequence (MCS) do not fit the results from either of our two 
LCM mutation studies in the human stomach. Dysplasia was shown to be clonal and 
GA demonstrates genetic heterogeneity through clonal evolution. Field cancerisation 
could not be detected in HDGC using TP53 as a clonal marker. The low incidence of 
OSCC patients with mutations implies that other genes may be involved in the 
premalignant pathway leading to OSCC. Oesophageal squamous cell dysplasia and 
OSCC demonstrate clonal expansion through tumour progression. RHBDF2 mutations 
do not occur in sporadic OSCC but germline RHBDF2 mutations can be lost during 
tumour progression in TOC patients with LOH in 17q. Overall, the somatic mutation 
theory of carcinogenesis seems to hold true for both the progression to GA and OSCC, 
as both carcinomas seem to evolve from a single mutated stem cell and acquire genetic 
heterogeneity as the tumours evolve. 
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GA – Gastric adenocarcinoma 
HDGC – Hereditary diffuse gastric cancer 
HGD – High grade dysplasia 
IBD – Inflammatory bowel disease 
ISC – Intestinal stem cell 
LCM – Laser-capture microdissection 
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K-RAS – Kirsten-RAS 
LEF – Lymphoid enhancer factor 
LGD – Low grade dysplasia 
LOH – Loss of heterozygosity 
MCR – Mutation cluster region 
MCS – Metaplasia-dysplasia-carcinoma sequence 
MET – Mesenchymal-epithelial transition 
MSI – Microsatellite instability 
mtDNA – Mitochondrial DNA 
NRF2 – nuclear factor erythroid-related factor 2  
OA – Oesophageal adenocarcinoma 
OSCC – Oesophageal squamous cell cancer    
PCR – Polymerase chain reaction 
PIK3CA – Phosphatidylinositol 3-kinase 
PTEN – Phosphatase and tensin homolog 
Rb – retinoblastoma protein 
RHBDF2  – Inactive Rhomboid Protease, also known as iRhom2 
ROS – Reactive oxygen species 
TA – Transit amplifying cell 
TCF – T-cell factor 
TOC – Tylosis with oesophageal cancer 
TP53 – Tumour protein 53 
TSG – Tumour suppressor gene 
UC – Ulcerative colitis 
WT – Wild type 
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1. Introduction	  
	  
1.1.  Gastrointestinal stem cells 
 
The gastrointestinal epithelial mucosa requires constant cellular regeneration due to its 
rate of cellular turnover. This continuous replacement maintains tissue homeostasis, 
and is dependent on the function of gastrointestinal tissue stem cells. Stem cells are 
undifferentiated, unspecialised cells whose potential ranges depending on their tissue-
specificity. All stem cells have the ability to self-renew, maintaining their numbers by 
symmetrical or asymmetrical division producing two daughter stem cells or one stem 
cell and a more rapidly replicating transit-amplifying (TA) cell or progenitor cell (1), 
respectively. Such progenitor cells have limited proliferation potential and eventually 
give rise to reproductively sterile terminally differentiated cells (2). In the intestine, 
TA cells are thought to divide in the crypt proliferative zone where their progeny 
ultimately differentiate into the mature intestinal epithelial cell types (3). 
 
Gastrointestinal stem cells are a subset of tissue-restricted adult stem cells and are 
generally considered multipotent and able to differentiate into a limited number of cell 
types. Although it is difficult to identify these adult stem cells morphologically, they 
are characterised by residing within a stem cell ‘niche’, a specialised stem cell 
compartment or anatomical location that provides an optimal micro-environment for 
stem cell function in tissue generation, maintenance and repair (4). Within the 
intestine, such compartments may be maintained by mesenchymal cells located within 
the underlying lamina propia (5); in the small intestine, by Paneth cells located in the 
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crypt underneath the +4 position (6); and in the colon, by a subset of c-kit positive 
goblet cells regulated by Notch signalling (7). 
 
Tissue-restricted stem cells are considered to be either quiescent or rapidly cycling and 
there is a great deal of debate as to their actual proliferative capacity (6). It has been 
hypothesised that quiescent bone marrow haematopoietic stem cells (HSCs) have a 
primary function in repair of injury and tissue damage (8). Moreover, it has also been 
documented that, in adult skin, a niche of quiescent stem cells located in the bulge (or 
stem cell reservoir) surrounding each hair follicle can be regenerated from 
engraftments of slow-cycling suprabasal bulge cells. These cells are located above the 
basal bulge cells between the old and the new hair follicle, and they become quiescent 
once they reach the niche (9). Potten and colleagues (10) showed that small intestinal 
stem cells retain the template DNA strands and lose the newly synthesised DNA 
strand following second division by labelling intestinal stem cells with tritiated 
thymidine (3HTdR) and bromodeoxyuridine (BrdU). Long-term administration of 
BrdU was followed by a long-term cessation in order to remove all BrdU staining 
from the rapidly dividing cells: proliferating cells dilute the label every time they 
undergo mitosis, the only cells remaining labelled are the quiescent stem cells (11). 
However in 2007, Hans Clevers and colleagues identified rapidly cycling leucine-rich 
orphan G protein-coupled receptor (Lgr5, also known as gpr49) positive cells as crypt 
base columnar cells (CBCs) between the Paneth cells in the mouse small intestine, 
which appear to cycle rapidly. These cells seem multipotent and have the ability to 
differentiate into all the different intestinal epithelial cell types (12). Since then, 
several markers have been identified which co-expressed with Lgr5, either supporting 
the rapidly cycling stem cell theory or arguing for the presence of slow cycling 
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intestinal stem cells (ISCs). Recently, telomerase reverse transcriptase (mTert) GFP-
knock in mice demonstrated multilineage differentiation from a single mTert cell, 
which can give rise to lgr5-positive cells (13). Interestingly the mTert-positive stem 
cell can also act as a label retaining cell by incorporating DNA synthesis labels for 
longer than TA cells, suggesting that there is a population of slowly-cycling stem cells 
that, upon stimulation, begin to proliferate and express lgr5 (13). It is possible that 
stem cell turnover rate may not be self-determined but is actually dictated by the 
surrounding micro-environment of the niche (14). Alterations in the niche, such as 
chronic inflammation, could initiate a burst of proliferation of either stem cells or their 
more committed progenitor cells (2). 
 
Stem cells in the gastrointestinal tract can be classified according to their anatomical 
location i.e. oesophageal, gastric, intestinal and colonic, each with their own unique 
features. Stem cells all produce progeny with a restricted lineage potential. Cheng and 
LeBlond (3) (1974) proposed the Unitarian hypothesis, suggesting that all the 
differentiated epithelial cell lineages within crypts are derived from a single, 
multipotent stem cell. Therefore each small intestinal stem cell would have the 
potential to give rise to enterocytes, enteroendocrine cells, goblet cells and Paneth 
cells. A single intestinal stem cell has the potential to expand and replace the whole 
stem cell niche population, known as niche succession (15). Mutations, either through 
genetic drift or by conferring a selective advantage over wild type stem cells, will 
accelerate this process. Once their progeny has taken over the whole crypt, this will 
become a monocryptal clone through a process known as monoclonal conversion; it is 
thought to be one of the earliest events in the progression to adenoma development 
(16, 17).  
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Despite remarkable progress that has taken place in the last few years in the field of 
intestinal stem cell research, there are still many uncertainties regarding the location, 
proliferation status and differentiation capacity of gastrointestinal stem cells mainly 
due to the limited number of accepted tissue stem cell markers.  
 
1.2.  Intestinal stem cells 
 
The flux of cell proliferation from the base of the intestinal crypt to the villus suggests 
that stem cells are located towards the base of the crypts yet superior to the Paneth 
cells (18) (19). However, recent studies have suggested that CBCs, which were first 
identified by Cheng and Leblond (3), could be the true stem cells, see Figure 1.1 (6).  
 
To positively identify a crypt stem cell, a marker must be shown to label cells that are 
capable of multilineage differentiation. This is the gold standard of stem cell 
identification in any tissue (20).  
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Figure 1.1. The structure of the human small and large intestinal crypt. Cartoons 
representing the colonic crypt (A) and the small intestine crypt-villus (B), with slow 
cycling label retaining cells (LRC) labelled in yellow and fast dividing crypt base 
columnar (CBC) cells in red. 
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1.2.1. Slowly cycling intestinal stem cells 
 
There is some evidence to suggest that the rate at which stem cells proliferate is 
heterogenous within the intestinal crypt, some quiescent or slowly cycling and some 
rapidly dividing (21). Slowly cycling cells would accrue fewer genetic abnormalities 
over its life than a fast cycling cell as methylation occurs at mitosis.  Stem cells are 
thought to be capable of retaining nucleotide-binding compounds such as bromo-5’-
deoxyuridine. The ‘immortal strand’ mechanism of preservation is an innate 
mechanism of genome protection that may also be responsible for label retention in 
slowly cycling cells. Coupled with the altruistic apoptosis of mutated stem cells, this 
preservation mechanism would ensure the resistance of epithelial stem cell systems to 
short exposures to DNA-damaging agents (22).  
 
After Potten and colleagues findings (11), it became apparent that the most common 
position for a label retaining cell (LRC) was around cell position +4 , 0 being the cell 
position at the very base of the crypt. 
 
LRCs have a distinctive program of gene expression and are marked notably by their 
enriched expression of Bmi1. Bmi1 encodes a chromatin remodelling protein of the 
polycomb ring finger oncogene group with essential roles in self-renewal of 
haematopoietic, neuronal and leukaemic cells. Sangiorgi and Capecchi (23) found 
Bmi1 expressed in cells in position +4 and showed their ability to proliferate and 
differentiate into all the cell lineages of the small intestinal crypt (lineage-tracing), by 
generating a tamoxifen inducible Bmi1-Cre-ER mouse model. Lessard and Sauvageau 
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(24) also observed that Bmi1 seemed to have a role regulating the proliferative activity 
in normal stem and progenitor cells, and probably also in leukaemic stem cells. 
 
Other potential stem cell markers have been identified apparently supporting the +4 
stem cell hypothesis, however lineage-tracing has not yet been carried out and 
therefore we must treat these markers as unproven. Potential markers include sFRP5, a 
Wnt signalling antagonist whose mRNA is present in +4 LRCs (25), PTEN 
(phosphatase and tensin homolog), AKT1 and β-catenin, essential Tcf action cofactor 
resulting in transcription and expression of target genes leading to cell proliferation 
(26, 27). The EGF receptor antagonist leucine-rich repeats and immunoglobulin-like 
domains 1 (Lrig1) has been shown to maintain human epidermal stem cells in a 
quiescent state (28) and, in murine epidermis, Lrig1+ cells can give rise to all of the 
adult epidermal lineages in skin reconstitution assays (29). Another marker is 
doublecortin CaM kinase-like-1 (DCAML-1 or DCLK-1), a microtubule-associated 
kinase discovered in intestinal epithelial progenitor cells (30) and identified in 
quiescent +4 LRCs in radiation experiments, showing the importance of these cells for 
tissue renewal (31). 
 
1.2.2. Fast dividing intestinal stem cells 
 
In 2007, the intestinal stem cell marker Lgr5 was identified, questioning the previous 
theory of the location of stem cells and their ability to proliferate (6). Barker and 
colleagues used two knock-in mouse models, lgr5-LacZ and Cre-activatable R26R-
LacZ reporter, confirming the expression of lgr5 in CBC cells and labeling them with 
BrdU; they established that CBC cells cycled on average every day. Crossing both 
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models they achieved a Cre-activatable lgr5-LacZ model, whose lgr5 positive cells in 
the small intestine and the colon were capable of generating all cell types of the 
epithelium. Therefore, via BrdU labeling and lineage tracing, Barker and colleagues 
proved that stem cells in the small intestine of the mouse can be rapidly proliferating 
cells (12). The LGR5 and LGR4 G-protein coupled receptors, as well as their 
homologues (32), have also been shown to be R-spondin receptors, binding the 
secreted Wnt signalling agonists R-spondins and, therefore, regulating embryonic 
patterning and stem cell proliferation (33).  
 
Later in 2009, prominin-1 (CD133), a five-transmembrane-domain-containing 
glycoprotein that is expressed on a variety of normal stem cells was present on some 
cells located at the base of the small intestinal crypts that also co-expressed LGR5 
(34). These cells were able to generate all intestinal epithelial cell lineages and 
therefore appear to be small intestinal stem cells (35). Furthermore, olfactomedin 4 
(OLFM4), a member of the olfactomedin-related protein family that has the ability to 
bind to cadherins and lectins and can mediate cell adhesion, was identified in a gene 
expression profile for LGR5-positive cells. CBC cells in the human small intestine and 
colon have been shown to express high levels of OLFM4, indicating that this gene 
might also be a marker for intestinal stem cells (36). 
 
Interestingly there are a few markers that have been found in lineage in both CBCs 
and 4+. One example is musashi 1 (Msi1), an RNA-binding protein involved in a 
unique autocrine signalling pathway activating both the Wnt and Notch pathways (37). 
Msi is known to maintain the proliferation of multipotential neural stem/progenitor 
cells, to be rapidly downregulated in post-mitotic neurons and to be upregulated in 
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tumours in the central nervous system (38). Another marker is cholecystokinin 2 
receptor (CCK-2R), the primary receptor for cholecystokinin (CCK) and amidated 
gastrin. CCK-2R has been found expressed in colon crypts adjacent to the proliferative 
zone and its inactivation affected both cell types DCAMKL-1-positive (4+) and 
LGR5-positive (CBCs) and also colonic crypt fission. These findings suggest that 
CCK-2R is expressed in the two potential intestinal stem cell types and that it may be 
a potential target in the treatment or prevention of colorectal cancer (CRC) (39). 
Another possible marker might be cytokeratin CK19, a bile duct marker that may also 
label intestinal stem cells as lineage-tracing studies found that almost the complete 
epithelium was labelled by this marker (40).  
 
1.2.3. Clonal analysis of the intestinal epithelium 
 
Monoclonal conversion, or clonal replacement, is the process whereby a mutated stem 
cell that has already established itself in the niche clonally expands to fill the entire 
crypt. There is a need to assess this process for the identification of stem cells and the 
location of stem-cell niches in the gastrointestinal tract, as it is essential to the 
understanding of tumour development in the colon (41). Moreover, clonality studies 
are essential to analyse lineage relationships and assess mutation order and timing in 
carcinogenesis, in order to establish the origins of colonic adenomas and CRC and also 
possible targeted therapies. Following the Unitarian hypothesis from Cheng and 
Leblond (3), a considerable body of research has used clonal analysis to study the 
clonality of small and large intestinal crypts. 
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Winton and Ponder, in 1990, found the first evidence for clonal mouse small intestinal 
crypts using whole mounts from heterozygous Dlb-1 locus mice with a peroxidase 
conjugate of the lectin Dolichus biflorus agglutinin (DBA-Px) (42). By inducing 
somatic mutations in individual cells in Dlb-1+/+ mice, the authors proved the existence 
of long-lived, pluripotent stem cells that can give rise to all epithelial cell lineages. 
Later, Bjerknes and Cheng performed chemical mutagenesis in Dlb-1-/- mice revealing 
the existence of a short-lived progenitor cell type generating committed progenitors 
for the different epithelial lineages (Mix), long-lived mucous and columnar 
progenitors (M0 and C0) and pluripotent stem cells generating additional cell lineages 
(S) (43).   
 
Williams and colleagues studied the loss of O-acetylation of sialomucins using the 
mild periodic acid-Schiff (mPAS) staining in individuals heterozygous for O-
acetyltransferase gene activity in colonic and small intestinal crypts, in patients with or 
without radiotherapy (44-46). These workers concluded that wholly mutated crypts are 
persistent, that partially mutated crypts are transient and that clonal stabilisation time 
in the colon is approximately one year in humans. The difference between species and 
the small and large intestine was attributed to the different number of stem cells in the 
niche and also to the rates of crypt fission and stem cell cycle time (46).  
 
In humans, an extremely rare case of familial adenomatous polyposis (FAP) in an 
XO/XY patient showed, by in situ hybridisation for the Y chromosome, that human 
small and large intestinal crypts were also clonal (expressing only XO or XY). 
Interestingly, Novelli and colleagues also observed that at least 76% of human 
colorectal microadenomas were polyclonal in origin (47). Thirlwell and colleagues 
 33 
confirmed this observation by analysing individually microdissected crypts of the 
same XO/XY patient individually and of other patients with either familial conditions 
(FAP or attenuated FAP) or with sporadic adenomas or carcinoma-in-adenomas (16). 
They found microadenoma polyclonality in FAP patients and also in some patients 
with sporadic lesions. The inherited abnormal genetic background and the local or 
regional exposure, such as chronic mucosal inflammation, can influence which 
mutations are selected. Therefore, the most likely cause of adenoma polyclonality 
could be the interaction between an initiated crypt and its neighbours, mainly due the 
aberrant epithelial-stromal interactions caused by APC mutations and predisposing 
wild-type non-dysplastic neighbouring crypts to select for an independent epithelial 
mutation. 
 
Findings in female mice heterozygous for the X-linked gene glucose-6-phosphate 
dehydrogenase (G6PD+/-) suggested that crypts were clonal in origin and that 
intestinal villi were polyclonal. Polyphenotypic villi were observed by X-linked 
enzyme histochemistry due to a contribution of epithelial cells from multiple crypts 
(48). Using the same technique on Sardinian females heterozygous for the G6PD 
Mediterranean mutation (Cys563Thr), Novelli and colleagues showed that clonal 
patches in the human colon could become relatively large and that human intestinal 
crypts are clonal (49). 
 
Mitochondrial DNA (mtDNA) mutations have been used as markers of clonal 
expansion allowing analysis of the clonal architecture of individual human epithelial 
units (50, 51). Mitochondria are the major cellular generators of adenosine 
triphosphate (ATP) and cells contain multiple copies of mitochondrial genomes. 
 34 
MtDNA is a small 16.6kb self-replicating molecule that encodes 13 proteins of the 
oxidative phosphorylation pathway, 2 ribosomal RNAs and 22 transfer RNAs (52). 
The mitochondrial genome is especially susceptible to mutation due to its lack of 
protective histones, its high oxidative stress location and its limited repair mechanisms 
(53). MtDNA mutations are random, increase with age, and they can either affect all 
copies (homoplasmy) or a portion of the copies (heteroplasmy) of the mitochondrial 
genome. For a mutation to result in a mutated cellular phenotype, homoplasmy or a 
high degree of heteroplasmy is necessary (54). When using mtDNA mutations to 
assess niche succession and clonal conversion in humans, it needs to be considered 
that monoclonal mutated crypts are very rare in patients under 40 years of age. This is 
due to the time needed for a mutation to occur in a single mitochondrion in an 
intestinal stem cell and also to the achievement of homoplasmy, in order to have a 
single mitochondrial DNA-mutated intestinal stem cell. In colonic crypt stem cells, 
Taylor and colleagues identified homoplasmy of mtDNA mutations using the 
biomarker of mtDNA defects cytochrome c oxidase deficiency (50). It has been found 
subsequently that these cytochrome c oxidase deficient mutated crypts can expand 
clonally by crypt fission, which can have important implications for the biology of the 
normal human colon (55). However, because such mtDNA mutations do not confer a 
selective advantage they need to expand by the same stochastic process as wild type 
intestinal stem cells, hence, only around 15% of the crypts are mutated by the time 
individuals reach the age of 80 (41).  
 
Original findings using methylation tags as a lineage-tracing marker suggested that 
there were multiple stem cells in the colonic crypts that eventually, due to a 
‘bottleneck effect’, become related to the closest stem cell ascendant (56). Kim and 
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Shibata used methylation patterns to determine if adjacent adult crypts have similar 
methylation patterns at CpG sites compared to widely separated crypts (57). No 
evidence was found to prove that directly adjacent or branched crypts are more highly 
related than the widely separated ones. This lack of similar methylation patterns 
between closely related crypts indicates that methylation patterns diverge rapidly 
during ageing in long-lived adult human colonic crypts. 
 
Microsatellites, also known as simple sequence repeats (SSR) or short tandem repeats 
(STRs), are widely dispersed, hypervariable regions of repetitive DNA sequences 
composed of 2-6 base pairs. Because of their polymorphic nature and inheritance in a 
Mendelian codominant manner, microsatellites have been previously used as clonal 
markers allowing distinction between chromosomes. The loss of heterozygosity 
(LOH) of microsatellites has been extensively studied to assess tumour suppressor loss 
in tumour development and to investigate genetic instability in the non-tumour 
epithelium surrounding areas of cancer in order to track mutated clones and to 
determine the risk of tumour regrowth (58-60). However, more than one microsatellite 
must display LOH in order to be considered a reliable clonal marker, as loss of only 
one microsatellite might be due to a field defect or coincidence. Therefore monoclonal 
proliferation will be ensured when multiple and consistent microsatellite markers 
along the same gene or region of interest with LOH are demonstrated (61).  Frumkin 
and colleagues studied the clonal origin of a mouse lymphoma by performing cell 
lineage reconstitution, genotyping 120 microsatellite loci from microdissected single 
cells from the tumour (62). Their reconstructed cancer cell lineage tree revealed a 
monoclonal origin for the carcinoma in a tumour founder cell and a clustering of the 
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tumour cancer cells and metastasis cells on the same subtree and, therefore, presenting 
a very similar microsatellite pattern.  
 
Field cancerisation is the process whereby a single clone can expand, preconditioning 
a large field of epithelium to undergo neoplastic transformation and ultimately develop 
into cancer. Such fields do not necessarily present a change in cell phenotype but 
constitute a distinct biological stage in epithelial carcinogenesis (63). Recent studies 
on long-standing Crohn’s disease patients have revealed that field cancerisation occurs 
in the large intestinal epithelium accounting for the extensive spread of pre-tumour 
clones in non-tumour epithelium throughout the colon and showing that dysplastic 
epithelium is an unreliable marker for cancer risk (64). We can conclude that the 
initiation of colorectal tumourigenesis is more complex than previously thought and 
that this complexity is likely to be representative of the overall tumourigenic process 
in the gastrointestinal tract. 
 
1.3.  Gastric stem cells 
 
The human gastric mucosa is divided into cardiac zone, corpus zone (including the 
fundus) and the antral or pyloric zone (Figure 1.2). There are different types of gastric 
glands: corpus glands (found in the fundus and corpus) and antral or pyloric glands 
(found in both cardiac and antral zones) (65). The corpus glands contain acid 
producing parietal cells and pepsin producing chief cells, whereas the pyloric glands 
consist of mucus secreting cells and are responsible for gastrin hormone production. 
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Figure 1.2. The structure of the human stomach and the gastric corpus and 
pyloric glands. Cartoons representing the human stomach (A), the corpus (B) and the 
pyloric (C) glands, with gastric stem cells labelled in red. 
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Human and mouse gastric epithelial stem cells are thought to be located around the 
isthmus/neck region of gastric glands, an area above the neck and underneath the pit of 
the gland (30, 66). This is based on the fact that there is bidirectional migration of 
proliferating cells up towards the pit and down the gland base. Gastric stem cells are 
capable of differentiating into foveolar surface cells (or surface mucous cells) forming 
the gastric pit, and parietal cells (or oxyntic cells) and chief cells (or zymogenic cells) 
lining the gland, see Figure 1.2 (67). 
 
1.3.1. Gastric progenitor and stem cell markers 
 
Gastric stem cells, like intestinal stem cells, are believed to be located within a niche 
maintained by mesenchymal cells. However, even though several possible stem cell 
markers have been found in the small intestine and colon, only a few have been found 
to label gastric stem or progenitor cells. One example is DCLK-1, which has been 
found to label single cells in the isthmal stem cell niche of gastric glands within the 
corpus (central) region of the stomach of adult mice (30). Giannakis and colleagues 
observed using a multilabel immunohistochemical study solitary DCLK-1-positive 
cells in the isthmus region positioned next to fast-dividing BrdU-positive progenitor 
cells. These cells did not express any gastric differentiation lineage markers and 
seemed to be produced by pre-neck cell progenitors, characterised by cored secretory 
granules and giving rise to the zymogenic cell lineage (66). These findings suggest 
that DCLK-1 is not only an intestinal stem cell marker, but also a marker of adult 
gastric stem cells.  
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Qiao and colleagues (68) identified a gastric progenitor cell (GPC) population using 
Villinβ-gal/+ transgenic mice. They observed one to two villin-positive cells in the lower 
third of the pyloric glands, located at or below the isthmus region, and showed that 
these GPCs have the ability to re-populate entire glands. Their BrdU study suggested 
that this cell population is also quiescent, indicating that villin might be a useful 
marker for slow cycling stem or progenitor cells. 
 
When Barker and colleagues confirmed Lgr5 expression in CBC cells in the small 
intestine and colon in their two knock-in mouse models, Lgr5-LacZ and Cre-
activatable R26R-LacZ reporter, they also found Lgr5 expression at the bottom of 
antral glands (6). Barker and colleagues later found Lgr5 expression in both human 
and mouse embryonic stomachs throughout the developing gastric glands (69). The 
results from their Lgr5-EGFP-ires- CreERT2 mice revealed that Lgr5-positive cells 
were found in the pylorus regions. These observations indicate that there are rapidly 
diving stem or progenitor cells that can repopulate the epithelium of the antrum and 
pyloric canal and that Lgr5 is a marker for stem or progenitor cells in the stomach. 
 
Quante and colleagues (67) showed that trefoil factor family 2 (TFF2) mRNA 
transcript expression (TTE) labels a multilineage gastric progenitor cell for parietal, 
mucus neck and zymogenic cell lineages in gastric corpus glands using a TFF2-BAC-
CreERT2 transgenic mouse model. Even though these TTE progenitor cells cannot 
differentiate into pit cells or neuroendocrine cells in the corpus, TTF2 can be used as a 
marker for oxyntic gastric gland progenitor cells. 
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1.3.2. Clonal analysis of the gastric epithelium 
 
In 1998, initial studies suggested that human gastric glands were polyclonal in origin 
by showing X-chromosome-linked inactivation of the HUMARA gene. These studies 
revealed that even though pyloric (antrum) glands appear homotypic and are thus 
monoclonal, 50% of fundic (oxyntic) glands are actually heterotypic and therefore 
polyclonal (70). Subsequently, other clonality studies analysing mutations in mtDNA 
showed that, like in the normal human colon, mtDNA mutations also establish 
themselves in stem cells within the normal human gastric corpus gland. These cells 
have the ability to differentiate into all gastric cell lineages, producing a new clonal 
gastric gland via niche succession and monoclonal conversion (71). McDonald and 
colleagues also demonstrated that mtDNA mutated gastric glands can divide by 
fission, leading to clonal patches sharing the same mtDNA mutation. CCO-deficient 
partially mutated glands are also observed, revealing the presence of multiple stem 
cells within the gastric gland.  
 
During field cancerisation in the stomach, Gutierrez-Gonzalez and colleagues showed 
that over time the field could become genetically diverse, suggesting that gastric 
cancers can arise from a subclone of the founding original mutation (72). These 
workers proved that intestinal metaplasia (IM) of the stomach can clonally expand by 
crypt fission and that dysplasia arises from a single mutated IM gland. Hence, IM is 
field cancerisation of the human stomach and gastric cancer develops through 
progression of the initial founder mutation. 
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1.4. Oesophageal stem cells 	  
The oesophagus is lined with stratified squamous epithelium that can be divided 
histologically into two layers, a differentiated layer composed of multiple layers of 
flattened and differentiated squames (keratinocytes) and a generative basal layer. This 
second layer is formed by a single layer of cells that adhere to the basement membrane 
followed by a variable number of cell layers above this (the epibasal or suprabasal 
layer). In humans, the lamina propia underneath this luminal surface of the oesophagus 
invaginates the epithelium at regular intervals dividing anatomically the basal layer 
into interpapillary basal layer (IBL) and papillary basal layer (PBL), see figure 1.3 
(73). 
 
 
Figure 1.3. The basic structure of human oesophageal epithelium. Cartoon 
representing the human stratified oesophageal epithelium, with papillary basal layer 
(PBL) cells labelled in red and interpapillary basal layer (IBL) cells labelled in yellow. 
 
Using a transgenic mouse model, Jones and colleagues suggested that the oesophageal 
epithelium is maintained by a single progenitor cell that divides stochastically with the 
same probability of generating proliferating or differentiating cells (74). After 
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wounding, the authors observed that these single progenitors have the ability to switch 
between homeostatic and regenerative behaviour without the need for a slow-cycling 
stem cell pool.  
 
Oesophageal stem cells are thought to reside and be restricted to the basal layer (75). 
Seery and Watt (76) observed that the IBL was enriched with slow proliferating cells 
and had a high proportion of asymmetrical mitoses, whereas cells in the PBL seemed 
to undergo symmetrical mitosis and divided frequently. Using fluorescence-activated 
cell sorting (FACS) and an in vitro study these authors had shown that stem cells in 
the oesophagus reside in the IBL and that transit-amplifying cells reside in the PBL. 
Cells are thought to migrate from the basal layer towards the oesophageal lumen and 
this is associated with initiation of differentiation followed by expression of 
differentiation markers (77).  
 
1.4.1. Oesophageal progenitor and stem cell markers 
 
The isolation and characterisation of oesophageal stem cells remains elusive as 
definitive progenitor or stem cell markers still remain to be found. Moreover, the 
stratified squamous epithelium of the oesophagus and the epidermis come from 
different embryological origins and exhibit different functions. Hence, stem cell 
markers from the epidermis cannot be related to the oesophageal epithelium. For 
example, some findings have suggested that adhesion molecules such as the β1 
integrin subunit might be a marker for keratinocytes given the high levels expressed in 
stem cells of the epidermis (78). However, the slow-dividing IBL stem cell expresses 
low levels of this marker (76). 
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The ability to exclude Hoechst 33342 DNA binding dye mediated by the ABCG2 
transporter was first used to isolate stem cells as a side population (SP) in the 
haematopoietic system. This HSC SP was shown to rescue lethally irradiated mice and 
to differentiate into both myeloid and lymphoid lineages (79). By using the Hoechst 
33342 dye efflux test, Kalabis and colleagues (80) isolated a SP from the oesophageal 
epithelium of previously BrdU-treated mice. A fraction of this SP was BrdU+ and was 
localised to the oesophageal basal cell compartment. Furthermore, the fraction of this 
SP expressed the bone marrow stem cell marker, CD34, formed colonies and matured 
into differentiated epithelium in an organotypic (3D) cell culture. This suggests that 
the CD34-positive fraction has the capacity for self-renewal, can participate in 
epithelial regeneration and also that CD34 is a potential candidate as an oesophageal 
stem cell marker. 
 
Croagh and colleagues observed three independent populations within the basal layer 
of the mouse oesophagus, based on the expression of α6 integrin and transferrin 
receptor (CD71) obtained by FACS (81). They found that the α6briCD71dim population 
(high α6 integrin combined with low CD71) had a slower turnover rate, maintaining 
BrdU expression the longest, and that it could regenerate the other two cell 
populations in the tissue reconstitution assay. These observations suggest that the 
α6
briCD71dim  population can self-renew and has an increased long-term proliferative 
capacity, indicating that high α6 integrin and low CD71 levels might serve as markers 
of oesophageal progenitor or stem cell markers. 
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1.5. Stem cells in cancer in the gastrointestinal tract 
 
Self-renewal, or the capability of a stem cell to maintain its own population, is thought 
to become dysregulated within a tumour (82). This has lead to the theory that there is a 
population of stem-like cells within tumours: the so-called cancer stem cell, which 
refers to the capacity of a subpopulation of cancer cells that can initiate tumourigenesis 
(83). If we also subscribe to the mutation and selection theory of cancer development, 
the longer a proliferative cell survives, the greater the chance of accruing increasing 
numbers of genetic abnormalities which can be passed on to its progeny. The tissue 
stem cell is a long-lived cell and is considered the prime suspect as the tumour-
initiating cell of many tumours (84). The cancer stem cell (CSC) theory was first 
proposed by Julius Cohnheim in 1867 and evidence demonstrated first by Hamburger 
and Salmon (1977) (85) who showed that only 1 in 1,000 to 1 in 5,000 cells from a 
cancer were able to grow macroscopic colonies on soft agar. Some 17 years later John 
Dick and colleagues were the first to show in vivo that acute myeloid leukaemia 
(AML) could be induced in SCID mice by transplantation of a subset of AML cells. 
They were able to identify an AML-initiating cell occurring with a frequency of 1 in 
250,000 peripheral blood cells and show that the initiating cell produces colony-
forming cells with cell-surface-marker expression CD34+ CD38- (86). Later studies 
have suggested that a similar model exists for solid tumours, however, some may 
conform to the clonal evolution model, in which a dominant population of 
proliferating cells drives tumorigenesis (87, 88). These two models are not mutually 
exclusive, as CSCs themselves undergo clonal evolution as shown for leukaemia stem 
cells (89). 
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Kirkland, in 1988, observed that a single human rectal adenocarcinoma cell was 
capable of generating tumours with columnar, mucous and endocrine cells lineages 
upon xenotransplantation in nude mice (90). Therefore, this study showed that all 
epithelial lineages are clonal. Since, Vermeulen and colleagues (91) performed a 
similar experiment and observed that the single cells responsible for reconstituting the 
original tumour contained expression of proposed markers for stem cell populations. 
This study showed that tumour heterogeneity might also be due to the multipotential 
characteristics of CSCs, instead of necessarily being caused by the presence several 
CSCs in a tumour (92). The CSC hypothesis may therefore need to be specific for 
different tumour-types, depending on the origin of the CSC and the changes that occur 
during tumour progression (93) (e.g. the epithelial-mesenchymal transition (EMT), 
characterised by the acquisition of motility, invasiveness, and self-renewal traits (94)). 
 
However, there is great debate within those who subscribe to the CSC theory of cancer 
development as to how common CSCs actually are. In the past, CSCs have been 
considered to be very rare, but it now appears that many combined factors may have 
greatly underestimated their frequency (93). The CSCs ratio obtained from 
immunodeficient mice transplantation experiments can be increased by enriching the 
number of CSCs selected and by providing them with a niche, after transplantation. 
This can be done by firstly selecting cells expressing either the ATP-Binding Cassette 
(ABC) transporter genes, the largest family of membrane transport proteins, and the 
aldehyde dehydrogenase (ALDH) gene family, responsible for the oxidation of 
aldehydes to carboxylic acids and therefore the ability to induce drug inactivation. 
Furthermore, the use of matrigel facilitated tumour growth of human melanoma 
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ABCB5 enriched circulating tumour cells (CTC) in NOD/SCID Il2rγ–/– mice (95), 
proving that a niche-like environment improves CTC detection in assays. 
 
1.5.1. Cancer stem cell markers in the gastrointestinal tract 
 
Two CSC markers have emerged as the most useful for identification purposes in a 
variety of systems. CD44 is the major ubiquitously expressed cell surface receptor for 
hyaluronic acid (HA) and is a known downstream target of the Wnt/β-catenin 
pathway. It is known to undergo complex alternative splicing and participate in 
cellular functions such as lymphocyte activation, recirculation and homing, 
haematopoiesis and tumour metastasis. CD44 was the first marker identified for a 
solid tumour in breast cancer, forming a subpopulation of tumourigenic cells when 
highly expressed and associated with low levels of CD24 (96). It has since been 
observed in hepatocellular carcinoma (97), in sporadic and hereditary gastric cancer 
(98) and used for isolating a population of gastric cancer cells with increased 
resistance to chemotherapy and radiotherapy induced cell death (99). It has also been 
found to label the CSC capable of generating multilineage differentiation in CRC 
combined with CD166, CD29, CD24, LGR5, nuclear B-catenin and prominin-1 
(CD133) (91). 
 
The pentaspan transmembrane glycoprotein prominin-1 (CD133) has also been 
identified as an alternative cancer stem cell marker for many tumours. The CD133 
protein is thought to function in maintaining stem cell properties by suppressing 
differentiation (20). It has been observed in neuroblastoma (100), endometrial cancer 
(101) and in a minority of cells in hepatocellular carcinoma (102). Even though 
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CD133 has been previously observed in CSC in CRC (91), Shmelkov and colleagues 
(103) found that CD133 was expressed in differentiated epithelial cells and that both 
CD133-positive and CD133-negative metastatic colon CSCs can initiate tumours. 
Similarly, another study carried out by Lugli and colleagues in a large archival cohort 
of patients showed inconclusive data related to the presence or absence of CD133 in 
CRC (104). Therefore, although CD133 might be used in combination with other 
markers to identify CSCs, these findings suggest that CD133 expression is not 
restricted to somatic and cancer stem cells (105). 
 
Schepers and colleagues observed that the crypt stem cell marker Lgr5 also marked a 
subpopulation of 5 to 10% of adenoma cells, which were responsible for generating 
further Lgr5-positive cells as well as all other adenoma cell types (106). Several other 
stem cell markers could be viable CSC markers. However putative markers still 
require further studies for a consensus to be reached as many experiments have only 
been carried out in immunodeficient animal models. Nevertheless, it is thought that 
targeting specific CSCs will allow the development of a much more effective 
treatment for cancer when restricted CSC markers are finally identified (107) (108). 
 
1.5.2. Models of neoplastic development  
 
There are two conflicting models of neoplastic development in colorectal adenomas; 
and both consider that the founder mutation occurs in stem cells of the colonic crypt. 
The ‘bottom-up’ hypothesis suggests that a clone of cells is produced by expansion of 
a mutated stem cell in the base of the crypt. This occurs either stochastically or due to 
selective advantage, and is followed by the colonisation of the entire crypt by this 
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dysplastic epithelium to form a clonal monocryptal adenoma (47). It was demonstrated 
that the “bottom-up histogenesis” (109) occurred when Barker and colleagues showed 
that Lgr5-positive cells comprise the tumour initiating cell population (110) and Tian 
and collagues proved that Bmi-positive cells can repopulate the Lgr5 population after 
tissue damage in intestinal cancer in mice (111). The crypt fission index (proportion of 
crypts in fission) is up-regulated in colorectal adenomas, colorectal hyperplastic 
polyps and other cases of genomic instability such as ulcerative colitis (UC) and 
Crohn’s disease (112).  
 
The ‘top-down’ hypothesis suggests that the mutated stem cells are located between 
the crypt orifices, in an intracryptal zone. From this area, it is thought that the 
dysplastic tissue spreads laterally and downwards into the adjacent crypts. It has been 
suggested that the stem cells might migrate to the intracryptal zone once the mutation 
is acquired before undergoing adenomatous spread (113). This has been observed in 
larger adenomas where evidence suggested an overspill of dysplastic tissue or an 
adenomatous field effect on neighbouring crypts. Recently, Schwitalla and colleagues 
used a mouse model to prove that Lgr5-negative enterocytes had the ability to 
dedifferentiate and reacquire stem cell properties by re-expressing Lgr5, supporting 
the ‘top-down’ hypothesis (114). Thus, the ‘bottom-up’ mechanism of clonal 
expansion occurs to form a monocryptal adenoma, which followed by the ‘top-down’ 
mechanism as the clone spreads into the adjacent crypts in larger adenomas (27, 115). 
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1.6. The adenoma-carcinoma sequence 
 
The principle generally held in cancer biology is that of the mutation and selection 
theory (116). Dating back to the 1970s, it suggests that clonal selection in the primary 
tumour drives cancer progression and metastasis (117). Morson and colleagues 
observed that even though not all benign adenomatous polyps or villous adenomas 
progress into CRC, the majority of colon and rectum cancers arise from previous 
adenomas (118). This concept was then termed the adenoma-carcinoma sequence 
(119), which is now accepted as the underlying process behind the majority of cancers 
(120). For a summary of the adenoma-carcinoma sequence (121), see Figure 1.4. 
 
The “Vogelgram”, or multistep cancer progression model of CRC, defined the genetic 
process behind the development and spread of neoplasia. This model is based on the 
order and the accumulative effect of the multiple mutations of oncogenes and tumour 
suppressor genes (TSGs) that lead from normal epithelium to pre-invasive neoplasms 
and finally to malignant tumours (122). It has since been adopted as a model for many 
other cancers (123-126).  
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Figure 1.4. The adenoma-carcinoma sequence leading to colorectal carcinomas. 
Figure adapted from Fodde and colleagues (121). APC mutations have been 
observed as the earliest genetic alteration in colorectal cancer development, followed 
by KRAS, SMAD2/SMAD4 and TP53 mutations.  LOH of chromosomes 18q and 17p 
has been found to occur simultaneously. Nuclear β-catenin levels have been shown to 
increase with chromosomal instability as malignancy progresses. 
 
 
1.7.  Genes involved in gastrointestinal cancers 
 
1.7.1. The Wnt signalling pathway 
 
The Wnt signalling pathway plays a crucial role in regulating cellular processes 
involved in development, differentiation, and adult tissue homeostasis (127). Wnts are 
a large family of secreted glycoproteins with 19 isoforms identified in humans. They 
have been found in many species including Drosophila, where is it known as the 
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wingless (Wg) gene, the best characterized Wnt gene. Aberrant signaling in this 
pathway has been associated to mutations in Axin, Adenomatous Polyposis Coli (APC) 
and CTNNB1 (β-catenin), where β-catenin is central in the signaling cascade.   
 
Under normal conditions, in the absence of Wnt signaling, cytoplasmic β-catenin is 
recruited into a destruction complex where it interacts with APC and Axin, and 
undergoes serial serine phosphorylation by the glycogen synthase kinase-3 β (GSK-
3β) and casein kinase 1α (CK1α).  The marked protein is then degraded via the 
ubiquitin-proteasome pathway resulting in low levels of cytoplasmic β-catenin and 
forcing the transcription factors lymphoid enhancer factor (LEF) and T-cell factor 
(TCF) to interact with their corepressor Grouchos in the nucleus in order to repress 
Wnt-specific target genes (128). However, when present, canonical Wnt ligands bind 
to Frizzled membrane receptors and LRP5-LRP6 co-receptors in the plasma 
membrane leading to the phosphorylation of LRP5 or LRP6 and the formation of the 
Dishevelled polymer. Amongst other roles, this polymer will mediate the translocation 
of Axin to the plasma membrane and will inactivate the destruction complex. The 
stabilization of β-catenin will lead to an increase of β-catenin in the cytoplasm 
followed by a translocation of β-catenin into the nucleus where it will displace 
Grouchos and will form a transcriptionally active complex with Tcf-4 (a member of 
the TCF/LEF family), and other co-activators. This will lead to the transcription and 
expression of Wnt target genes responsible for cell proliferation, such as the 
protooncogene MYC and cyclin D1 (26, 129). Wnt signaling has been found to play 
an important role in cancers of the gastrointestinal tract (130). 
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1.7.1.1. 	  Adenomatous	  Polyposis	  Coli	  
 
APC is a classified tumour suppressor gene (TSG), known to be located in the long 
arm of chromosome 5, between positions q21 and q22. Loss of control of the Wnt 
signalling pathway due to mutation of the tumour suppressor APC is known to be an 
early event in colorectal adenocarcinoma formation, particularly familial adenomatous 
polyposis (FAP) associated with one or more genes on chromosome 5q21 (131). FAP 
results from a germline inherited mutation on an APC allele followed by a subsequent 
‘second hit’ on the other allele, rendering the tumour suppressor inactive. Miyoshi and 
colleagues observed that over 60% of the somatic mutations observed in their cohort 
of FAP patients were clustered in a small region of exon 15 in the APC gene known as 
the mutation cluster region (MCR) (132). The inability of the APC protein destruction 
complex to degrade cytosolic β-catenin leads to over-transcription of target genes. 
This will cause the formation of multiple bowel adenomas (27).  
 
Sivak and colleagues observed that gastric cancer risk is at least ten times higher in 
FAP patients than in the general population (133). Two studies by Horii, Nakatsuru 
and colleagues using ribonuclease (RNAse) protection analysis coupled with PCR 
sequencing revealed that a high proportion of very well differentiated gastric 
adenocarcinomas (GAs) and signet-ring cell carcinomas exhibited mutations in the 
APC gene, suggesting that APC plays a role in gastric carcinogenesis in these two 
types of cancer, but not in poorly differentiated GAs (134, 135). However another 
study by Fang and colleagues observed APC mutations in 33% of intestinal-type GA, 
independent of grade of differentiation, tumor size, depth of invasion or node 
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metastasis. They observed, however, that diffuse gastric cancers have a much lower 
frequency of APC mutations (136).  
 
1.7.1.2. β-catenin 
 
As mentioned in 1.7.1, β-catenin is a ubiquitous intracellular protein with an essential 
role in the Wnt canonical pathway. However, it is also very important for intercellular 
adhesion by linking the cytoplasmic domain of cadherin to α-catenin, resulting in the 
anchoring of the adhesion complex to the cytoskeleton (137). CTNNB1 mutations have 
been observed in several types of cancer, such as colorectal, endometrial, 
hepatocellular, ovarian, prostate, intestinal gastric cancer and uterine endometrioid 
carcinoma (138-141).  
 
Park and colleagues observed that over a quarter of the intestinal-type GAs in their 
cohort presented mutations in the CTNNB1 gene. All of the mutations they observed 
were missense mutations clustered in a region of exon 3 responsible for encoding the 
GSK-3β phosphorylation consensus region of the CTNNB1 gene. Their findings 
revealed no CTNNB1 mutations in hereditary-diffuse gastric cancer patients (142). 
However, Clements and colleagues observed that 23% of intestinal-type gastric 
tumours and 38% of diffuse-type tumours presented mutations in CTNNB1 (143). 
Tong and colleagues also found one CTNNB1 mutation in a diffuse-type cancer but 
observed a very low frequency of CTNNB1 mutations in intestinal-type gastric cancer 
(144). Therefore, the frequency of CTNNB1 mutations seems variable between 
cohorts, but it is apparent that CTNNB1 mutations and the canonical Wnt-pathway 
activation contribute to gastric carcinogenesis. 
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1.7.2. The TP53 signalling pathway 
 
The tumour protein gene (TP53) is a 20kb gene located on the short arm of 
chromosome 17 (17p13.1). It encodes a tumour suppressor protein, a transcription 
factor which functions as a gatekeeper for cell division and growth. Most of the 
downstream targets of p53 are responsible for: inhibiting cyclin-cyclin-dependent 
kinases and inducing cell cycle arrest (p21, WAF1 and Clip1); DNA damage repair 
(GADD45); apoptosis (Bax); and blocking mitogenic growth factor signalling (IGF-
BP3) (145). Mdm2, another p53 downstream target, is responsible for the inactivation 
of p53-mediated transcription, forming a negative auto-regulatory loop and causing 
p53 to undergo ubiquitin-mediated proteolysis in the cytoplasm (146). 
 
The p53 protein is activated by DNA damage caused UV light exposure, ionising 
radiation, chemical damage and hypoxia or genotoxic stress. Once activated it leads to 
DNA repair and cell cycle arrest and p53 protein activation can eventually result in 
apoptosis or cellular senescence. P53 becomes active after phosphorylation at its N-
terminus and is stabilized by p19ARF which blocks the Mdm2-mediated degradation 
and neutralizes the inhibition of p53 by Mdm2. Tao and colleagues observed via 
heterokaryon assays that this process most likely occurs by p19ARF inhibition of 
nuclear-cytoplasmic export of Mdm2 (146).  
 
1.7.2.1. 	  TP53	  in	  cancer	  
 
Most TP53 gene mutations are clustered in exons 5-8, known to be responsible for the 
p53 DNA binding domain, which prevent DNA binding and disrupt the transcription 
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of p53 downstream targets. These mutations are found in over 50% of human cancers. 
For instance, TP53 mutations have been observed in up to 70% of CRC and they are 
thought to be one of the late events in CRC development (147). Loss of p53-mediated 
apoptosis is considered to be an important step in the progression from colorectal 
adenoma to carcinoma and is consistent with the view that transformed cells have less 
efficient cell cycle checkpoint controls (148, 149). Nevertheless, Galandiuk and 
colleagues recently published a study on field cancerisation on long-standing Crohn’s 
disease patients and showed TP53, CDKN2A and K-RAS mutations as possible 
independent initiating events in colon cancer development (64). 
 
TP53 is mutated in over 33% of gastric cancers. Tamura and colleagues originally 
postulated that TP53 mutations occur late in the development of gastric cancer and 
that these mutations are associated with DNA ploidy alterations in the tumours (150). 
However, Renault and colleagues observed that allelic loss of 17p13 chromosomal 
regions occurred in the later stages of GA and that TP53 mutations had preceded such 
chromosomal loss (151). Shiao and colleagues, using PCR sequencing, showed that 
37.5% of a cohort of intestinal metaplasia (IM) cases, 58.3% of dysplasia cases and 
almost 67% of GA cases displayed TP53 mutations. These workers suggested that 
TP53 mutations occurred as an early event in gastric carcinogenesis (152). Correa and 
Shiao then went on to establish the phenotypic and genotypic events in gastric 
carcinogenesis where they concluded that TP53 mutations probably occur after IM 
onset (153). 
 
A study by Flejou and colleagues showed a higher incidence of TP53 mutations in GA 
of the cardia than that of the antrum. This suggested that GA of the cardia might be 
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related to oesophageal adenocarcinoma (OA) and therefore have different clinical and 
epidemiological characteristics than GA of the body and antrum (154). Another study 
by Hanazono and colleagues labelled cardiac carcinomas as OAs, and body or antrum 
carcinomas as GAs. TP53 mutations were found in all cancer types, showing that 
37.5% of cardiac samples and 44.4% of body and antrum samples were mutated. The 
authors also noted that immunohistochemical analysis (IHC) of p53 did not correlate 
with TP53 mutations (155). This lack of correlation was also found in a study 
assessing the relationship between TP53 mutations and IHC staining in hepatocellular 
carcinoma (156).  TP53 mutations have been found in Barrett’s oesophagus (BO), a 
premalignant condition that increases the risk of developing OA by 30- to 40-fold. 
Different studies have shown that TP53 mutations occur at a high rate in OA and TP53 
has been implicated in the malignant transformation of BO to OA through a 
metaplasia-dysplasia-carcinoma sequence (157-159).  
 
Finally, TP53 mutations are also common genetic events in the pathogenesis of 
oesophageal squamous cell cancer (OSCC) (160). LOH of areas on chromosome 17q 
have been observed in a high proportion of OSCCs (161). LOH of chromosome 
17q25.2 - 25.3 has been linked to tylosis, an autosomal-dominant trait associated with 
a high risk of oesophageal SCC (162). Recently, Blaydon and colleagues have 
identified the underlying cause for tylotic oesophageal cancer (TOC) to be the inactive 
rhomboid protease RHBDF2, also known as iRhom2 (163). 
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1.7.3. The CDKN2A signalling pathway 
 
The CDKN2A or p16INK4A gene belongs to a small family of tumour suppressor genes 
that can alternatively splice, generating p15INK4B, p19ARF (or ARF) and p16INK4A. The 
gene is located in a small 35kb locus on chromosome 9. Both related isoforms, 
p15INK4B and p16INK4A, are cyclin-dependent kinase inhibitors that function as 
inhibitors for cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), and thus render 
the retinoblastoma (Rb) protein inactive. This inactivation will block the transcription 
of important cell-cycle regulatory proteins, which suggests that both INK4 isoforms 
and p19ARF carry out an important role regulating the cell cycle, especially in cell cycle 
G1 progression (164) (see explanation in 1.7.2).  
 
Alterations in the CDKN2A tumour suppressor gene have been observed in many 
tumours either as LOH, point mutation or methylation of its promoter. In the 
gastrointestinal tract, this has mainly been shown in gastric cancer (165), OA (166), 
oesophageal SCC (167) and occasionally in intestinal cancer (64). 
 
1.8.  Cancers of the small intestine, colon and rectum 
 
CRC is a major cause of morbidity and mortality throughout the world, being the third 
most common cancer in men and the second in women. It accounts for 8% of all 
cancer deaths, and it is the fourth most common cause of death from cancer (168). 
Even though the incidence for small intestinal cancer has increased over the past 
decades, its overall incidence is much lower than that of CRC (169). Potten and 
colleagues provide a possible explanation for this much lower incidence by identifying 
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an innate mechanism of genome protection in the slow cycling small intestinal stem 
cells (10). Another explanation might be the higher incidence of ‘spontaneous 
apoptosis’ observed in the small intestinal epithelium, which is associated with the 
stem cell position in the crypt and is both DNA damage and p53 independent (149). 
Nevertheless, recent studies analysing the hierarchical clustering of array comparative 
genomic hybridization (ACGH) datasets of 85 microsatellite stable (MSS) 
adenocarcinomas from the stomach, colorectum and small bowel have revealed that 
small bowel adenocarcinomas (SMAs) are more similar to colorectal adenocarcinomas 
than GAs (170). These findings, based on genome-wide DNA copy number 
aberrations, may provide insight into the treatments for MSS SMAs similar to that of 
colorectal adenocarcinomas. 
 
1.9.  Gastric cancer 
 
Gastric cancer is a major cause of morbidity and mortality throughout the world, being 
the fourth most common cancer in the world and the second leading cause of cancer 
death in both sexes worldwide (9.7% of the total deaths from 2008) (168). The Lauren 
classification (171) divides gastric cancer into 2 major histologic types: intestinal or 
diffuse. Tumours are described by this system on the basis of microscopic 
configuration and growth pattern. Hence, the majority of the cases are sporadic in 
nature and belong to the intestinal type of GAs. This histological variant is associated 
with a sequential chain of events initiated by chronic inflammation that can eventually 
lead to the replacement of normal gastric glands by glands of an intestinal crypt 
phenotype, known as intestinal metaplasia (IM) (153). However, diffuse-type cancers 
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have noncohesive tumor cells diffusely infiltrating the stroma of the stomach and often 
exhibit deep infiltration of the stomach wall with little or no gland formation (171).  
 
1.9.1. CDH1 mutations in hereditary diffuse gastric cancer 
 
In diffuse-type gastric cancers, a minority of cases (10%) exhibit familial clustering. 
Only 1-3% of all cases show evidence of inherited susceptibility to the disease and 
these are diagnosed with hereditary diffuse gastric cancer (HDGC) (172). Germline 
mutations in the cell-cell adhesion protein E-cadherin (CDH1) are considered to be the 
most important cause of HDGC. E-cadherin is a type I classical cadherin (see Figure 
1.5). Classical cadherins share a conserved histidine-alanine-valine (HAV) tripeptide 
motif in their first extracellular domain (173), which has been shown to initiate an 
important step in cadherin mediated adhesion (174). Another highly conserved 
sequence across all species is the one responsible for Ca2+ binding sites. Haussinger 
and colleagues, using NMR spectrometry, demonstrated that a single amino acid 
substitution in a calcium-binding domain could abolish cell adhesion, proving 
therefore that such domains are crucial for cell adhesion by cadherins (175). The 
intracellular domain of E-cadherin interacts with β-catenin, α-catenin and p120 
catenin and forms a cytoplasmic cell adhesion complex, thereby forming links with the 
actin cytoskeleton (see Figure 1.5) (176, 177). 
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Figure 1.5. Schematic illustration of interaction between E-cadherin and actin 
cytoskeleton. E-cadherin is seen on purple in the cytoplasmic membrane, the 
interactions in the adherens junctions occur between the external domains of E-
cadherin homodimers. CM, cytoplasmic membrane; ED, extracellular domain; ID, 
intracellular domain; Ca2+, Calcium; AC, actin cytoskeleton; 1, p120; 2, β-catenin; 3, 
α-catenin.  
 
E-cadherin is the central component of epithelial cell-cell adhesion and is required for 
the maintenance of the integrity of epithelial layers (178). During cancer development, 
some adherent epithelial tumour cells can acquire the ability to invade the extracellular 
matrix having undergone epithelial-mesenchymal transition (EMT); this process 
occurs in most types of cancer (179). Undergoing such a transition involves changes in 
the cadherin-mediated cell-cell adhesion, the actomyosin-mediated contraction due to 
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intercellular signaling and internalization of E-cadherin can then be targeted for 
degradation (180). 
 
HDGC is characterised as an autosomal dominant cancer syndrome where the second 
hit is usually methylation of the CDH1 gene, but can also occur through LOH (181). 
Hence, CDH1 is a classic tumour suppressor gene (182). Nevertheless, not all CDH1 
mutations cause complete inactivation of E-cadherin and CDH1 germline mutations 
present with incomplete penetrance (183), carriers having a 70% lifetime risk of 
developing HDGC (184). CDH1 germline mutations are an indication for total 
gastrectomy in these patients (185). 
 
1.9.2. The gastric adenocarcinoma premalignant pathway 
 
GA has been associated with risk factors such as chronic inflammation and 
Helicobacter pylori infection (186). These risks are thought to initiate the progression 
to GA by the initial transition from normal gastric mucosa to atrophic gastritis. The 
phenotypic step-wise progression has been studied extensively and all the histological 
steps have been characterised (Figure 1.6) (153). 
 
Normal gastric epithelium exhibits very low levels of inflammatory cell infiltration 
and these are normally present in the lamina propria surrounding the gastric glands 
(Figure 1.6). However, gastritis is characterized by increased infiltration of the lamina 
propria that can either be due to acute (polymorphonuclear neutrophils) or a chronic 
(mononuclear leukocytes) inflammation (Figure 1.6). Two types of gastritis have been 
characterized: non-atrophic gastritis (NAG), in which the gastric gland structure is 
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preserved, and atrophic gastritis, in which the gastric glands become damaged and the 
specialized glandular tissue is lost (187). Atrophic gastritis can either have a 
multifocal, known as multifocal atrophic gastritis (MAG), or a diffuse pattern in 
gastric tissue and it is associated with the presence of spasmolytic polypeptide-
expressing metaplasia (SPEM), which is a form of mucous metaplasia or 
pseudopyloric metaplasia (188). Atrophic gastritis represents a recognizable step in the 
precancerous cascade (187). 
 
Figure 1.6. The currently accepted metaplasia-dysplasia-carcinoma pathway in 
the development of Gastric Adenocarcinoma. This pathway was published in 1994 
by Correa and colleagues (153). The involvement of APC was not specified at the 
time, therefore, APC is marked here in blue at the stages where it has seen to be 
mutated since (72). 
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The most frequent cause of gastritis and peptic ulcers is chronic colonization of the 
human stomach by the Gram-negative bacterium, H. pylori. The pathogenicity of H. 
pylori depends on the virulence of the infecting strain, as strains containing the 40kb-
long cytotoxic associated gene (cag) pathogenicity island (PAI) induce more severe 
inflammatory reactions. The most virulent protein responsible for H. pylori-induced 
gastric inflammation and gastric malignancy is the H. pylori cytotoxin-associated gene 
A (cagA), which is injected into the host cells disrupting epithelial cell functions. 
Together with H. pylori, cag PAI is responsible for the general inflammatory stress 
within the gastric mucosa inducing cell growth and a tissue repair response (189) that 
leads to the activation of multiple oncogenic pathways in epithelial cells. These 
pathways include NF-kappaB, activator protein-1, PIK3CA, signal transducers and 
activators of transcription 3, Wnt/B-catenin and cyclooxygenase 2 (190). H. pylori 
infection also induces epigenetic changes that affect gene expression and play an 
important role in cell differentiation. The epigenetic changes include DNA 
methylation and histone modification, which have been found to play critical roles in 
oncogenic transformation by increasing significantly the risk of developing GA (191).  
 
1.9.3. Intestinal metaplasia in the human stomach 
 
GA was first linked to IM in 1938 when Bonne and colleagues compared gastric 
specimens from Malay patients, with a low frequency of GA, and Chinese immigrants, 
with a high frequency of GA, and observed that the Chinese patients presented a much 
higher frequency of ‘goblet cell metaplasia’ (187). IM has been classified into two 
main types according to enzyme histochemistry and the histopathology of the gastric 
epithelium: the complete type (or small intestinal, designated type I), and the 
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incomplete type (or colonic, designated types both II and III). Types II and III of IM 
were thought to differ in the mucins secreted by columnar cells: type II secreting 
neutral and acid sialomucins and type III secreting sulfomucins, although it is now 
thought that the difference might be related to the processes of mucin glycosylation 
rather than to the pattern of mucin expression (192). 
 
In a study involving 160 patients from a high risk GA area in Colombia, Gong and 
colleagues observed that KRAS mutations occur very early in the development of 
gastric cancer and suggested that IM can contain the same genetic abnormalities as the 
associated preneoplastic lesions (193). Therefore, IM might be a premalignant 
condition from which a carcinoma can develop. Using cytochrome c oxidase (CCO) 
enzyme histochemistry and mtDNA sequencing of individual cells, McDonald and 
colleagues later observed that human intestinal metaplastic glands are clonal and that 
they clonally expand by crypt fission (71). By microdissecting individual IM and 
dysplastic glands, Gutierrez-Gonzalez and colleagues then showed that in the human 
stomach intestinal metaplastic glands clonally expand by field cancerisation and give 
rise to an entire dysplastic lesion (72). 
 
1.9.4. Dysplasia and gastric adenocarcinoma 
 
Dysplasia is characterised by a neoplastic phenotype, displaying cells with enlarged, 
heterochromatic nuclei that undergo mitosis frequently. Dysplasia presents a disrupted 
architecture, showing bifurcating, branching or irregularly shaped gastric glands. In 
the western world, dysplasia is considered non-invasive and therefore the cells remain 
within the boundaries of the lamina propria. There are two types, low-grade and high-
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grade dysplasia, the latter having more malignant potential and greatly predisposing an 
individual to cancer development (187). Once neoplastic cells penetrate the 
surrounding stroma the lesion has become invasive: GA has developed and metastasis 
can follow.  
 
There is a need to establish which genes are possible targets of mutation and whether 
the mutations are pathogenic during the process of invasion and metastasis. Alpizar-
Alpizar and colleagues recently observed, using immunohistochemistry, that urokinase 
plasminogen activator receptor (uPAR) is expressed in approximately 50% of gastric 
cancer cells in both the intestinal and the diffuse type. uPAR was expressed in 
macrophages and neutrophils in both types. This receptor facilitates the degradation of 
the extracellular matrix (ECM) and can activate other matrix degrading proteins. Even 
though uPAR expression did not vary according to the differences seen in incidence 
and mortality rates according to geographical regions, these workers noted that uPAR 
was expressed at higher levels in patients infected with H.pylori (194). 
 
Several genes have been studied as possible targets of mutation in the associated 
gastric cancer CSCs. Koshikawa and colleagues observed that the ErbB family of 
epidermal growth factor (EGF) receptors play a role in mediating enhanced heparin-
binding EGF (HB-EGF) activity by membrane type 1-matric metalloproteinase (MT1-
MMP) converting HB-EGF into a heparin-independent growth factor with enhanced 
mitogenic activity (195). The authors of this study showed that when both HB-EGF 
and MT1-MMP are expressed in human gastric cancer cells, the invasive growth of the 
cancer cells could be supported, resulting in costimulation of tumour cell growth. 
Another potential target is ERas, a member of the Ras family, which was found to be 
expressed using immunohistochemistry in approximately 40% of human GA 
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specimens (196).  Kubota and colleagues suggest that ERas may play a crucial role in 
gastric cancer cell survival and metastasis to the liver via down-regulation of E-
cadherin. Moreover, monocyte chemoattractant protein 1 (MCP-1) has been observed 
in human GA and expression found to play a major role in monocyte and lymphocyte 
migration, and in macrophage infiltration due to MCP-1 secretion. Even though 
H.pylori has been reported to stimulate MCP-1 secretion from gastric mucosa, Mutoh 
and colleagues suggest that IM and GA might themselves induce MCP-1 expression 
independently of H. pylori infection (197).  
 
There are also other cancer-associated events that might lead to human gastric cancer. 
For instance, Zhi and colleagues suggest that cancer-associated fibroblasts (CAFs) are 
positively correlated with metastatic potential in human GA (198). Using 
immunohistochemistry and real time-PCR for CAF specific proteins, CAFs have been 
found to play a prominent role in promoting tumour growth, invasion and metastasis 
and to be frequently present in gastric cancer tissues. Other findings suggest that 
mesenchymal stem cells (MSC)-like cells are components of the tumour 
microenvironment and provide proof for the origin of CAFs, and that both MSC-like 
cells and CAFs could be potential targets for gastric cancer diagnosis and therapy 
(199). 
 
1.9.5. Genetic instability in gastric adenocarcinoma	  
 
Nearly 75% of all reported mutations in GA occur in TP53, APC, CTNNB1, K-RAS, 
CDKN2A, PIK3CA and PTEN (summary found in Table 1.1) (135, 152, 153, 200, 
201). However, two recent exome sequencing studies found that ARID1A, a member 
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of the SWI-SNF chromatin remodeling family, is very commonly mutated in GA with 
microsatellite instability (MSI). The ARID1A mutations were associated with a better 
prognosis and negatively related to TP53 mutations (202). Moreover, the authors 
found that the genes involved in cell-adhesion were also frequently mutated with 
FAT4, a cadherin family gene, having the highest mutation rate amongst them (203). 
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Genes 
commonly 
mutated 
 
 
Function 
Percentage 
of 
mutation 
in 
COSMIC 
 
References 
TP53 
 
TSG, functions as a gatekeeper 
for cell division and growth 
33.3% (151, 152, 154, 204, 
205) 
APC 
 
TSG, part of the Wnt signalling 
pathway, targets β-catenin for 
degradation and plays a crucial 
role in development, 
differentiation, and adult tissue 
homeostasis 
18% (135, 136, 142, 206, 
207) 
CTNNB1 
 
β-catenin is a ubiquitous 
intracellular protein with an 
essential role in the Wnt 
canonical pathway. Also very 
important for intercellular 
adhesion  
9% (141-143) 
KRAS 
 
Oncogene, crucial role in cell 
division regulation 
7% (193, 208, 209) 
CDKN2A 
 
TSG, inhibitor for cyclin-
dependent kinases 4 and 6 and 
important in cell cycle 
regulation 
7% (165, 201, 210) 
PIK3CA 
 
Oncogene, heterodimeric lipid 
kinase that plays a crucial role in 
cell growth, survival, apoptosis, 
proliferation, motility and 
adhesion. 
12% (200, 211-213) 
PTEN 
 
TSG, crucial for cell cycle 
regulation 
7% (214-216) 
ARID1A 
 
AT-rich interactive domain-
containing protein 1A, member 
of the SWI/SNF chromatin 
remodelling family, possible 
TSG 
11% (202, 203) 
FAT4 
 
Cadherin family gene, possible 
TSG in breast cancer and GA, 
key role in vertebrate core 
planar cell polarity 
-- (203) 
 
 
Table 1.1. The most commonly mutated genes in gastric adenocarcinoma 
development. TSG, tumour suppressor gene. 
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1.10.  Oesophageal cancer 
 
Oesophageal cancer is a major cause of morbidity and mortality throughout the world, 
being the eight most common cancer worldwide and the sixth most common cause of 
death from cancer (5.4% of the total). These values include both types of oesophageal 
cancer, oesophageal adenocarcinoma (OA) and oesophageal squamous cell cancer 
(OSCC), and both cancers appear to be two to four times more common in men than 
women. OSCC has a higher prevalence in Eastern Asian and Southern African 
countries (168).  
 
1.10.1. Barrett’s Oesophagus 
 
Barrett’s oesophagus (BO) occurs when the normal oesophageal stratified squamous 
epithelium is replaced by columnar-cell metaplasia in response to inflammation and 
ulceration provoked by duodeno-gastroesophageal reflux (GORD) (217). As 
mentioned in 1.7.2.1, OA can arise from progression through a metaplasia-dysplasia-
carcinoma sequence (MCS) and the presence of Barrett’s oesophagus increases the 
risk of OA. The size of this excess risk is difficult to quantify. The lowest estimate is 
0.12% per annum by 0.12% (218) but other studies have found significantly greater 
risks. Publication bias is a problem but a risk of around 0.4-0.5% per annum is widely 
accepted for endoscopically visible and histologically confirmed Barrett's oesophagus. 
The incidence of oesophageal adenocarcinoma has risen at an alarming rate over the 
past four decades in many regions of the Western world, and there are indications that 
the incidence of this disease is on the rise in Asia. Nevertheless, BO rarely progresses 
to OA and the incidence increase in OA is thought to be partly due to increases in the 
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prevalence of known risk factors such as obesity, alcohol, cigarette smoking, GORD 
and a poor diet (219).  
 
Neoplastic progression to OA is thought to be due to an accumulation of genetic 
defects within the Barrett’s glands and the driving forces are thought to be genomic 
instability, disruption of the regulatory pathways and the evolution of the mutated 
clones modulated either by host, environmental risk or protective factors (220). 
Findings by the Reid group in Seattle suggested that such genetic defects expand to 
encompass the entire field of Barrett’s oesophagus, known as a selective sweep to 
fixation (166, 221). However, Leedham and colleagues have demonstrated that clonal 
heterogeneity exists within fields of Barrett’s epithelium and that multiple independent 
clones are present (Figure 1.7). Findings by Leedham et al indicate that there may be a 
competitive interaction between these clones in the progression to cancer, but to date 
only mathematical models suggest that such competition exists. Their data also 
suggested that wild type squamous gland ducts of the oesophagus might be the 
potential source for a progenitor cell susceptible to mutation and hence responsible for 
the conversion of stratified squamous epithelium into BO. The ducts may also provide 
a progenitor cell that might be able to expand and create neo-squamous islands (157). 
Moreover, Nicholson and colleagues observed, using cytochrome c oxidase (CCO) 
histochemistry, that Barrett’s glands are clonal, they contain multiple stem cells and 
that are most likely to expand clonally by crypt fission (222). These workers also 
observed that a CCO mutated cell could give rise to both squamous and glandular 
epithelium, corroborating that squamous gland ducts may be the source of progenitor 
cells in the oesophagus. 
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Figure 1.7. Clonal evolution models for Barrett’s oesophagus from Leedham and 
colleagues (157). (A) Selective sweep to fixation model from Reid and colleagues 
(221). (B) Clonal interference model proposed by Leedham and colleagues showing 
genetic heterogeneity within Barrett’s segments. 
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1.10.2.  Genetic instability in Barrett’s oesophagus and oesophageal 
adenocarcinoma 
 
Even though the mechanisms are currently unclear, mutations in TSGs such as TP53 
and CDKN2A are implicated in the development of BO and play a role in neoplastic 
progression to OA (223). Wong and colleagues findings suggest that CDKN2A 
mutations enhance the clonal expansion ability of Barrett’s mucosa, creating a field in 
which other abnormalities arise, which can then lead to OA (224). Other TSGs which 
have been invoked in the development of BO associated adenocarcinomas include c-
erbB2, Rb, BRCA1, Smad4, DCC and hMSH2 (161). 
 
Members of the Wnt signalling pathway have been shown to play a crucial role in 
controlling the balance between squamous and glandular differentiation (73). The role 
of these pathways in the pathogenesis of BO and adenocarcinoma is still unclear. 
However, many reports have also detected reduced expression of cadherins and 
catenins in tumours, including those of the gastrointestinal tract. These proteins are 
known to maintain the adult tissue architecture, E-cadherin being expressed in most 
epithelia and probably co-expressed with P-cadherin in the basal layers of the stratified 
epithelium. However, as seen in other tissues, E-cadherin expression is further 
downregulated as BO progresses to oesophageal adenocarcinoma. Although present in 
OA, E-cadherin expression is usually absent in both BO and dysplasia (225). 
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1.10.3. Oesophageal squamous cell carcinoma 
 
OSCC is the most common oesophageal cancer worldwide. Some of the different 
histopathological steps that can be seen in the course of OSCC development are: 
oesophagitis (marked by neutrophil and eosinophil infiltration of the epithelium); and 
basal cell hyperplasia (BCH, marked by the increased thickness of the basal layer), 
followed by low-grade and high-grade dysplasia. Dysplasia is marked by atypical cells 
in the lower part of the epithelium ascending as the grade of dysplasia becomes more 
severe. Carcinoma in-situ can also be observed, where the full thickness of the 
epithelium presents atypical cells but there is no invasion. Eventually OSCC can 
develop when neoplastic cells invade the muscularis.  
 
There has been great controversy in the identification of the histopathological steps 
that lead to OSCC development and, to date, it is still not widely accepted that 
histological oesophagitis or atrophy have a higher prevalence in the high versus low 
risk populations (226, 227). Wang and colleagues showed in a 13 year prospective 
study that the only histopathological lesions associated with an increased risk of 
oesophageal SCC development were squamous cell dysplasia and carcinoma in-situ 
(228). 
 
The squamous epidermis is thought to be analogous to the squamous oesophagus. 
Clayton and colleagues have shown that clones in the epidermis can expand 
progressively over time and that asymmetrical division occurs in the vast majority of 
epidermal progenitor cell divisions (229). This suggests a new model of epidermal 
homeostasis involving only one type of progenitor cell, which could undergo both 
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symmetric and asymmetric divisions to ensure epidermal homeostasis.  Nicholson and 
colleagues observed patches of CCO deficient cells ranging from around 30µm to 
about 1mm in the normal squamous epithelium. They suggested that if Clayton’s 
observations are applicable to their findings then it is possible that lateral replacement 
of the stem cell pool along the basal layer of the squamous epithelium occurs and that 
a process analogous to niche succession also takes place in the normal oesophagus 
(222). Mandard and colleagues found in the same patient two different histological 
oesophagitis patches with two independent TP53 mutations where a different TP53 
mutation was also present later in the cancer. All of these mutations were functional 
and occurred in the DNA binding domain of p53. These findings suggested that field 
cancerisation occurs in the oesophagus prior to malignant transformation and that, 
regardless of the controversy questioning oesophagitis as a crucial histopathological 
step towards OSCC, it may be a target for early detection of OSCC (162).  
 
1.10.4.  Genetic instability in oesophageal squamous cell carcinoma 
 
OSCC has mainly been associated with: mutations and LOH of the TSG TP53; 
mutations, LOH and promoter methylation of p15INK4b and p16INK4a respectively; 
reduced Rb expression and cyclin D1; mutations in the ras pathway and Notch1 
signalling pathway; and EGFR and c-myc gene amplifications (162, 167, 230-233). 
Recently, the nuclear factor erythroid-related factor 2 gene (NRF2, also known as 
NFE2L2), known to encode a transcription factor that induces the expression of 
antioxidant enzymes upon oxidative stress, has also been found to be mutated in a high 
percentage of OSCCs (234). NRF2 mutations have been associated with tumour 
recurrence and poor prognosis due to resistance conferred to stressors, including anti-
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cancer therapy. Kim and colleagues observed, via PCR sequencing, that all of the 
mutations were near or within the NRF2-KEAP1 interaction motifs, inactivating the 
KEAP1-mediated degradation of NRF2. However, no KEAP1 mutations were found 
(235). These authors also observed NRF2 mutations in skin squamous cancers and 
noted an increase in nuclear NRF2 in both OSCCs and skin squamous cancers, 
indicating that NRF2 mutations play a role in the development of both cancer types. 
DeNicola and colleagues showed that, in murine embryonic fibroblasts, oncogenic 
alleles of Kras, BRaf and Myc increased transcription of Nrf2 thereby elevating the 
antioxidant program and reducing the ROS intracellular levels (236). Hence, increased 
NRF2 antioxidant and cellular detoxification program, either by a mutation preventing 
NRF2-degradation or by a mutated oncogene, represents a previously unappreciated 
mediator of oncogenesis. 
 
1.10.5. Tylosis with oesophageal cancer 
 
Tylosis with oesophageal cancer (TOC) is a rare familial syndrome inherited in an 
autosomal-dominant manner. Symptoms include palmoplantar keratoderma (PPK), 
oral keratosis and follicular papules and it can be associated with a high risk for 
oesophageal SCC development (up to a 95% by the age of 65) (237-239). Rhomboids 
are intramembrane serine proteases, which typically contain six or seven 
transmembrane domains (TMD) classified into four subgroups: Secretase A and B, 
Presenilin-Associated-Rhomboid-Like (PARL) and iRhoms (240). The gene 
responsible for TOC was recently identified as the inactive rhomboid protease 
RHBDF2, also known as iRhom2 (163). iRhoms are predicted to localise to the 
endoplasmic reticulum (ER) membrane (241) although in the epidermis and 
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oesophagus RHBDF2 is also localised at the plasma membrane (163). The TOC 
mutations have been found clustered in the highly conserved extended N-terminal 
domain of RHBDF2, suggesting an important function for this region of the RHBDF2 
protein (see Figure 1.8) (242).  
 
 
 
 
 
Figure 1.8. RHBDF2 structure and working model of RHBDF2 and ADAM17 
interaction in tylosis with oesophageal cancer. (A) Topology model illustrating the 
protein structure of human RHBDF2; highlighted is the fourth transmembrane domain 
and the lack of catalytic residues in inactive Rhomboid proteins. (B) Working model 
of the function of RHBDF2 in the ER and translocating Pro-ADAM17 into the Golgi 
as well as the role of ADAM17 and RHBDL2. Adapted from Etheridge et al (242). 
 
 
 
The Secretase A type Rhomboid RHBDL2 is the active Rhomboid relative of iRhom1 
and RHBDF2 (240). RHBDL2 is known to be responsible for EGF cleavage 
independently of ADAM (A Desintegrin And Metalloprotease) family members (243). 
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Both iRhom1 and RHBDF2 lack the catalytic residues present in active Rhomboid 
proteases and, instead, they present an invariant proline residue that is N terminal to 
the expected location of the catalytic serine (i.e., GPx replacing the GxS rhomboid 
catalytic motif) (Figure 1.8 A) (244, 245). Using immunoprecipitation, Zettl and 
colleagues showed that human iRhom1 and mouse RHBDF2 interact directly with the 
RHBDL2 ligand EGF in the ER and they were both found to target EGF for ER-
associated degradation (ERAD) (245). Keratinocytes from TOC patients are 
unresponsive to exogenous EGF; but, in the absence of exogenous EGF cell migration 
and proliferation are maintained whereas both are significantly reduced in control 
keratinocytes (163). These results suggest that EGF levels might be higher in TOC 
patients and that human RHBDF2 also plays a physiological role in EGF signaling 
(163, 242). 
 
By generating RHBDF2 knock-out mice (RHBDF2-/-), studies by both Adrian and 
McIlwan showed that RHBDF2 is critical for the TNFα convertase (TACE) ADAM17 
maturation and trafficking from the endoplasmic reticulum (ER) (243, 246). Lack of 
activated ADAM17 in the cell membrane prevents the cleavage-mediated activation of 
TNFα, leading to a severe reduction of TNFα levels in RHBDF2-/- mice. Overall, 
these findings suggest that RHBDF2 binds to ADAM17 in the ER and is crucial for 
the trafficking of ADAM17 from the ER into the Golgi, where ADAM17 undergoes 
furin-mediated cleavage activation before trafficking to the cell surface (243). 
Unpublished data suggests that the RHBDF2 gain of function TOC mutations leads to 
an increased level of ADAM17-mediated shedding of EGF signalling molecules in 
TOC cells (242). This increased activation would account, in part, for the 
unresponsiveness of TOC keratinocytes to exogenous EGF and also for the 
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hyperproliferative epidermal phenotype observed in tylotic patients (242). The 
epidermal hyperproliferation observed in the areas undergoing frequent wound healing 
might be due to the excessive ADAM17 activation, as observed in TOC, because 
wound healing is mediated, in part, via EGFR signalling in keratinocytes (247). 
 
Hence, RHBDF2 appears capable of regulating EGFR signalling through two separate 
pathways by controlling the shedding of pro-EGF targeting for ERAD and also by 
controlling the rate of that shedding through the regulation of ADAM17 maturation 
and transit from the ER into the Golgi.  
 
1.11.  Hypothesis and Aims 
 
The high incidence of gastrointestinal cancers in the general population and the 
presence of premalignant dysplastic precursor lesions in the gastrointestinal tract make 
the gastrointestinal tract an ideal environment for the study of cancer clonality and 
clonal expansion. Moreover, the model proposed by Nowell on clonal evolution in 
neoplasia, caused by further accumulation of mutations in the subclones of the original 
cancer as a result of genetic instability, still needs to be studied in further detail in 
gastrointestinal cancers. Therefore, the main areas of interest for this project are pre-
malignant lesions and gastric adenocarcinoma of the human stomach, and dysplastic 
lesions and invasive squamous cell cancer of the oesophagus.  
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Project 1: Clonal expansion in the human stomach 
 
McDonald and colleagues established that intestinal metaplastic glands in the stomach 
are clonal and contain multiple stem cells, which are able to spread by fission (248). 
These workers suggested that the mechanism of gland fission causes field 
cancerisation in the stomach. Following on from this work, the hypothesis of the first 
project presented here is that gastric adenocarcinoma progresses through a series of 
genetic events arising from a founder mutation.  
 
The aims of this project were: 
1. To demonstrate the clonal origins of dysplasia from IM 
2. To determine the clonal architecture of GA 
3. To assess clonal expansion in HDGC  
 
Project 2: Clonal expansion in oesophageal squamous cell cancer 
 
Nicholson and colleagues observed clonal patches in the normal squamous oesophagus 
ranging from around 30µm to about 1mm (222). They suggested that if Clayton’s 
observations are applicable to their findings then it is possible that lateral replacement 
of the stem cell pool along the basal layer of the squamous epithelium occurs and that 
a process analogous to niche succession also takes place in the normal oesophagus 
(222, 229). Moreover, Mandard and colleagues observed the expansion of independent 
TP53 mutated clones in an oesophageal squamous cell cancer patient in areas of 
oesophagitis and cancer. These workers suggested that field cancerisation occurs prior 
to malignant transformation in the human oesophagus (162). Following on from this 
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work, the hypothesis of the second part of the project presented here was that 
oesophageal squamous cell cancer occurs by a process of field cancerisation of the 
oesophagus. 
 
The aims of this project were: 
1. To assess the mutation frequencies of genes known to be involved in the development 
of OSCC 
2. To determine the clonal architecture of OSCC 
 
Project 3: Investigating iRhom2 and ADAM17 in sporadic and tylosis oesophageal 
squamous cell cancer 
 
Tylosis with oesophageal cancer (TOC) is a rare familial syndrome inherited in an 
autosomal-dominant manner, which can be associated with a high risk for oesophageal 
SCC development (up to a 95% by the age of 65) (237-239). Blaydon and colleagues 
identified the mutation responsible for TOC as the inactive rhomboid protease 
RHBDF2 (iRhom2) (163). The protein has been found to localize to the ER and to 
promote ER-associated degradation of RHBDL2 ligands such as EGF (245).  
 
RHBDF2 knock-out mice (RHBDF2-/-) studies showed that RHBDF2 is critical for the 
TNFα convertase (TACE) ADAM17 maturation and trafficking from the endoplasmic 
reticulum (ER) to the golgi (243, 246). RHBDF2 mutations seen in TOC appear to be 
gain of function mutations, as EGF dysregulation was observed in TOC keratinocytes 
(163). Following on from this work, the hypothesis of this project is to investigate if 
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TOC associated RHBDF2 mutations persist during tumour progression in TOC and to 
determine RHBDF2 localisation in the oesophageal tumour. 
 
The aims of this project are: 
1. To characterise the mutational state of RHBDF2 in sporadic OSCC 
2. To determine if RHBDF2 germline gain of function mutations persist during tumour 
progression in TOC 
3. To assess the localisation of RHBDF2 and ADAM17 in sporadic OSCC and TOC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 82 
2.  Materials and Methods 
 
2.1. Patients 
 
2.1.1. Patients from Chapter 3.2.1 
 
Intestinal metaplastic and dysplastic formalin-fixed paraffin-embedded and frozen 
specimens were obtained from patients undergoing resection for either GA or high-
grade dysplasia and from pathology archives. A total of 23 patient specimens were 
used in this study. Ethical approval was sought and obtained as per United Kingdom 
Human Tissue Act (2006 from UCH, reference 07/Q1604/17) and Hikone Municipal 
Hospital (Japan) regulations. The histology of each specimen was confirmed by 2 
pathologists (N.A.W. and M.R.J.). All specimens showed IM surrounding or in 
between large areas of dysplasia (or early gastric cancer) and this was consistent 
through multiple blocks from each patient. 
 
2.1.2. Patients from Chapter 3.2.2 
 
Intestinal metaplastic, dysplastic and gastric adenocarcinoma formalin-fixed paraffin-
embedded specimens were obtained from patients undergoing resection for GA and 
from pathology archives. A total of 51 patient specimens (age range 29-85) were used 
in this study. Ethical approval was sought and obtained as per United Kingdom 
Human Tissue Act (2006 from UCH, reference 07/Q1604/17). The histology of each 
specimen was confirmed by 2 pathologists (N.A.W. and M.R.J.). All specimens 
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showed gastric adenocarcinoma and this was consistent through multiple blocks from 
each patient. 
 
2.1.3. Patients from Chapter 3.2.3 
 
Normal gastric epithelium and hereditary diffuse-gastric cancer formalin-fixed 
paraffin-embedded specimens were obtained from patients undergoing full 
gastrectomy and from pathology archives. A total of 5 patient specimens from 2 
different families (age range 22-59) were used in this study. Ethical approval was 
sought and obtained as per United Kingdom Human Tissue Act (2011 from the Royal 
London Hospital, reference 11/L0/1613). The histology of each specimen was 
confirmed by 2 pathologists (N.A.W. and J.C.A.). All specimens considered for this 
study showed diffuse-gastric cancer areas and this was consistent through multiple 
blocks from each patient. 
 
2.1.4. Patients from Chapter 4 and Chapter 5 
 
Normal oesophageal squamous epithelium, low grade dysplasia, high grade dysplasia 
and oesophageal squamous cell cancer formalin-fixed paraffin-embedded specimens 
were obtained from patients undergoing oesophageal resection and from pathology 
archives. A total of 34 patient specimens were used in this study. Ethical approval was 
sought and obtained as per United Kingdom Human Tissue Act (2006 from UCH, 
reference 07/Q1604/17; 2011 from the Royal London Hospital, reference 11/L0/1613; 
and MREC 02/8/1). The histology of each specimen was confirmed by a minimum of 
2 pathologists (N.A.W., M.R.J. and J.C.A.). All specimens considered for this study 
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showed oesophageal squamous cell carcinoma areas and this was consistent through 
multiple blocks from each patient. 
 
2.2. Tissue macrodissection  
 
Five serial sections from paraffin blocks (4µm) of each specimen were prepared. All 
sections were cut onto normal glass slides and were either left overnight at 37°C or 
incubated for 2 hours at 65°C. The slides were dewaxed and then first slide for each 
patient was stained with Haematoxylin and Eosin (H&E) and mounted (see full 
methods in 2.7.1). Suitable cancer areas for dissection were identified using the H&E 
slide. The same areas were identified on slides 2-5 and dissected using needle 
macrodissection (BD Microlance 3, NJ, USA) and immersed in 30-50 µl of proteinase 
K solution (Arcturus Bioscience, Mt View, California, USA). Negative control tubes 
containing proteinase K solution and no macrodissected material were included. Tubes 
were then centrifuged at 4.5 g for 1 min and incubated at 65°C during 16hours, 
followed by a 10 min incubation at 95°C, which denatured the proteinase K. The tubes 
were centrifuged at 4.5 g for 1 min and the lysate was either used for PCR or stored at 
-20°C. 
 
2.3. Laser-capture microdissection 
 
Seven serial sections from paraffin blocks of each specimen were prepared. Section 1 
(4µm) was cut onto a normal glass slide, and section 2-7 (6µm) were cut onto 
P.A.L.M. MembraneSlide 1.0 PEN slides (Zeiss Microimaging, Munich, Germany). 
All sections were either left overnight at 37°C or incubated for 2 hours at 65°C. The 
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slides were dewaxed and then the normal slide for each patient was stained with H&E 
and mounted (see full methods in 2.7.1). The P.A.L.M. membrane slides were stained 
with methylene green (2%; Sigma, Poole, UK) and then air-dried. Suitable crypts or 
cancer areas for dissection were firstly identified on the H&E slide and were then 
located on the P.A.L.M. membrane slides (slides 2-7). Individual crypts or cancer 
areas were cut out from the laser capture slides and catapulted into the adhesive caps 
of eppendorfs using the P.A.L.M. Laser Microdissection system. Catapulted sections 
on the cap were immersed in 14 µl of proteinase K solution (Arcturus Bioscience, Mt 
View, California, USA). Negative control tubes containing proteinase K solution and 
no laser capture material were included. Tubes were then centrifuged at 4.5 g for 1 min 
and incubated at 65°C during 16hours, followed by a 10 min incubation at 95°C, 
which denatured the proteinase K. The tubes were centrifuged at 4.5 g for 1 min and 
the lysate was either used for PCR or stored at -20°C. 
 
2.4. Genomic PCR Sequencing  
 
The needle macrodissected lysate was used to screen for mutations via nested PCR 
reactions in a variety of genes according to the cancer type. The total gene list that we 
screened for is: APC (adenomatous polyposis coli mutation cluster region), TP53 
(exons 5–8), KRAS (codons 12 and 13), CTNNB1 (B-catenin, exon 11), CDKN2A 
(p16, exon 2), PTEN (phosphatase and tensin homolog exons 5, 6, and 8), PIK3CA 
(exons 9 and 20), NRF2 (exon 2) and RHBDF2 (exons 5 and 6). Primer and reaction 
conditions are shown in Table 6.1 in the Appendix. After nested PCR reactions the 
samples were run on a 1% Agarose Gel (Ultrapure Agarose, Invitrogen) made with 
10% TBE Buffer (Electran, VWR). All successful reactions were then subjected to an 
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ExoSAP-IT reaction following manufacturer protocol (Affymetrix) in order to remove 
any excess of nucleotides and primers from the PCR product. The samples were 
subsequently sequenced using BigDye Terminator v3.1 reaction mix (Applied 
Biosystems) and 5x Sequencing Buffer (Applied Biosystems) following manufacturer 
protocol. Purification of sequencing products for capillary electrophoresis was 
performed using ethanol/EDTA precipitation. All samples were mixed with 2.5µl of 
125mM EDTA pH:6 (Sigma-Aldrich, USA) and 30µl of 100% ethanol. After a 15 
minute incubation the mixture was centrifuged in the plate spinner at 4000rpm for 30 
minutes. The supernatant with unincorporated dyes and primers was subsequently 
removed by inverting the plate and spinning the samples at 800rpm for 20 seconds. 
The pellet was washed by adding 120µl of 70% ethanol into each sample and spinning 
the samples at 4000rpm for 10 minutes. The supernatant removal process was then 
repeated and samples were loaded onto the ABI PRISM TM 3130xl Genetic Analyser 
by adding 10µl of deionized Hi-Di Formamide (stored at -20C, Applied Biosystems) 
and sealing the well with a 3100 Genetic Analyser plate septa 96-well (Applied 
Biosystems). 
 
All of the genes screened for account for approximately 75% of all somatic mutations 
previously reported in either gastric adenocarcinomas or oesophageal squamous cell 
carcinoma according to the catalogue of somatic mutations in cancer (COSMIC) 
database (www.sanger.ac.uk/genetics/cgp/cosmic). Most mutations within the 
COSMIC database have been identified in cancer specimens and may be late events in 
the dysplasia:carcinoma sequence. After a mutation was detected in tissue lysate, 
every laser-captured area would then be screened individually for that mutation using 
the nested PCR protocol. 
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2.5. Microsatellite Loss of Heterozygosity Analysis 
 
Microsatellite Loss of heterozygosity (LOH) analysis was performed on individual 
cancer areas lysates using a multiplexed microsatellite assay. Eleven highly 
polymorphic microsatellites, located on chromosomes 3p (FHIT), 5q (APC), 9q 
(CDKN2A), 17p (TP53), 17q, and 18q (SMAD4), were amplified in 3 separate 
reactions using a multiplex PCR kit (Qiagen, Crawley, UK). Constitutional DNA was 
extracted from normal smooth muscle. Marker accession numbers and primer and 
reaction details are shown in Table 6.2 in the Appendix. Primers were tagged at the 5’ 
end with either a FAM (tetrachloro-6-carboxyfluorescin) or a HEX (hexachloro-6-
carboxyfluorescin) fluorescent marker. Successfully amplified PCR products were 
analyzed on an ABI 3100 Genetic analyser (Applied Biosystems) by adding 7.6µl of 
deionized formamide (stored at -20C, Applied Biosystems) and 0.4µl of ROX500 
(Applied Biosystems) to each sample and sealing the well with a 3100 Genetic 
Analyser plate septa 96-well (Applied Biosystems). LOH was calculated measuring 
the area under curve using Peak Scanner software (Applied Biosystems). LOH was 
then considered present if the area under 1 allelic peak was more than twice that of the 
other, after normalizing the peak areas relative to the constitutional DNA. 
 
 
2.6. DNA preparation and pyrosequencing 
 
As per personal communication, Dr J. Risk, Dr A.Ellis and Dr J.K Field performed 
these experiments at the Department of Molecular & Clinical Cancer Medicine, 
Institute of Translational Medicine. For full methods please refer to Blaydon et al 
(163).  
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DNA was extracted from frozen tumour tissue taken from surgical resections from 
patients 33 and 34 using resin-binding technology (Nucleon kit from Scotlab) and 
ethanol precipitation.  These two samples were assessed for LOH at the listed 
microsatellites (D17S515, D17S929, D17S186, D17S1839, D17S1603, D17S785, 
D17S801 and D17S1790) using pyrosequencing. PCR primers and a pyrosequencing 
primer were designed to cover the c.557T>C RHBDF2 mutation site. Hot-start PCR 
was carried out with 50 ng/ml of DNA template in each reaction (PCR conditions: 94C 
for 5 min; 35 cycles of 94C for 30 s, 65C for 40 s, and 72C for 30 s; and a final 
extension of 72C for 10 min). Confirmation of PCR product quality and freedom from 
contamination was established on 2% agarose gels with ethidium bromide staining. 
Pyrosequencing was carried out with the PSQ 96MA System (Biotage), including 
Single-Stranded Binding Protein (PyroGold reagents), according to the manufacturers’ 
protocol.   
 
Primers Used for Pyrosequencing Assay: 
- Forward primer (biotin-labelled): GGACCCTAATGGCTCTGCTT 
- Reverse primer: ATGTCCATCTCCTCCGGGT 
- Pyrosequencing primer: GCCAGCGGATCCACA  
 
2.7. Histological staining and immunohistochemistry 
 
2.7.1. Haematoxylin and Eosin staining 
 
The slides were dewaxed in xylene (twice for 2 minutes) and rehydrated through 
decreasing ethanol concentrations (100%, 100%, 90% and 70%) to water. Slide 1 was 
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stained with Haematoxylin (1-5 minutes), 1% Acid Alcohol (2 seconds) and Eosin (2 
minutes) and then mounted with Eukitt quick-hardening mounting medium (FLUKA 
BioChemika, Sigma-Aldrich, USA). 
 
2.7.2. AB-PAS staining 
 
This staining was performed using the Leica Autostainer for special staining by the 
BICMS pathology department. In brief, the slides were dewaxed in xylene, rehydrated 
in IMS, stained in 1% Alcian Blue pH:2.5 for 30 minutes, washed, treated with 1% 
Periodic Acid solution for 5 minutes, washed, stained in Schiffs Reagent for 10 
minutes and washed. Finally, the slides were stained in Gills Haematoxylin for 2 
minutes, washed, dipped in 1% Acid Alcohol, dehydrated in IMS, cleared in Xylene 
and finally mounted in DPX. 
 
2.7.3. E-cadherin staining 
 
This staining was performed using the Leica Autostainer for special staining by the 
BICMS pathology department. The E-cadherin primary antibody (NCL-L-E-Cad, 
Leica Biosystems) was used at the recommended concentration, 1:25, for 30 minutes 
at 25 °C after epitope retrieval at pH 6. After the staining procedure, the slides were 
then dehydrated and mounted in DPX. 
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2.7.4. RHBDF2 staining 
 
The BICMS pathology department optimised the RHBDF2 primary antibody 
(HPA018080, Sigma). They later performed the staining on all slides. In brief, the 
slides were dewaxed in xylene, rehydrated in IMS and pretreated in a pH 6 Buffer for 
25 minutes in the microwave. The primary antibody was used at a concentration of 
1:100 followed by an RTU kit and 2 component DAB procedure. The slides were then 
dehydrated and mounted in DPX. 
 
2.7.5. ADAM17 staining 
 
The BICMS pathology department optimised the ADAM17 primary antibody (ab2051, 
Abcam). They later performed the staining on all slides. In brief, the slides were 
dewaxed in xylene, rehydrated in IMS and pretreated in a pH 8.1 Buffer for 35 
minutes in the microwave. The primary antibody was used at a concentration of 1:100 
followed by vector RTU and 2 component DAB procedure. The slides were then 
dehydrated and mounted in DPX. 
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3. Clonal expansion in the human stomach 
 
 
3.1. Introduction 
 
Gastric carcinoma is the fourth most common cancer and the second leading cause of 
cancer death worldwide (168). Most cases (90%) are sporadic in nature and belong to 
an intestinal type of cancer (172), called gastric adenocarcinoma (GA). However, a 
minority of cases show evidence of inherited susceptibility to the disease and are 
diagnosed with hereditary diffuse gastric cancer (HDGC) (172). 
 
GA is thought to be the culmination of a sequential chain of events initiated by chronic 
inflammation.  The replacement of normal gastric glands by glands of an intestinal 
crypt phenotype, intestinal metaplasia (IM), was first linked to GA in 1938, when a 
high frequency of GA was observed in Chinese patients with high incidence of ‘goblet 
cell metaplasia’ (249). The development of IM, as a result of Helicobacter pylori 
infection, is now known to be a major risk factor for GA.  
 
Work published by our laboratory has shown that human IM glands are clonal and 
expand by crypt fission (248); IM might represent field cancerisation in the human 
stomach (72, 248). Moreover, the fields of dysplasia associated with GA could 
potentially be initiated by multiple mutational events or by the clonal expansion of one 
single dysplastic gland carrying a single mutation. Other recent work published by our 
laboratory has indicated that familial adenomatous polyposis (FAP)–associated 
colorectal adenomas as well as some sporadic lesions are polyclonal (16) and we have 
independent results that Barrett’s oesophagus may originate from multiple clones 
(157); it remains to be seen if polyclonality also occurs in GA.  
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The current dogma for GA development proposes a stepwise progression through the 
Metaplasia-Dysplasia-Carcinoma sequence (MCS) and that the mutation and selection 
theory of cancer development also holds true for GA (187). Furthermore, the dogma 
proposes that as a stem cell acquires more mutations, its progeny becomes more likely 
to develop into a neoplasm (153). This has led to the hypothesis that specific genes 
become mutated at specific stages in the progression to cancer. Whether it is possible 
to establish an order of mutations in which specific genetic events occur during the 
MCS in the development of GA remains open to question (64).   
 
The part played by field cancerisation, the process by which a field of phenotypically-
normal epithelial cells is preconditioned for neoplastic development, in GA 
development remains unclear (250). Clones of cells with mutations that confer a 
selective advantage have the potential to develop into carcinoma within a field; 
following surgical removal of the primary carcinoma any mutated clones remaining in 
unresected fields will provide a reservoir for the possible development of recurrent 
tumours.  
 
The clonal origin of many tumours is unclear because of incorrect assumptions made 
especially in the application of X-inactivation analysis of tumours. This was 
demonstrated by in situ hybridization in an XO/XY mosaic individual that proved the 
polyclonal origin of colonic microadenomas (49). Nowell, in 1976, proposed a model 
of clonal evolution in neoplasia where tumours originate from a single cell. This 
model, thought to fit most cancer types, proposed that the originating mutated clone 
acquired further mutations as a result of genetic instability and eventually led to a 
tumour composed of subclones with a higher selective advantage to that of the original 
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tumour initiating clone (88). However, differences in the clonal origin of cancer in 
different organs can be due to a number of factors, including different mutation rates, 
clonal competition, undetected founder mutations or to underlying chronic diseases or 
germline mutations, each of which can influence field cancerisation (251).  
 
To date, many markers of genetic progression of gastrointestinal tumours have been 
identified, such as Kirsten rat sarcoma viral oncogene homolog (KRAS), Adenomatous 
polyposis coli (APC) and Tumour protein 53 (TP53) (252). These progression 
markers, or driver mutations in cancer development, are currently used to assess the 
mutational status of gastrointestinal cancer patients, and are associated with the 
heterogeneity in tumour sizes and the rate of tumour development (253). Nevertheless, 
previous studies have not taken under consideration the spatial distribution of 
mutations or the different mutated populations within the tumour, which can be carried 
out by microdissection using laser-capture microdissection (LCM) techniques.  
 
Therefore, to understand the clonal origins and progression of dysplasia and GA, the 
presence of single or multiple clones in pre-neoplastic and malignant epithelium needs 
to be assessed alongside clonal analysis of the lineage relationships and mapping of 
the expansion of mutated clones within the tumour. This will provide insight into the 
stepwise progression model, namely the order of mutations, proposed for GA 
development (153, 187). 
 
HDGC is caused by germline mutations in the cell-cell adhesion protein E-cadherin 
(CDH1) (254). This protein is the central component of epithelial cell-cell adhesion 
and, hence, is required for the maintenance of the integrity of epithelial layers (178). 
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HDGC is characterised as an autosomal dominant cancer syndrome where the second 
hit is normally methylation of the CDH1 gene, leading to E-cadherin loss and cancer 
development (181). However, not all CDH1 mutations cause complete inactivation of 
E-cadherin and CDH1 germline mutations present with incomplete penetrance, having 
a 70% lifetime risk of developing HDGC (184). Therefore, CDH1 germline mutations 
are an indication for total gastrectomy in these patients (185).  
 
Khayat and colleagues used FISH and immunohistochemistry on 20 gastric cancer 
samples to suggest that TP53 deletion, chromosome 17 aneusomy and TP53 mutations 
may be implicated in the development of diffuse and intestinal-type gastric carcinomas 
(204). Ranzani and colleagues suggested that TP53 mutations might be a transitional 
step between metaplasia and dysplasia in GA, but that such mutations may be a late 
event in diffuse-type gastric carcinoma leading to tumour progression (205). Their 
results were obtained from PCR-sequencing and immunohistochemistry. Shiao and 
colleagues also suggested that TP53 mutations, including gene silencing by 
methylation, played an important role during gastric carcinogenesis regardless of 
histology (255). The identification of mutations and methylation changes in CDH1 is 
very difficult to assess and previous studies have shown that TP53 mutations are 
relatively common in HDGC. Therefore, in order to assess clonal expansion in diffuse 
gastric carcinomas in this study the presence or absence of TP53 mutations was 
investigated. 
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3.1.1. Hypothesis and Aims 
 
The hypothesis for this project is: GA progresses through a series of genetic events 
arising from a founder mutation.  
 
The aims of this study were: 
1. To demonstrate the clonal origins of dysplasia from IM 
2. To determine the clonal architecture of GA 
3. To assess clonal expansion in HDGC 
 
3.2. Results 
 
3.2.1. The clonal origins of dysplasia from intestinal metaplasia 
 
In order to investigate the origins of dysplasia within the human stomach, areas of 
dysplasia from each patient was needle macrodissected and screened for mutations in 
genes commonly mutated in GA, (for full methods see 2.1.1, 2.2 and 2.4): APC (MCR 
region), CTNNB1, KRAS, CDKN2A, TP53 and PTEN. Overall, these genes account for 
approximately 75% of all somatic mutations previously reported in GA, according to 
the catalogue of somatic mutations in cancer (COSMIC) database 
(www.sanger.ac.uk/genetics/cgp/cosmic, 16/05/2013).  From the 23 patients screened, 
3 showed a mutation common to both metaplasia and dysplasia (Table 3.1). 
Interestingly, 20 patients did not present any mutations in the dysplasia (72).  
 
 
 96 
Table 3.1. Only three patients had lesions with mutations in the dysplasia. This 
table shows the mutations found in the dysplastic gastric epithelium of 3 out of the 23 
patients screened. Dr Lydia Gutierrez-Gonzalez carried out the work on patient 3 and 
the data is presented in Gutierrez-Gonzalez et al (72). 
 
 
Patient Gene mutated Mutation 
Patient 1 APC c.4683insA 
Patient 2 APC c.4667insA 
Patient 3 TP53 c.G643A 
 
 
In order to determine how dysplasia originates and spreads in the human stomach, 
LCM was performed on individual hyperplastic, metaplastic and dysplastic glands. 
Nested PCR sequencing was then carried out for the region in the mutation cluster 
region (MCR) of APC. 
 
All hyperplastic glands were APC-wild type (for patients 1 and 2) and TP53-wild type 
(in the case of patient 3, see Table 3.2). The vast majority of IM glands were also wild 
type (83.3%-95.8%); however, IM glands were occasionally found to contain the 
mutation that was present in the dysplasia (4.2%-16.6%). All high-grade dysplasia 
(HGD) glands were mutated (Table 3.2).  
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Table 3.2. Most metaplastic glands are wild type and all dysplastic glands are 
mutated. Summary table of the data collected from patients 1, 2 and 3 via laser-
capture microdissection of individual gastric glands with varying histology: 
hyperplastic; metaplastic; and dysplastic glands. 
 
 
                                       Hyperplastic           Metaplastic         Dysplastic 
Patient Wild type (%) 
Mutated 
(%) 
Wild type 
(%) 
Mutated 
(%) Wild type 
Mutated 
(%) 
1 10 (100) 0 35(83.3) 7 (16.6) 0 22(100) 
2 15 (100) 0 73 (93.6) 5 (6.4) 0 67 (100) 
3 14 (100) 0 49 (95.8) 3 (4.2) 0 158(100) 
 
 
 
 
The set of experiments presented here was performed using tissue from patients 1 and 
2. Every individually microdissected gland was mapped according to both its 
phenotype and its genotype. Tissue from patient 1 showed an APC mutation 
c.4683insA; strips of gastric epithelium from this patient can be seen in Figures 3.1, 
3.2 and 3.3. Tissue from patient 2 presented with an APC mutation c.4667insA; three 
strips of gastric epithelium from this patient can be seen in Figure 3.4. 
 
Wild type (WT) microdissected hyperplastic and IM glands were observed next to 
large areas of APC-mutated HGD glands (Figures 3.1 and 3.2). All of the figures 
include the previous serial section to the post-LCM section stained with haematoxylin 
and eosin to act as a guide for laser capture, and the highlighted areas are then seen in 
higher power. The corresponding raw data indicating the phenotype and the matching 
genotype for each gland can be found in Tables 3.3 and 3.4.  
 
WT hyperplastic and IM glands were again found to surround areas of mutated HGD 
glands in a third strip of gastric epithelium from patient 1 (Figure 3.3). However, one 
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IM gland showed the same APC-mutation found in the HGD, the APC mutation 
c.4683insA. The corresponding raw data is given in Table 3.5. 
 
All HGD glands from patient 2 showed the c.4667insA mutation and were, therefore, 
all clonal. The IM glands surrounding the fields of HGD were found to be WT (Figure 
3.4). The corresponding raw data is presented in Table 3.6. 
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Table 3.3. Association of the identified mutation with histology shows wild type 
intestinal metaplastic glands adjacent to large areas of mutated dysplastic glands 
in a strip of gastric epithelium from patient 1, block 6 strip 1. WT, wild type. 
 
 
Patient 1 Histology c.4683insA 
Block 6:1 
 
APC 
1 Metaplastic WT 
2 Metaplastic WT 
3 Metaplastic WT 
4 Metaplastic WT 
5 Metaplastic WT 
6 Metaplastic WT 
7 Metaplastic WT 
8 Metaplastic WT 
9 Metaplastic WT 
10 Metaplastic WT 
11 Metaplastic WT 
12 Metaplastic WT 
13 Metaplastic WT 
14 Metaplastic WT 
15 Metaplastic WT 
16 Metaplastic WT 
17 Metaplastic WT 
18 Metaplastic WT 
19 Metaplastic WT 
20 Metaplastic WT 
21 Metaplastic WT 
22 Metaplastic WT 
23 Metaplastic WT 
24 Metaplastic WT 
25 Metaplastic WT 
26 Metaplastic WT 
27 Metaplastic WT 
28 Metaplastic WT 
29 Metaplastic WT 
30 Dysplastic MUTATED 
31 Dysplastic MUTATED 
32 Dysplastic MUTATED 
33 Dysplastic MUTATED 
34 Dysplastic MUTATED 
35 Dysplastic MUTATED 
36 Dysplastic MUTATED 
37 Hyperplastic WT 
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Table 3.4. Association of the identified mutation with histology shows wild type 
intestinal metaplastic glands adjacent to large areas of mutated dysplastic glands 
in a second strip of gastric epithelium from patient 1, block 8 strip 3. WT, wild 
type; --, denotes insufficient DNA to obtain results. 
 
 
Patient 1 Histology c.4683insA 
Block 8:3 
 
APC 
1 Metaplastic WT 
2 Metaplastic WT 
3 Metaplastic WT 
4 Metaplastic WT 
5 Metaplastic WT 
6 Metaplastic WT 
7 Metaplastic WT 
8 Metaplastic WT 
9 Metaplastic WT 
10 Metaplastic WT 
11 Metaplastic WT 
12 Metaplastic WT 
13 Metaplastic WT 
14 Metaplastic WT 
15 Metaplastic WT 
16 Metaplastic WT 
17 Metaplastic WT 
18 Metaplastic WT 
19 Dysplastic MUTATED 
20 Metaplastic WT 
21 Metaplastic WT 
22 Metaplastic WT 
23 Metaplastic WT 
24 Metaplastic -- 
25 Metaplastic WT 
26 Dysplastic MUTATED 
27 Dysplastic MUTATED 
28 Dysplastic MUTATED 
29 Dysplastic MUTATED 
30 Dysplastic MUTATED 
31 Dysplastic MUTATED 
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Table 3.5. Association of the identified mutation with histology suggests the clonal 
origins of dysplasia from intestinal metaplasia in a third strip of gastric 
epithelium from patient 1, block 9 strip 2. Dr Lydia Gutierrez-Gonzalez obtained 
the remaining of the sequencing data for this block (72). WT, wild type. 
 
 
Patient 1 Histology c.4683insA 
Block 9:2 
 
APC 
1 Dysplastic MUTATED 
2 Dysplastic MUTATED 
3 Dysplastic MUTATED 
4 Dysplastic MUTATED 
5 Metaplastic WT 
6 Dysplastic MUTATED 
7 Dysplastic MUTATED 
8 Metaplastic WT 
9 Metaplastic WT 
10 Metaplastic WT 
11 Metaplastic WT 
12 Metaplastic WT 
13 Metaplastic WT 
14 Hyperplastic WT 
15 Metaplastic MUTATED 
16 Metaplastic WT 
17 Metaplastic WT 
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Figure 3.4. Analysis of sequential strips of gastric epithelium from patient 2 
suggests that large areas of dysplasia are clonal. (A, C, E) H&E pictures of entire 
sections of gastric mucosa showing gastritis, intestinal metaplasia (IM) and high grade 
dysplasia (HGD) from patient 2. (B, D, F) serial sections showing post laser-capture 
microdissection (LCM). Yellow areas represent APC WT IM glands and dark blue 
areas represent APC mutated HGD glands. (G and H) Two representative traces 
showing the APC mutation c.4667insA (G), an APC WT trace (H). (I) Key for patient 
2 on post LCM section. 
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Table 3.6. Association of the identified mutation with histology suggests that large 
areas of dysplasia are clonal in sequential strips of gastric epithelium from 
patient 2, block A20-1 strips 4, 6 and 7. WT, wild type. 
 
 
 
Patient 2 Histology c.4667insA 
Block A20-1: 4 
 
APC 
  
 
   1 Metaplastic WT 
2 Dysplastic MUTATED 
3 Dysplastic MUTATED 
4 Metaplastic WT 
5 Dysplastic MUTATED 
6 Dysplastic MUTATED 
7 Dysplastic MUTATED 
8 Dysplastic MUTATED 
9 Dysplastic MUTATED 
10 Metaplastic WT 
   Block A20-1: 6 Histology c.4667insA 
  
APC 
   1 Dysplastic MUTATED 
2 Dysplastic MUTATED 
3 Dysplastic MUTATED 
4 Metaplastic WT 
5 Metaplastic WT 
6 Metaplastic WT 
7 Dysplastic MUTATED 
8 Dysplastic MUTATED 
9 Dysplastic MUTATED 
   Block A20-1: 7 Histology c.4667insA 
  
APC 
   1 Dysplastic MUTATED 
2 Dysplastic MUTATED 
3 Dysplastic MUTATED 
4 Dysplastic MUTATED 
5 Dysplastic MUTATED 
6 Dysplastic MUTATED 
7 Dysplastic MUTATED 
8 Dysplastic MUTATED 
9 Dysplastic MUTATED 
10 Dysplastic MUTATED 
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3.2.2. Clonal expansion in gastric adenocarcinoma 
 
Common cancer-associated mutations are found in gastric adenocarcinomas and 
occur as a single event 
 
To assess the clonal architecture of GA within the human stomach, one carcinoma area 
from 51 GA patients was needle macrodissected and screened for mutations in genes 
commonly associated with cancer: APC (MCR region); CTNNB1; KRAS; CDKN2A; 
TP53; PTEN; and PIK3CA. From these 51 GA patients, 31.4% (16/51) had a single 
mutation in the cancer (Table 3.7, see Table 7.3 in Appendix for full summary of the 
clinicopathological features). 
 
Next, we compared the frequencies of mutations found in GA with those previously 
reported in the COSMIC database (www.sanger.ac.uk/genetics/cgp/cosmic 
16/05/2013) to confirm we had sufficient coverage of known mutations (see Table 3.8 
for full details on the patients presenting mutations). The frequency of mutation for 
each gene was: APC, 6.5% (3/46); CDKN2A, 2.6% (1/38); TP53, 23.4% (11/47); 
CTNNB1, 2.2% (1/46); 1 in KRAS, 2.3% (1/43); PTEN, 0% (0/51); and PIK3CA, 0% 
(0/24). All of our mutation frequencies were comparable to previous reports in the 
COSMIC database (Figure 3.5) (256). Even though the majority of mutations found in 
TP53 (7 out of the 11 mutations) occurred in exon 8, there has been no previously 
published correlation between specific exon 8 mutations and GA. Therefore, this high 
mutation frequency in exon 8 may be either cohort-specific or due to an increased 
hotspot in TP53 exon 8 in GA. 
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It is important to note that during the course of the screening, some DNA samples 
were exhausted and, unfortunately, some of the blocks were unavailable and could not 
be retrieved from UCH. The white areas in Table 3.7 represent insufficient DNA to 
obtain results. Therefore, the percentages of mutations per genes seen in Figure 3.5 
were calculated for the total number of patients for which there was enough DNA; 
samples with insufficient DNA were excluded. The screening for PIK3CA was not 
included in Table 3.7 or in Figure 3.5 because there was only enough DNA to do the 
nested-PCR sequencing for approximately 50% of the samples. 
 
Interestingly, only 1 GA (1.96%, 1/51) showed two independent functional mutations 
(TP53 and CTNNB1). This indicated that either a functional mutation occurs as a 
single event in the development of GA or that other genes not included in the 
screening may play an important role in the development of GA. This lack of 
mutations in a large percentage of the cohort was also found when assessing clonal 
expansion in patients with dysplasia in 3.2.1.  
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Table 3.7. Summary of mutations in genes selected from the COSMIC database 
for gastric adenocarcinoma. Screening of 51 gastric adenocarcinomas (GA) for 
mutations within genes accounting for 75% of known mutations in GA (256): APC, 
CTNNB1, KRAS, CDKN2A, TP53 and PTEN. White denotes insufficient DNA to 
obtain results; light grey stands for WT and dark blue stands for mutated sample. The 
red rectangles highlight the six samples analysed by laser-capture microdissection. 
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Table 3.8. Summary of mutations identified in a cohort of gastric 
adenocarcinoma. 31.4% (16/51) of patients presented a single mutation in gastric 
adenocarcinoma and only one sample (1.96%, 1/51) had two mutations. The patients 
highlighted in red denote the six samples analysed by laser-capture microdissection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient	   Gene	   Mutation	  
7	   APC	   c.G4729A	  p.Glu1576Lys	  
8	   CTNNB1	   c.A121G	  p.Thr41Ala	  
8	   TP53	   c.G743A	  p.Arg248Gln	  
10	   TP53	   c.C493T,p.Gln165	  Stop	  
13	   TP53	   c.C916T	  p.Arg306STOP	  
17	   TP53	   c.A488G	  p.Tyr163Cys	  
19	   TP53	   c.C916T	  p.Arg306STOP	  
20	   APC	   c.C4123A	  His1375Tyr	  
22	   TP53	   c.C455T	  p.Pro152Leu	  
27	   TP53	   c.G818A	  p.Arg273His	  
28	  
29	  
APC	  
TP53	  
c.C4285T	  p.Gln1429STOP	  
c.C844G	  p.Arg282Gly	  
33	   TP53	   G14439A	  INTRON	  SPLICE	  SITE	  
34	   TP53	   c.G882T	  p.Glu294Asp	  
39	   CDKN2A	   c.G207C	  p.Glu69Asp	  
49	   KRAS	   c.G38A	  p.Gly13Glu	  
51	   TP53	   c.G824A	  p.Cys275Tyr	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Figure 3.5. Mutation frequencies are comparable to reports for gastric 
adenocarcinoma held in the COSMIC database. Statistical analysis of results 
obtained from the screening of 51 gastric adenocarcinoma patients. (A-E) Tables show 
the frequency of mutations within APC (A), CTNNB1 (B), KRAS (C), TP53 (D) and 
CDKN2A (E) in our patient cohort compared with the COSMIC database (256). (F) 
Table showing the percentages of mutated samples. P value was obtained by Chi-
square test using Yates correction (two-tailed). 
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Gastric adenocarcinoma is clonal  
 
To assess clonal expansion in GA, six patients were selected and analysed by LCM. 
These were patients 8, where the GA showed two independent functional mutations, 
10, 22, 27, 33 and 51 (see mutational details for the patients highlighted in red in 
Table 3.8). LCM was then performed for areas of chronic gastritis, IM, dysplasia and 
carcinoma, where present in the available tissue for each patient (see Table 3.9). 
 
Table 3.9. Randomly selected patients for laser-capture microdissection. List of 
the blocks of gastric epithelium used for laser-capture microdissection from the six 
patients selected randomly.  
 
Patient	  
Genes	  
mutated	  
Block	  
number	   Histopathological	  phenotypes	  present	  
8	   TP53	  	   6	   Gastritis	  and	  IM	  
	  	   	  +	  CTNNB1	   7	   GA	  
	  	   	  	   8	   GA	  
10	   TP53	   5	   Gastritis	  ,	  IM	  and	  GA	  
22	   TP53	   6	   GA	  
27	   TP53	   3	   Squamous	  epithelium,	  gastritis,	  IM,	  GA	  
	  	   	  	   5	   Gastritis	  and	  GA	  
33	   TP53	   5	   Gastritis,	  IM	  and	  GA	  
	  	   	  	   6	   Gastritis,	  IM	  and	  HGD	  
51	   TP53	   5	   Gastritis,	  IM,	  HGD	  and	  GA	  
 
 
Dissected gastritic and IM areas from patient 8 were WT, although most dissected IM 
areas showed LOH for microsatellite markers D17S1832, D17S1176, D17S1678, 
D17S1881 and D17S1506E for TP53 at the 17p locus (Figure 3.6). The associated 
poorly differentiated GA had three different populations of cells with specific 
mutations within the carcinoma: WT TP53 and WT CTNNB1; mutated TP53 and WT 
CTNNB1; and mutated TP53 and mutated CTNNB1 (Figure 3.8). A consecutive 
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specimen of gastric mucosa from patient 8, again with a poorly differentiated GA, 
showed two of the different populations of cells within the carcinoma: WT TP53 and 
WT CTNNB1; and mutated TP53 and mutated CTNNB1 (Figure 3.9). All three 
populations of cells present LOH for the same markers in the cancer as in the IM (see 
Figure 3.7 for representative traces showing controls and LOH traces for the 5 
microsatellite markers for patient 8). The raw data associating the identified mutations 
and LOH status for each microdissected area with histology can be found in Figure 3.7 
and Tables 3.10 and 3.11, respectively. 
 
A specimen of gastric epithelium from patient 10 presented areas of chronic gastritis, 
IM, GA and muscle with a high level of GA infiltration (Figure 3.10). Microdissected 
areas of chronic gastritis and IM were WT and did not show LOH for markers at the 
17p and 17q loci. All areas of GA and invaded muscle were mutated; they all 
presented LOH for microsatellite markers D17S1881 and D17S250 (see Figure 3.11 
for representative traces showing controls and LOH traces, and for the corresponding 
raw data). Due to the reduced number of informative microsatellite markers in 
chromosome 17 for this patient, LOH was only recorded when the two informative 
markers were lost in each individual area.  
 
A poorly differentiated adenocarcinoma from patient 22 had two different populations 
of cells harbouring WT TP53 or mutated TP53 (Figure 3.12); both populations showed 
LOH for microsatellite markers D17S1881, D17S1506E, D17S1176 and D17S250 
from the 17p and 17q chromosomal region (see Figure 3.13 for representative traces 
showing controls and LOH traces, and for the corresponding raw data).  
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Dissected gastritis and muscle areas from patient 27 were WT, but all GA areas were 
TP53 mutated (Appendix Figure 7.16). Another specimen of gastric epithelium from 
this patient showed that benign areas (gastritis and muscle) and pre-neoplastic lesions 
(IM) were WT; however, all GA areas were TP53 mutated (Appendix Figure 7.17). 
Patient 27 was not informative for any microsatellite marker on the 17p locus. The raw 
data associating the identified TP53 mutation for each microdissected area with 
histology can be found in the appendix in the corresponding Tables 7.4 and 7.5. 
 
TP53 mutations could also be found in GA microdissected areas but not in those IM 
areas dissected from patient 33 (Figure 3.14). LOH was observed for microsatellite 
markers D17S1678 and D17S1176 mapped to the 17p locus in most GA areas. There 
was one IM area that also presented LOH for both markers (see Figure 3.15 for 
representative traces showing controls and LOH traces, and for the corresponding raw 
data). The TP53 mutation could not be found in any HGD or any benign areas in a 
consecutive specimen of gastric mucosa from patient 33 (Figure 3.16; see Table 3.12 
for the corresponding raw data). Once again, due to the limited number of informative 
microsatellite markers in chromosome 17 for this patient, LOH could only be 
identified when the two informative markers were lost in each individual area.  
 
A strip of gastric epithelium from patient 51 displaying chronic gastritis, IM, HGD 
and GA was examined. The chronic gastritis and IM areas were found to be TP53 WT, 
whereas the areas with HGD and GA were all TP53 mutated. Chronic gastritis and IM 
did not show LOH, but some GA did show LOH for microsatellite markers D17S1832 
and D17S1506E for TP53 from the 17p locus (Figure 3.17; see Figure 3.18 for 
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representative traces showing controls and LOH traces, and for the corresponding raw 
data). 
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Figure 3.6. Intestinal metaplastic glands are wild type but show loss of 
heterozygosity for microsatellites at 17p in patient 8. (A) A H&E of an entire 
section of gastric mucosa showing normal epithelium and intestinal metaplasia (IM) 
from patient 8, specimen block 6. (B) Higher power of highlighted areas, showing 
from left to right gastritis and two areas of IM. (C) Serial section showing post laser-
capture microdissection (LCM). Yellow areas are TP53 WT and light blue areas are 
CTNNB1 WT. Areas with loss of heterozygosity (LOH) at 17p for markers D17S1832 
(180bp), D17S1881 (210bp), D17S1506E (150bp), D17S1678 (120bp) and D17S1176 
(80bp) are distinguished by an orange border and areas without LOH by a green 
border. (D, E, F and G) Four representative traces showing the TP53 mutation 
c.G743A (D), a TP53 WT trace (E), the CTNNB1 mutation c.A121G (F), and a 
CTNNB1 WT trace (G). (H) Key for patient 8 on post LCM section. 
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Figure 3.7. Association of identified mutations with histology and loss of 
heterozygosity shows intestinal metaplastic glands are wild type but show loss of 
heterozygosity for microsatellites at 17p in patient 8. (A) This table corresponds to 
the laser-capture microdissection data presented in Figure 3.6, tissue from patient 8, 
specimen block 6. (B, D, F, H and J) Five representative traces showing controls 
where both alleles are present (+) and (C, E, G, I and K) five representative traces 
where loss of heterozygosity (LOH) has occurred for markers D17S1832 (180bp) (B, 
C), D17S1881 (210bp) (D, E), D17S1506E (150bp) (F, G), D17S1678 (120bp) (H, I) 
and D17S1176 (80bp) (J, K) at 17p from patient 8. An enlarged version of traces B to 
K can be seen in Figures 7.1 to 7.5 in the Appendix. WT, wild type; +, both alleles are 
present in chromosome 17; ND, not determined due to insufficient DNA; LOH was 
calculated by measuring the area under the curve of the samples compared to that of a 
normalized control (gastritis or muscle epithelium areas from the same patient). LOH 
was considered when the area under the curve was <0.5 or >2.0. 
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Figure 3.8. Clonal ordering of mutations in gastric adenocarcinoma shows clonal 
evolution in patient 8. (A) A H&E of an entire section of gastric mucosa showing a 
poorly differentiated gastric adenocarcinoma (GA) from patient 8, specimen block 7. 
(B) Higher power of highlighted areas showing from left to right a muscle area and 
three areas of highly necrotic GA. (C) Serial section showing post laser-capture 
microdissection (LCM). Yellow areas are TP53 WT whereas dark blue areas are 
positive for the TP53 mutation c.G743A. Light blue areas are CTNNB1 WT whereas 
dark red areas are positive for the CTNNB1 mutation c.A121G. Areas with loss of 
heterozygosity (LOH) at 17p for markers D17S1832 (180bp), D17S1881 (210bp), 
D17S1506E (150bp), D17S1678 (120bp) and D17S1176 (80bp) are distinguished by 
an orange border. (D, E, F and G) Four representative traces showing the TP53 
mutation c.G743A (D), a TP53 WT trace (E), the CTNNB1 mutation c.A121G (F), and 
a CTNNB1 WT trace (G). (H) Key for patient 8 on post LCM section. 
NOTE: Large areas of necrosis were present in the adenocarcinoma, these could 
account for the WT genotype of some of the TP53 and CTNNB1 GA areas. 
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Table 3.10. Association of identified mutations with histology and loss of 
heterozygosity shows clonal evolution in gastric adenocarcinoma in patient 8. 
This table corresponds to the laser-capture microdissection data presented in Figure 
3.8, tissue from patient 8, specimen block 7. The representative traces showing 
controls where both alleles are present (+) and samples where loss of heterozygosity 
(LOH) has occurred for markers D17S1832 (180bp), D17S1881 (210bp), D17S1506E 
(150bp), D17S1678 (120bp) and D17S1176 (80bp) at 17p from patient 8 is shown in 
Figure 3.7. An enlarged version of traces B to K can be seen in Figures 7.1 to 7.5 in 
the Appendix. 
 
 
 
 
NOTE: WT, wild type; +, both alleles are present in chromosome 17; ND, not 
determined due to insufficient DNA; LOH was calculated by measuring the area under 
the curve of the samples compared to that of a normalized control (gastritis or muscle 
epithelium areas from the same patient). LOH was considered when the area under the 
curve was <0.5 or >2.0. 
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Figure 3.9. Clonal ordering of mutations in a sequential specimen of gastric 
adenocarcinoma shows again clonal evolution in patient 8. (A) A H&E of an entire 
section of gastric mucosa showing a poorly differentiated gastric adenocarcinoma 
(GA) from patient 8, specimen block 8. (B) Higher power of highlighted areas, 
showing three areas of highly necrotic GA. (C) Serial section showing post laser-
capture microdissection (LCM). The space left by the LCM areas have been coloured 
to reflect the genotype. Yellow areas are TP53 WT whereas dark blue areas are 
positive for the TP53 mutation c.G743A. Light blue areas are CTNNB1 WT whereas 
dark red areas are positive for the CTNNB1 mutation c.A121G. Areas with loss of 
heterozygosity (LOH) in 17p for markers D17S1832 (180bp), D17S1881 (210bp), 
D17S1506E (150bp), D17S1678 (120bp) and D17S1176 (80bp) are distinguished by 
an orange border. (D, E, F and G) Four representative traces showing the TP53 
mutation c.G743A (D), a TP53 WT trace (E), the CTNNB1 mutation c.A121G (F), and 
a CTNNB1 WT trace (G). (H) Key for patient 8 on post LCM section. 
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Table 3.11. Association of identified mutations with histology and loss of 
heterozygosity shows clonal evolution in a sequential specimen of gastric 
adenocarcinoma in patient 8. This table corresponds to the laser-capture 
microdissection data presented in Figure 3.9, tissue from patient 8, specimen block 8. 
The representative traces showing controls where both alleles are present (+) and 
samples where loss of heterozygosity (LOH) has occurred for markers D17S1832 
(180bp), D17S1881 (210bp), D17S1506E (150bp), D17S1678 (120bp) and D17S1176 
(80bp) at 17p from patient 8 is shown in Figure 3.7. An enlarged version of traces B to 
K can be seen in Figures 7.1 to 7.5 in the Appendix. 
 
 
 
NOTE: WT, wild type; Grey coloured area denotes no result from PCR reaction; +, 
both alleles are present in chromosome 17; ND, not determined due to insufficient 
DNA; LOH was calculated by measuring the area under the curve of the samples 
compared to that of a normalized control (gastritis or muscle epithelium areas from the 
same patient). LOH was considered when the area under the curve was <0.5 or >2.0. 
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Figure 3.10. TP53 mutations could be found in gastric adenocarcinoma but not in 
intestinal metaplastic glands in patient 10. (A) A H&E showing areas of gastritis, 
intestinal metaplastic glands (IM) and gastric adenocarcinoma (GA). (B) Higher power 
of highlighted areas showing from left to right an area of gastritis, invasive GA within 
the muscle, IM, another area of gastritis and GA. (C) Serial section showing post 
laser-capture microdissection (LCM). Yellow areas are TP53 WT whereas dark blue 
areas are positive for the TP53 mutation c.C493T. Areas with LOH at 17p for markers 
D17S1881 (210bp) and D17S250 (140bp) are distinguished by an orange border and 
areas without LOH by a green border. (D, E) Two representative traces showing the 
TP53 mutation c.C493T (D) and a TP53 WT trace (E). (F) Key for patient 10 on post 
LCM section.  
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Figure 3.11. Association of the identified mutation with histology and loss of 
heterozygosity shows TP53 mutations could be found in gastric adenocarcinoma 
but not in intestinal metaplastic glands in patient 10. (A) Table corresponding to 
the laser-capture microdissection data presented in Figure 3.10, from patient 10. (B 
and D) Two representative traces showing controls where both alleles are present (+) 
and (C and E) two representative traces where loss of heterozygosity (LOH) has 
occurred for markers D17S1881 (210bp) (B, C) and D17S250 (140bp) (D, E) at 17p 
from patient 10. An enlarged version of traces B to E can be seen in Figures 7.6 and 
7.7 in the Appendix. WT, wild type; +, both alleles are present in chromosome 17; 
ND, not determined due to insufficient DNA; LOH was calculated by measuring the 
area under the curve of the samples compared to that of a normalized control (gastritis 
or muscle epithelium areas from the same patient). LOH was considered when the area 
under the curve was <0.5 or >2.0. 
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Figure 3.12. Wild type and mutated clones demonstrate a clonal relationship in 
patient 22. (A) A scanned H&E picture of an entire section of gastric mucosa showing 
a poorly differentiated gastric adenocarcinoma (GA). (B) Higher power of highlighted 
areas, showing from top to bottom two areas of poorly differentiated GA, a muscle 
area and another poorly differentiated GA area. (C) Serial section showing post laser-
capture microdissection (LCM). Yellow areas are TP53 WT whereas dark blue areas 
are positive for the TP53 mutation c.C455T. Areas with loss of heterozygosity (LOH) 
at 17p for markers D17S1881 (210bp), D17S1506E (150bp), D17S1176 (80bp), and 
D17S250 (140bp) are distinguished by an orange border and areas without LOH by a 
green border. (D, E) Two representative traces showing the TP53 mutation c.C455T 
(D) and a TP53 WT trace (E). (F) Key for patient 22 on post LCM section. 
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Figure 3.13. Association of identified mutations with histology and loss of 
heterozygosity shows that wild type and mutated clones demonstrate a clonal 
relationship in patient 22. (A) This table corresponds to the laser-capture 
microdissection data presented in Figure 3.12, from patient 22. (B, D, F and H) Four 
representative traces showing controls where both alleles are present (+) and (C, E, G 
and I) four representative traces where loss of heterozygosity (LOH) has occurred for 
markers D17S1881 (210bp) (B, C), D17S1506E (150bp) (D, E), D17S1176 (80bp) (F, 
G) and D17S250 (140bp) (H, I) at 17p from patient 22. An enlarged version of traces 
B to I can be seen in Figures 7.8 to 7.11 in the Appendix. WT, wild type; +, both 
alleles are present in chromosome 17; ND, not determined due to insufficient DNA; 
LOH was calculated by measuring the area under the curve of the samples compared 
to that of a normalized control (gastritis or muscle epithelium areas from the same 
patient). LOH was considered when the area under the curve was <0.5 or >2.0. 
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Figure 3.14. TP53 mutations found in gastric adenocarcinoma but not in intestinal 
metaplastic glands in patient 33. (A) A H&E of an entire section of gastric mucosa 
showing a poorly differentiated gastric adenocarcinoma (GA) with areas of gastritis 
and intestinal metaplasia (IM) from patient 33, specimen block 5. (B) Higher power of 
highlighted areas, showing from top to bottom two areas of poorly differentiated GA, 
an area of gastritis and an area of IM. (C) Serial section, showing post laser-capture 
microdissection (LCM). Yellow areas are TP53 WT whereas dark blue areas are 
positive for the TP53 mutation G14439A. Areas with loss of heterozygosity (LOH) at 
17p for markers D17S1678 (120bp) and D17S1176 (80bp) are distinguished by an 
orange border and areas without LOH by a green border. (D, E) Two representative 
traces showing the TP53 mutation c G14439A (D) and a TP53 WT trace (E). (F) Key 
for patient 33 on post LCM section. 
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Figure 3.15. Association of identified mutations with histology and loss of 
heterozygosity shows that TP53 mutations were found in gastric adenocarcinoma 
but not in intestinal metaplastic glands in patient 33. (A) This table corresponds to 
the laser-capture microdissection data presented in Figure 3.14, tissue from patient 33, 
specimen block 5. (B and D) Two representative traces showing controls where both 
alleles are present (+) and (C and E) two representative traces where loss of 
heterozygosity (LOH) has occurred for markers D17S1678 (120bp) (B, C) and 
D17S1176 (80bp) (D, E) in 17p from patient 33. An enlarged version of traces B to E 
can be seen in Figures 7.12 and 7.13 in the Appendix. WT, wild type; +, both alleles 
are present in chromosome 17; ND, not determined due to insufficient DNA; the 
purple vertical line on the traces denotes a high concentration of PCR product; LOH 
was calculated by measuring the area under the curve of the samples compared to that 
of a normalized control (gastritis or muscle epithelium areas from the same patient). 
LOH was considered when the area under the curve was <0.5 or >2.0. 
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Figure 3.16. TP53 mutations were not found in high grade dysplasia or intestinal 
metaplasia in patient 33. (A) A H&E picture of an entire section of gastric mucosa 
showing high grade dysplasia (HGD), and areas of gastritis and intestinal metaplasia 
(IM) from patient 33, specimen block 3. (B) Higher power of highlighted areas, 
showing from top to bottom an area of HGD, an area of gastritis, an area of IM and 
another area of gastritis. (C) Serial section, showing post laser-capture microdissection 
(LCM). Yellow areas are TP53 WT. Areas with loss of heterozygosity (LOH) at 17p 
for markers D17S1678 (120bp) and D17S1176 (80bp) are distinguished by an orange 
border and areas without LOH by a green border. (D, E) Two representative traces 
showing the TP53 mutation c G14439A (D) and a TP53 WT trace (E). (F) Key for 
patient 33 on post LCM section. 
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Table 3.12. Association of identified mutations with histology and loss of 
heterozygosity shows that TP53 mutations were not found in high grade dysplasia 
or intestinal metaplasia in patient 33. This table corresponds to the laser-capture 
microdissection data presented in Figure 3.16, from patient 33 specimen block 3. The 
representative traces showing controls where both alleles are present (+) and samples 
where loss of heterozygosity (LOH) has occurred for markers D17S1678 (120bp) and 
D17S1176 (80bp) at 17p from patient 33 is shown in Figure 3.15. An enlarged version 
of traces B to E can be seen in Figures 7.12 and 7.13 in the Appendix.  
 
 
 
 
NOTE: WT, wild type; +, both alleles are present in chromosome 17; ND, not 
determined due to insufficient DNA; the purple vertical line on the traces denotes a 
high concentration of PCR product; LOH was calculated by measuring the area under 
the curve of the samples compared to that of a normalized control (gastritis or muscle 
epithelium areas from the same patient). LOH was considered when the area under the 
curve was <0.5 or >2.0. 
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Figure 3.17. TP53 mutations were found in high grade dysplasia and in gastric 
adenocarcinoma but not in intestinal metaplasia in patient 51. (A) A H&E picture 
of an entire section of gastric mucosa showing gastritis, intestinal metaplasia (IM), 
high grade dysplasia (HGD) and gastric adenocarcinoma (GA) from patient 51. (B) 
Higher power of highlighted areas showing from left to right gastritis, IM, HGD, GA 
and an area of IM within GA. (C) Serial section, showing post laser-capture 
microdissection (LCM). Yellow areas are TP53 WT whereas dark blue areas are 
positive for the TP53 mutation c.G824A. Areas with loss of heterozygosity (LOH) at 
17p for markers D17S1832 (180bp) and D17S1506E (150bp) are distinguished by an 
orange border and areas without LOH by a green border.  (D, E) Two representative 
traces showing the TP53 mutation c.G824A (D) and a TP53 WT trace (E). (F) Key for 
patient 51 on post LCM section. 
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Figure 3.18. Association of identified mutations with histology and loss of 
heterozygosity shows that TP53 mutations were found in high grade dysplasia 
and in gastric adenocarcinoma but not in intestinal metaplasia in patient 51. (A) 
Table corresponding to the laser-capture microdissection data presented in Figure 
3.17, tissue from patient 51.  (B and D) Two representative traces showing controls 
where both alleles are present (+) and (C and E) two representative traces where loss 
of heterozygosity (LOH) has occurred for markers D17S1832 (180bp) (B, C) and 
D17S1506E (150bp) (D, E) at 17p from patient 51. An enlarged version of traces B to 
E can be seen in Figures 7.14 to 7.15 in the Appendix. WT, wild type; +, both alleles 
are present in chromosome 17; ND, not determined due to insufficient DNA; the 
purple vertical line on the traces denotes a high concentration of PCR product; LOH 
was calculated by measuring the area under the curve of the samples compared to that 
of a normalized control (gastritis or muscle epithelium areas from the same patient). 
LOH was considered when the area under the curve was <0.5 or >2.0. 
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Gastric adenocarcinoma demonstrates genetic heterogeneity through clonal 
evolution 
 
Six phylogenetic trees were used to summarise the data for patients 8, 10, 22, 33 and 
51 (Figure 3.19 B, C, D, E and F respectively) and patient 27 (Appendix Figure 7.18). 
A schematic representation of the location of the microsatellite markers used for LOH 
analysis has also been included (Figure 3.19A). 
 
In the case of patient 8 it is probable that at some point in the development of IM, 
LOH of TP53 markers develops (Figure 3.19B) and as the mutated clone spreads, a 
TP53 exon 7 mutation and eventually a CTNNB1 mutation are acquired through clonal 
evolution. The data presented indicated that the three populations observed are clonal 
and, by inference, that GA is clonal with new mutations acquired through the 
evolution of the carcinoma clones due to the bottleneck effect. It is likely, therefore, 
that a founder mutation caused the transition from IM to dysplasia and to GA. This 
may have occurred either before or after the development of LOH. Our findings 
suggested that LOH occurred during the IM and that this was followed by a mutation 
in an unidentified gene during either the IM or the dysplasia that led to GA 
development.  
 
The phylogenetic tree of patient 10 demonstrated that LOH might occur during the 
development of IM, since one of the microsatellite markers has already been lost in the 
dissected IM area of this patient. Because GA areas and carcinoma-infiltrated muscle 
areas present the same TP53 mutation, the data suggested that GA is clonal and that as 
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the carcinoma becomes more invasive the TP53 mutated clone persisted (Figure 
3.19C). 
 
In the case of patient 22, a TP53 mutation arose during clonal expansion, which 
probably led to further progression of the carcinoma. The data suggested that the two 
carcinoma areas are clonal and, therefore, that GA is clonal (Figure 3.19D).  
 
The data from patient 27 suggests again that GA is clonal, as all GA areas in the two 
consecutive specimens present the same TP53 mutations (Appendix Figure 7.18). 
 
All pre-malignant areas appear WT in patient 33. However, the data suggested that 
LOH occurred in the IM and also that another unknown mutation in a gene that was 
not included in our screening was likely to have caused the transition from IM to 
dysplasia and to GA (Figure 3.19E). 
 
In the case of patient 51 a TP53 mutation developed at some point in the HGD (Figure 
3.19F), giving the clone the potential to progress to a carcinoma, which was then 
followed by LOH for TP53 at 17p. This showed that a mutation present in cells within 
a dysplastic area can clonally expand to form an associated carcinoma and, in this 
case, the GA is therefore clonal. 
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3.2.3. Clonal expansion in hereditary diffuse gastric cancer 
 
To assess clonal expansion in HDGC within the human stomach, areas of HDGC from 
5 patients from 2 different families were microdissected by LCM and screened for 
mutations in TP53 in exons 5, 6, 7 and 8 (see Table 3.13 for full patient summary). 
These patients could not be screened by needle macrodissection due to the small size 
of the clusters of signet ring cells forming the diffuse-type tumours. Each of these 
individuals had a germline mutation in the CDH1 gene responsible for cell-cell 
adhesion. Individuals from family A carried a c.1565+2dupT mutation in intron 10 and 
those from family B had the familial splicing mutation c.G832A.  
 
This study was performed using tissues from two patients from family A, who had 
both been found to carry the familial c.1565+2dupT mutation in intron 10: 
 
- Patient A3: 22 year old female where 69 diffuse-type tumours had been found ranging 
between 1 to 7 mm. An ovarian mature cystic teratoma with no gastric tissue had also 
been found in this patient. 
 
- Patient A4: 43 year old female where 16 diffuse-type tumours had been found ranging 
between 1 to 4 mm. Ectopic duodenal tissue and granulomatous lymphadenitis was 
also observed in this patient. Patient A4 is patient A3’s aunt.  
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The study was also performed using tissues from three patients from family B, who 
had all been found to carry the familial splicing mutation c.G832A: 
 
- Patient B1: 22 year old male where 267 diffuse-type tumours had been found ranging 
between 1 to 3 mm. IM was also present in the cardia area of the stomach in this 
patient. 
 
- Patient B4: 33 year old female where 47 diffuse-type tumours had been found ranging 
from 1 to 2 mm. Leiomyomata and fundic gland polyps were also observed in this 
patient. Patient B4 is patient B1’s second cousin. 
 
- Patient B5: 59 year old female where 80 diffuse-type tumours had been found ranging 
from 1 to 3 mm. Gastrointestinal stromal tumours (GIST) positive for C-KIT 
mutations and granulomatous lymphadenitis were also observed in this patient. Patient 
B5 is patient B4’s mother and patient B1’s second aunt. 
 
 
Table 3.13. Summary of patients carrying E-cadherin mutations from families A 
and B. The two families present two different germline mutations in CDH1, 
c.1565+2dupT in family A and c.G832A in family B. 
 
Patient	   Family	  
CDH1	  
mutation	   Gender	   Age	   Relationship	  
Number	  
HDGC	  
A3	   A	   c.1565+2dupT  F 22 niece	   69	  
A4	   A	   c.1565+2dupT  F 43 aunt	   16	  
B1	   B	   c.G832A	   M	   22	   second	  cousin	  +	  nephew	   267	  
B4	   B	   c.G832A	   F	   33	  
second	  cousin	  +	  
daughter	   47	  
B5	   B	   c.G832A	   F	   59	   mother	  +	  second	  aunt	   80	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E-cadherin immunohistochemistry (IHC) and Alcian Blue and Periodic acid-Schiff 
staining were performed on tissues from these five patients. The HDGC area from 
patient A3 seemed to present a low level of expression of E-cadherin protein even 
though the CDH1 germline mutation had been confirmed (Figure 3.21 C and G). On 
the other hand, all HDGC areas from patients A4 and B5 were negative for E-cadherin 
expression by IHC (Figure 3.23 C and G; and Figure 3.29 C and G, respectively). 
HDGC areas from Patients B1 and B4 showed a mixture of HDGC E-cadherin 
negative areas and HDGC areas with a low level of expression of E-cadherin positive 
(Figure 3.25 C and G; and Figure 3.27 C and G, respectively) (see full percentages in 
Table 3.14). 
 
Table 3.14. E-cadherin protein can be found expressed at a low level in the 
membrane of signet ring cells in some hereditary diffuse gastric cancer areas. 
This has been observed in patients presenting a CDH1 germline mutation. 
 
 
Patient	  
HDGC	  CDH1	  	  
negative	  areas	  
HDGC	  CDH1	  	  
positive	  areas	  
A3	   0	   1	  (100%)	  
A4	   1	  (100%)	   0	  
B1	   1	  (50%)	   1	  (50%)	  
B4	   4	  (66.67%)	   2	  (33.33%)	  
B5	   3	  (100%)	   0	  
 
 
In summary, all HDGC areas were WT for TP53 exons 5, 6, 7 and 8 in these five 
patients. Only the largest HDGC areas were microdissected and analysed by nested-
PCR sequencing. No mutated areas were found and therefore LOH was not assessed.  
 
The results for the field cancerisation study using TP53 mutations from HDGC areas 
from patients A3, A4, B1, B4 and B5 are shown in figures 3.20, 3.22, 3.24, 3.26 and 
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3.28. The raw data associating the genotype of each dissected area to the histology and 
the high power images compiling the summary of the IHC results are found in the 
corresponding Figures 3.21, 3.23, 3.25, 3.27 and 3.29.  
 
The lack of TP53 mutations on the largest HDGC areas from these patients indicates 
that none of these patients showed TP53 mutations. However, it is possible that these 
mutations might be a later step in the development of diffuse-type gastric carcinoma as 
Ranzani and colleagues (205) have suggested. Moreover, it could also be possible that 
field cancerisation does not occur in diffuse-type gastric cancers - it has never been 
reported. Nevertheless, it is most likely that the germline mutation acts as the field-
cancerisation event, which then probably leads to the methylation of the WT CDH1 
allele, loss of function and to genetic instability. 
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Figure 3.20. Field cancerisation was not observed when using TP53 mutations as a 
clonal marker in HDGC tissue from patient A3. (A) Gastric mucosa showing a strip 
of gastric epithelium with areas of hereditary diffuse gastric cancer (HDGC) from 
patient A3, which presents a c.1565+2dupT mutation in intron 10 of the CDH1 gene. 
(B) Higher power of highlighted regions showing three different areas of HDGC. (C) 
Serial section, showing post laser-capture microdissection (LCM). All areas were WT 
for TP53 exons 5, 6, 7 and 8 and are all coloured in yellow. (D) Key for patient A3 on 
post LCM section. 
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Figure 3.21. Screening for TP53 exons 5 to 8 mutations and E-cadherin 
immunohistochemistry in HDGC tissue from patient A3. This figure shows that all 
hereditary diffuse gastric cancer areas are TP53 wild type but that some areas still 
express very low levels of E-cadherin despite carrying a germline mutation and having 
a signet ring cell phenotype in patient A3. (A) This table corresponds to the laser-
capture microdissection data presented in figure 3.20 for TP53 exons 5, 6, 7 and 8, 
tissue from patient A3. (B-I) High power (x10) images of two hereditary diffuse 
gastric cancer (HDGC) areas in patient A3 showing haematoxylin and eosin staining 
(H&E) (B, D); E-cadherin immunohistochemistry (C, G); Alcian Blue and Periodic 
acid-Schiff stain (D, H); and the immunohistochemistry negative control for each area 
(E, I). WT, wild type; ND, not determined due to insufficient DNA. 
 141 
 
Figure 3.22. Field cancerisation was not observed when using TP53 mutations as a 
clonal marker in HDGC tissue from patient A4. (A) Gastric mucosa showing a strip 
of gastric epithelium with areas of diffuse gastric cancer from patient A4, which 
presents a c.1565+2dupT mutation in intron 10 of the CDH1 gene. (B) Higher power 
of highlighted regions showing three different areas of hereditary diffuse gastric 
cancer (HDGC). (C) Serial section, showing post laser-capture microdissection 
(LCM). All areas were WT for TP53 exons 5, 6, 7 and 8 and are all coloured in 
yellow. (D) Key for patient A4 on post LCM. 
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Figure 3.23. Screening for TP53 exons 5 to 8 mutations and E-cadherin 
immunohistochemistry in HDGC tissue from patient A4. This figure shows that all 
hereditary diffuse gastric cancer areas are TP53 wild type and that none of these areas 
express E-cadherin in patient A4. (A) This table corresponds to the laser-capture 
microdissection data presented in figure 3.20 for TP53 exons 5, 6, 7 and 8, tissue from 
patient A4. (B-I) High power (x10) images of two hereditary diffuse gastric cancer 
(HDGC) areas in patient A3 showing haematoxylin and eosin staining (H&E) (B, D); 
E-cadherin immunohistochemistry (C, G); Alcian Blue and Periodic acid-Schiff stain 
(D, H); and the immunohistochemistry negative control for each area (E, I). WT, wild 
type. 
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Figure 3.24. Field cancerisation was not observed when using TP53 mutations as a 
clonal marker in HDGC tissue from patient B1. (A) Gastric mucosa showing a strip 
of gastric epithelium with areas of diffuse gastric cancer from patient B1, which 
presents a c.G832A mutation in intron 10 of the CDH1 gene. (B) Higher power of 
highlighted regions showing three different areas of hereditary diffuse gastric cancer 
(HDGC). (C) Serial section, showing post laser-capture microdissection (LCM). All 
areas were WT for TP53 exons 5, 6, 7 and 8 and are all coloured in yellow. (D) Key 
for patient B1 on post LCM. 
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Figure 3.25. Screening for TP53 exons 5 to 8 mutations and E-cadherin 
immunohistochemistry in HDGC tissue from patient B1. This figure shows that all 
hereditary diffuse gastric cancer areas are TP53 wild type but that some areas still 
express faint levels of E-cadherin despite carrying a germline mutation and having a 
signet ring cell phenotype. (A) This table corresponds to the laser-capture 
microdissection data presented in figure 3.20 for TP53 exons 5, 6, 7 and 8, tissue from 
patient B1. (B-I) High power (x10) images of two hereditary diffuse gastric cancer 
(HDGC) areas in patient A3 showing haematoxylin and eosin staining (H&E) (B, D); 
E-cadherin immunohistochemistry (C, G); Alcian Blue and Periodic acid-Schiff stain 
(D, H); and the immunohistochemistry negative control for each area (E, I). WT, wild 
type. 
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Figure 3.26. Field cancerisation was not observed when using TP53 mutations as a 
clonal marker in HDGC tissue patient B4. (A) Gastric mucosa showing a strip of 
gastric epithelium with areas of diffuse gastric cancer from patient B4, which presents 
a c.G832A mutation in intron 10 of the CDH1 gene. (B) Higher power of highlighted 
regions showing three different areas of hereditary diffuse gastric cancer (HDGC). (C) 
Serial section, showing post laser-capture microdissection (LCM). All areas were WT 
for TP53 exons 5, 6, 7 and 8 and are all coloured in yellow. (D) Key for patient B4 on 
post LCM. 
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Figure 3.27. Screening for TP53 exons 5 to 8 mutations and E-cadherin 
immunohistochemistry in HDGC tissue from patient B4. This figure shows that all 
hereditary diffuse gastric cancer areas are TP53 wild type but that some areas still 
express very low levels of E-cadherin despite carrying a germline mutation and having 
a signet ring cell phenotype in patient B4. (A) This table corresponds to the laser-
capture microdissection data presented in figure 3.20 for TP53 exons 5, 6, 7 and 8, 
tissue from patient B4. (B-I) High power (x10) images of two hereditary diffuse 
gastric cancer (HDGC) areas in patient A3 showing haematoxylin and eosin staining 
(H&E) (B, D); E-cadherin immunohistochemistry (C, G); Alcian Blue and Periodic 
acid-Schiff stain (D, H); and the immunohistochemistry negative control for each area 
(E, I). WT, wild type; ND, not determined due to insufficient DNA. 
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Figure 3.28. Field cancerisation was not observed when using TP53 mutations as a 
clonal marker in HDGC tissue from patient B5. (A) Gastric mucosa showing a strip 
of gastric epithelium with areas of diffuse gastric cancer from patient B5, which 
presents a c.G832A mutation in intron 10 of the CDH1 gene. (B) Higher power of 
highlighted regions showing two different areas of hereditary diffuse gastric cancer 
(HDGC). (C) Serial section, showing post laser-capture microdissection (LCM). All 
areas were WT for TP53 exons 5, 6, 7 and 8 and are all coloured in yellow. (D) Key 
for patient B5 on post LCM. 
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Figure 3.29. Screening for TP53 exons 5 to 8 mutations and E-cadherin 
immunohistochemistry in HDGC tissue from patient B5. This figure shows that all 
hereditary diffuse gastric cancer areas are TP53 wild type and that none of these areas 
express E-cadherin. (A) This table corresponds to the laser-capture microdissection 
data presented in figure 3.20 for TP53 exons 5, 6, 7 and 8, tissue from patient B5. (B-
I) High power (x10) images of two hereditary diffuse gastric cancer (HDGC) areas in 
patient A3 showing haematoxylin and eosin staining (H&E) (B, D); E-cadherin 
immunohistochemistry (C, G); Alcian Blue and Periodic acid-Schiff stain (D, H); and 
the immunohistochemistry negative control for each area (E, I). WT, wild type. 
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3.3. Discussion 
 
As had previously been published by McDonald and colleagues, IM glands are clonal 
and expand by crypt fission (248). Large fields of IM in the human stomach have 
previously been linked to a higher incidence of GA (187). Moreover, another study 
observed the same genetic mutations in IM and in the associated preneoplastic lesions 
found in the follow-up biopsies (193). However, previous genetic studies had analysed 
large areas of tissue or biopsies and could not rule out the presence of other clones, 
since the large number of cells can mask genetic heterogeneity. Therefore there was a 
need to assess the mutational status of IM and the associated dysplastic lesions on a 
gland-by-gland basis, since there was limited evidence for IM being an immediate 
precursor to dysplasia.  
 
The results from our study show that all glands within an entire region of dysplasia 
contain a founder mutation and, therefore, that the lesion is clonal (Figures 3.1, 3.2 
and 3.4). The total percentage of mutated IM glands was very small, ranging from 
4.2% to 16.6% of all IM glands (Table 3.2) (72). This indicated that when a mutation 
occurred in IM, cellular expansion can take place rapidly and dysplasia follows after 
that, thereby forming very large clonal lesions. IM can therefore be perceived as field 
cancerisation of the human stomach, as it seems to predispose large areas of 
epithelium to progress into more malignant preneoplastic lesions and also to promote 
genetic instability.  
 
We have screened for mutations in the genes that account for approximately 75% of 
all somatic mutations reported previously for GA in the COSMIC database (256). 
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Originally, tumour tissue from 23 patients was included in our study on the clonal 
origins of dysplasia from IM (72). Nevertheless, only 3 out of the 23 (13%) patients 
presented with single identifiable functional mutations in the dysplasia. In the study on 
clonal expansion in GA, 31.4% of the patients presented with functional mutations and 
only 1 patient (1.96%) presented two functional mutations. Overall, the mutation 
frequencies obtained were comparable to those from previous reports (Figure 3.5). The 
absence of mutations in a large proportion of our GA patients (68.6%) could also 
indicate that other mutated genes, such as ARID1A and FAT4 (202, 203), may play an 
important role in GA development. Further exome sequencing studies will hopefully 
reveal novel target genes pertinent to the development of carcinoma of the stomach. 
 
To study clonal expansion in GA tissue from 6 patients presenting with detectable 
mutations were studied by LCM of the FFPE specimens, which showed varied 
histology including gastritis, IM, dysplasia and carcinoma. The data suggested that 
during field cancerisation a mutation arises in IM followed by the development of 
dysplasia, which then becomes the focus of subsequent mutations (Figure 3.19). 
Clonal expansion within the dysplasia eventually leads to progression to an 
adenocarcinoma. In the carcinoma tissue from patients 8, 22 and 33 it appears that a 
founder mutation in an unknown gene must have taken place previously or at the same 
time as the LOH, since a WT TP53 population was found with the same LOH pattern 
present in the TP53 mutated population. Both WT and mutated populations are clonal 
and have evolved through clonal evolution, as suggested in Nowell’s model of clonal 
evolution (88). Moreover, HGD and GA are clonal as they display the same TP53 
mutation in Patient 51 (Figure 3.19). 
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Our results, here and previously (72), differ from those obtained from the clonal origin 
of Barrett’s lesions (157) and colorectal microadenomas (16). Leedham and colleagues 
observed different mutations in different populations in metaplasia and dysplasia 
within Barrett’s oesophagus: the Barrett’s glands were a mosaic of multiple 
genetically distinct independent clones (157). Clonal analysis on a crypt-by-crypt basis 
in familial and sporadic adenomas, and in carcinoma-in-adenomas suggested that 
colorectal adenomas can be polyclonal and that clonal evolution takes place 
throughout adenoma development (16). In contrast, Galandiuk and colleagues 
analyzed tumours from Crohn’s disease patients by LCM, which produced similar 
findings to those reported here (64). They detected a mutation within non-tumour 
tissue that was also found in the presenting tumour, suggesting a clonal relationship 
between the tumour and the surrounding pre-neoplastic mucosa due to field 
cancerisation. Overall, it would appear that different underlying pre-neoplastic 
conditions, such as FAP (16) or Crohn’s (64), lead to different modes of clonal 
evolution. Interestingly, both studies (16, 64) revealed an absence of a clear order of 
genetic events for the development of tumours in FAP and Crohn’s patients, in 
contrast to the hypothesis that the genetic events described in the adenoma-carcinoma 
sequence always occurred in a defined sequence in the development of colorectal 
carcinomas (121).  
 
The usual mutational events established for GA development during the MCS (153) do 
not fit the results from either of our two LCM mutation screening studies (72). Correa 
and colleagues proposed a stepwise progression towards GA by compiling results 
from several different studies and not by detection of specific mutations in a cohort of 
GA tumours as conducted here. Our results indicated that the specific genetic events 
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described during the MCS might not be true for GA. Mutations do not occur at 
specific stages during tumour development and we have not observed an accumulation 
of driver mutations during tumourigenesis in our GA patient cohort. Indeed, if the 
Correa hypothesis were correct then one would expect to find more cases with 
multiple mutations and all GA would present with the same mutation signature (Figure 
3.30).  
 
 
Figure 3.30. Comparison between the phenotypic and genotypic events. Figures 
show a comparison between the observation of Correa and colleagues (153, 187) (A) 
that supports an order of mutations during the Metaplasia-Dysplasia-Carcinoma 
sequence (MCS) and the mutational events observed in the studies of the clonal 
origins of dysplasia from intestinal metaplasia (72) and the clonal architecture of GA 
(B). 
 
Our study shows that field cancerisation and mutated pre-malignant clones can drive 
tumour progression. This is very relevant clinically, since lesions such as IM are not 
removed at surgery unless the carcinoma has already developed. Our study would 
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suggest that the increased surveillance based on mutational screening of biopsy 
specimens might form part of a patient management regime for GA in the future.  
 
In summary, the proposal that the monoclonal origin of GA from one progenitor cell, 
which subsequently acquires genetic heterogeneity through clonal evolution, fits with 
the current study on the clonal origins of dysplasia and clonal expansion in GA (72). 
This study is the most exhaustive carried out in a large cohort of patients and we have 
observed different populations within the same tumour and established the mutational 
status of individual tumour areas. However, the phylogenetic trees produced for the 
lesions investigated will only be complete when deep sequencing and validation 
studies are undertaken.  
 
The results from these two studies indicated that it was possible that an event similar 
to field cancerisation occurred in HDGC. Mutations in the TP53 gene have been 
previously reported in HDGC, although the mutations were suggested to occur at a 
later stage leading to tumour progression (205). When the largest lesions were located 
in 5 members of the two families, these areas were LCM and analysed for mutations in 
exons 5, 6, 7 and 8 of TP53. Nevertheless, the results obtained were negative and no 
TP53 mutations could be observed in any HDGC lesion. This suggested that either 
field cancerisation does not occur in HDGCs or that, because all of these patients have 
a germline CDH1 mutation, field cancerisation might be due to events such as 
promoter methylation of the wild type CDH1 allele. CDH1 methylation is thought to 
be the second hit mutation in over 50% of diffuse gastric carcinoma cases (257), 
hence, TP53 mutations might arise after field cancerisation has occurred in a 
background where one of the alleles is mutated and the other silenced.  
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Immunohistochemistry results for E-cadherin staining in these patients revealed that 3 
out of the 5 patients (60%) presented some signet ring areas positive for E-cadherin 
membranous staining but with the same mucin production as that of the E-cadherin 
negative areas (seen by AB-PAS staining). E-cadherin background staining was not 
observed in any of the negative control serial sections and, therefore, it was deemed 
that none of the positive signet ring cell areas were due to antibody artefact. 
Nevertheless, the epitope for the mouse-monoclonal antibody corresponds to the N-
terminal external region of E-cadherin, which would not be affected by either of the 
mutations found in family A or B.  These results could suggest that incomplete CDH1 
methylation might be sufficient for the formation of signet ring diffuse carcinoma 
areas or that CDH1 might become partially unmethylated once the tumour areas have 
formed. Moreover, normal membranous immunohistochemical staining for E-cadherin 
has been previously shown in samples with or without CDH1 methylation (258). In 
conclusion, the faint membrane staining observed in some of the patients with a CDH1 
germline mutation was probably due to the fact that immunohistochemical staining 
was less sensitive than PCR in detecting subpopulations of cells with gene methylation 
and hence downregulation of E-cadherin. 
 
Overall, these three studies highlight the importance of clonal expansion in carcinoma 
development in gastric epithelium. Cancer screening of commonly mutated genes and 
the analysis of clonal evolution through microdissection will keep revealing the 
underlying mechanism of clonal expansion in cancer; such as in sporadic and tylotic 
oesophageal squamous cell carcinoma. 
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4.  Clonal expansion in oesophageal squamous cell cancer 
 
 
4.1. Introduction 
 
Barrett’s oesophagus (BO) occurs when oesophageal stratified squamous epithelium is 
replaced by columnar-cell metaplasia and it increases the risk of OA to at least 0.12% 
per annum (and possibly more) (218). There have been many studies analysing 
neoplastic progression from BO to OA, which is considered to occur due to the 
accumulation of genetic defects within the Barrett’s glands and environmental factors 
such as GORD, diet, smoking and alcohol (219, 220). There are currently two clonal 
evolution models proposed for BO: the selective sweep to fixation model detailed by 
the Reid group (221) and the clonal interference model proposed by Leedham and 
colleagues (157) (see Figure 1.7). Nicholson and colleagues observed that Barrett’s 
glands are clonal, contain multiple stem cells and are likely to divide by crypt fission 
(222). The possibility that different mutated stem cells could be involved in the 
formation of a pre-neoplastic lesion is important in order to assess clonal competition. 
However, it is the identification of mutated clones within pre-neoplastic lesions that is 
crucial, since these clones have the potential to expand by crypt fission and to cause 
OA development. 
 
Leedham and colleagues have also suggested that WT squamous ducts of the 
oesophagus might be the potential source for a progenitor cell that could give rise to 
both stratified squamous epithelium and columnar-cell metaplasia (157). Nicholson 
and colleagues corroborated that squamous gland ducts might be the source of 
progenitor cells in the oesophagus when they observed a CCO deficient patch 
containing both squamous and glandular epithelium (222). 
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Oesophageal cancer is a major cause of morbidity and mortality throughout the world, 
and the most common type is OSCC (168). The different histopathological steps 
observed in the course of OSCC development are: oesophagitis; basal cell hyperplasia 
(BCH) followed by low-grade and high-grade dysplasia; carcinoma in-situ; and OSCC 
can develop when neoplastic cells invade the muscularis. Currently, no pre-neoplastic 
histopathological lesions are considered to represent field cancerisation in OSCC 
(228).  However, Nicholson and colleagues suggested that lateral replacement of the 
stem cell pool occurs along the basal layer of the squamous epithelium (222), which 
might lead to the spread of preconditioned phenotypically-normal squamous epithelial 
cells that will eventually cause tumour development. Furthermore, Mandard and 
colleagues observed two independent patches of oesophagitis containing two different 
TP53 mutations. Interestingly, only one of the TP53 mutations was found later in the 
associated OSCC (162). Similar to BO, findings by both Mandard and Nicholson 
suggested that field cancerisation could indeed occur in stratified squamous 
epithelium, leading to OSCC development.  
 
The observation of polyclonal lesions within the metaplasia and dysplasia in Barrett’s 
oesophagus (BO) by Leedham et al (157) has lead to three different hypothesis 
explaining the origin and maintenance of genetic diversity in BO (251); previously 
explained in section 3.3. Even though OSCC does not arise as a result from GORD, it 
is possible that inflammatory events such as chronic oesophagitis might increase the 
mutation rate. It is also possible that a mutation might spread through field 
cancerisation in OSCC or that multiple clones might arise in fields of oesophagitis 
leading to clonal competition. However, Shima and colleagues analysis of needle 
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microdissected areas within 16 OSCC tumours revealed homogeneous LOH patterns 
mixed with either genetic progression or divergence (259). Both of these processes 
occurred through clonal evolution: it was suggested that the initial homogenous clone 
might have acquired further LOH of other microsatellite markers as the neoplasm 
evolved. Following on from Mandard’s and Nicholson’s work, these results suggest 
that OSCC might be clonal and that it would progress through clonal evolution. 
 
Therefore, to understand clonal expansion and progression in oesophageal squamous 
cell dysplasia (OSCD) and OSCC, the presence of single or multiple clones presenting 
somatic mutations in genes involved in OSCC development needs to be assessed in 
pre-neoplastic and malignant epithelium. This might be expected to give insight into 
the process of field cancerisation and clonal expansion in OSCC.  
 
4.1.1. Hypothesis and Aims 
 
The hypothesis for the project presented here is that OSCC occurs by a process of field 
cancerisation of the oesophagus. 
 
The aims of this project are: 
1. To assess the mutation frequencies of genes known to be involved in the development 
of OSCC 
2. To determine the clonal architecture of OSCD and OSCC 
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4.2.  Results 
 
Common cancer-associated mutations are found in oesophageal squamous cell 
carcinoma and occur mostly as a single event 
 
To assess the clonal architecture of OSCC, areas of carcinoma or dysplasia from 34 
patients were needle macrodissected and screened for mutations in genes commonly 
mutated in OSCC (for full methods see sections 2.1.4, 2.2 and 2.4). The most 
commonly mutated genes were TP53, CDKN2A and NRF2, according to the catalogue 
of somatic mutations in cancer (COSMIC, 16/05/2013) database (256). Patient 1 was 
removed from the screening due to insufficient DNA to obtain PCR results. From the 
33 remaining patients, 36.36% (12/33) presented with mutations in the cancer (see 
Table 4.1 and Table 7.6 in the appendix). 
 
Next, we compared the frequencies of mutations found in OSCC with those reported 
previously in the COSMIC database to confirm we had sufficient coverage of known 
mutations (see Table 4.1 for full details on the patients presenting mutations). The 
frequency of mutation for each gene was: TP53, 27.27% (9/33); CDKN2A, 9.09% 
(3/33); and NRF2, 12.12% (4/33). On correction of multiple testing using the 
Bonferroni adjustment (r=3), the significant P value was lowered to 0.01667. 
Therefore, the number of TP53 mutated samples is not statistically significant and the 
mutation frequencies observed were comparable to previous reports in the COSMIC 
database (Figure 4.1) (256).  
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Interestingly, only 2 OSCC (6.06%, 2/33) presented with two independent functional 
mutations (TP53 and NRF2; and CDKN2A and NRF2). This low incidence of OSCC 
patients with mutations indicated either that most functional mutations occur as a 
single event or that other genes not included in this screening may be involved in the 
premalignant pathway that eventually leads to OSCC.  
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Table 4.1. Summary of mutations in genes selected from the COSMIC database 
for oesophageal squamous cell carcinoma. Screening of 33 oesophageal squamous 
cell carcinomas (OSCC) for genes detailed in the COSMIC database (16/05/2013) that 
account for mutations in over 70% of OSCCs (256): TP53, CDKN2A and NRF2 (or 
NFE2L2). Light grey stands for WT and dark blue stands for mutated samples, where 
the mutations found are written in bold. Patient 1 was removed from the screening due 
to insufficient DNA to obtain PCR results. The red rectangles highlight the three 
samples analysed by laser-capture microdissection. 
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Figure 4.1. Mutation frequencies are comparable to reports for oesophageal 
squamous cell carcinoma held in the COSMIC database. Statistical analysis of 
results obtained from the screening of 33 oesophageal squamous cell carcinoma 
patients. (A-C) Tables show the frequency of mutations within TP53 (A), CDKN2A 
(B) and NRF2 (C) in our patient cohort compared with the COSMIC database (256). 
(D) Table showing the percentages of mutated samples. P value was obtained by Chi-
square test using Yates correction (two-tailed). After using the Bonferroni adjustment 
(r=3) the significant P value was lowered to 0.01667, therefore the number of TP53 
mutated samples is not statistically significant. 
 
 
Oesophageal squamous cell dysplasia and carcinoma are clonal  
 
To assess clonal expansion in OSCC, three patients were selected and analysed by 
LCM. These were patient 4, where the OSCC showed two independent functional 
mutations: a TP53 exon 8 (c.G818A p.Arg273His) and an NRF2 (c.T70C p.Trp24Arg) 
mutations; patient 26, where the OSCC showed a TP53 exon 5 mutation (c.G856A 
p.Glu286Lys); and patient 28, where the oesophageal squamous cell dysplasia had a 
TP53 exon 5 mutation (c.C493T Gln165Stop). LCM was then performed for 
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hyperplastic, dysplastic and carcinoma areas, when present in the available tissue for 
each patient (see Table 4.2). 
 
Table 4.2. Randomly selected patients for laser-capture microdissection. List of 
the blocks of oesophageal epithelium used for laser-capture microdissection from the 
three patients selected randomly. Oesophageal squamous cell carcinoma, OSCC. 
 
Patient	  
Genes	  
mutated	   Block	  	   Histopathological	  phenotypes	  present	  
4	  
TP53	  
+	  NRF2	   B	   Hyperplasia,	  dysplasia	  and	  OSCC	  
26	   TP53	  	   H	   Hyperplasia	  and	  OSCC	  
	  	   	  	   J	   Hyperplasia	  and	  OSCC	  
	   	  
L	   OSCC	  
28	   TP53	  	   7	   Dysplasia,	  focal	  OSCC	  and	  infiltrated	  ducts	  
	  	  
	  
8	   Dysplasia	  and	  infiltrated	  ducts	  
	  	   	  	   9	   Dysplasia	  and	  focal	  OSCC	  
 
 
A specimen of oesophageal epithelium from patient 4 had muscle, hyperplastic and 
dysplastic areas that were WT for both TP53 and NRF2 (Figure 4.2). The surrounding 
invasive OSCC only showed one population of cells, mutated TP53 and mutated 
NRF2 within all areas of carcinoma (Figure 4.2). OSCC dissected area 14 appeared 
WT for both TP53 and NRF2; however, this was due to the high levels of 
keratinisation and inflammatory cells present in that carcinoma area, which meant that 
the sample had extremely low numbers of carcinoma cells (see Table 4.3). 
 
The dissected muscle and hyperplastic areas from patient 26 were WT in the three 
consecutive specimens of oesophageal epithelial mucosa (Figures 4.3, 4.4 and 4.5). 
Areas of highly invasive OSCC with elevated levels of keratinisation were present in 
the same specimens and these had the TP53 mutation c.G856A (Figures 4.3, 4.4 and 
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4.5). However, around 4.6% of carcinoma areas (3/65) did not show the mutation. This 
again seemed to be due to the high levels of keratinisation and inflammatory cells 
within the carcinoma, which diluted the quantity of OSCC cells present in samples 14 
(specimen block H), 15 (specimen block J) and 18 (specimen block L). The raw data 
linking the identified mutations to each microdissected area with the relevant histology 
can be found in Tables 4.4, 4.5 and 4.6, respectively. 
 
All muscle areas microdissected from three consecutive blocks from patient 28 were 
WT for TP53 (Figures 4.6, 4.7 and 4.8). Areas of dysplasia, focal invasive OSCC and 
infiltrated oesophageal ducts showed the TP53 mutation c.C493T. Nevertheless, 
around 3% of dysplastic areas (3/98) found amongst fields of TP53 mutated dysplasia 
appeared TP53 WT. This lack of mutations could either be due to poor DNA quality 
and artefact during the PCR reaction, sample contamination with surrounding 
inflammatory cells, LOH of the TP53 mutated allele or the actual lack of mutation 
within these specific dysplastic areas. The raw data linking the identified TP53 
mutation for each microdissected area with the histology can be found in Tables 4.7, 
4.8 and 4.9, respectively. 
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Figure 4.2. TP53 and NRF2 mutations were found in all areas of oesophageal 
squamous cell carcinoma but not in dysplasia or hyperplasia in patient 4. (A) A 
H&E of an entire section of oesophageal mucosa showing a moderately well 
differentiated oesophageal squamous cell carcinoma (OSCC) with dysplasia and 
hyperplasia; tissue from patient 4. (B) Higher power of highlighted areas showing 
from left to right two areas of OSCC, an area of dysplasia and an area of hyperplasia. 
(C) Serial section showing post laser-capture microdissection (LCM). Yellow areas 
are TP53 WT whereas dark blue areas are positive for the TP53 mutation c.G818A. 
Light green areas are NRF2 WT whereas pink areas are positive for the NRF2 
mutation c.T70C. (D, E, F and G) Four representative traces showing the TP53 
mutation c.G818A (D), a TP53 WT trace (E), the NRF2 mutation c.T70C (F), and a 
NRF2 WT trace (G). (H) Key for patient 4 on post LCM section. 
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Table 4.3. Association of the identified mutations with histology shows TP53 and 
NFR2 mutations were found in all areas of oesophageal squamous cell carcinoma 
but not in dysplasia or hyperplasia in patient 4. This table corresponds to the laser-
capture microdissection data presented in Figure 4.2, tissue from patient 4. WT, wild 
type. 
 
 
 
 
 
 
 
 
 
 
 
 166 
 
 
 
Figure 4.3. TP53 mutations were found in all areas of oesophageal squamous cell 
carcinoma but not in hyperplasia in patient 26. (A) A H&E of an entire section of 
oesophageal mucosa showing a poorly differentiated oesophageal squamous cell 
carcinoma (OSCC) with hyperplasia, tissue from patient 26, specimen block H. (B) 
Higher power of highlighted areas showing from left to right two areas of OSCC and 
an area of hyperplasia. (C) Serial section showing post laser-capture microdissection 
(LCM). Yellow areas are TP53 WT whereas dark blue areas are positive for the TP53 
mutation c.G856A. (D and E) Two representative traces showing the TP53 mutation 
c.G856A (D) and a TP53 WT trace (E). (F) Key for patient 26 on post LCM section. 
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Table 4.4. Association of the identified mutation with histology shows TP53 
mutations were found in all areas of oesophageal squamous cell carcinoma but 
not in hyperplasia in patient 26. This table corresponds to the laser-capture 
microdissection data presented in Figure 4.3, tissue from patient 26, specimen block 
H. WT, wild type. 
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Figure 4.4. TP53 mutations were found in all areas of oesophageal squamous cell 
carcinoma but not in hyperplasia in patient 26. (A) A H&E of an entire section of 
oesophageal mucosa showing a poorly differentiated oesophageal squamous cell 
carcinoma (OSCC) with hyperplasia, tissue from patient 26, specimen block J. (B) 
Higher power of highlighted areas showing from left to right two areas of OSCC and 
an area of hyperplasia. (C) Serial section showing post laser-capture microdissection 
(LCM). Yellow areas are TP53 WT whereas dark blue areas are positive for the TP53 
mutation c.G856A. (D and E) Two representative traces showing the TP53 mutation 
c.G856A (D) and a TP53 WT trace (E). (F) Key for patient 26 on post LCM section. 
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Table 4.5. Association of the identified mutation with histology shows TP53 
mutations were found in all areas of oesophageal squamous cell carcinoma but 
not in hyperplasia in patient 26. Table corresponding to the laser-capture 
microdissection data presented in Figure 4.4, tissue from patient 26, specimen block J. 
WT, wild type. 
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Figure 4.5. TP53 mutations were found in all areas of oesophageal squamous cell 
carcinoma in patient 26. (A) A H&E of an entire section of oesophageal mucosa 
showing a poorly differentiated oesophageal squamous cell carcinoma (OSCC), tissue 
from patient 26, specimen block L. (B) Higher power of highlighted areas showing 
three areas of OSCC. (C) Serial section showing post laser-capture microdissection 
(LCM). Yellow areas are TP53 WT whereas dark blue areas are positive for the TP53 
mutation c.G856A. (D and E) Two representative traces showing the TP53 mutation 
c.G856A (D) and a TP53 WT trace (E). (F) Key for patient 26 on post LCM section. 
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Table 4.6. Association of the identified mutation with histology shows TP53 
mutations were found in all areas of oesophageal squamous cell carcinoma in 
patient 26. This table corresponds to the laser-capture microdissection data presented 
in Figure 4.5, tissue from patient 26, specimen block L. WT, wild type. 
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Figure 4.6. TP53 mutations were found in all dysplastic areas, in focal areas of 
invasive oesophageal squamous cell carcinoma and in infiltrated oesophageal 
ducts in patient 28. (A) A H&E of an entire section of oesophageal mucosa showing 
dysplasia and small areas of invasive oesophageal squamous cell carcinoma (OSCC), 
tissue from patient 28, specimen block 7. (B) Higher power of highlighted areas 
showing from left to right an area of dysplasia, an area of dysplasia with a small 
invasive island of OSCC and another area of dysplasia. (C) Serial section showing 
post laser-capture microdissection (LCM). Yellow areas are TP53 WT whereas dark 
blue areas are positive for the TP53 mutation c.C493T. (D and E) Two representative 
traces showing the TP53 mutation c.C493T (D) and a TP53 WT trace (E). (F) Key for 
patient 28 on post LCM section. 
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Table 4.7. Association of the identified mutation with histology shows TP53 
mutations were found in all dysplastic areas, in focal areas of oesophageal 
squamous cell carcinoma and in infiltrated oesophageal ducts in patient 28. This 
table corresponds to the laser-capture microdissection data presented in Figure 4.6, 
tissue from patient 28, specimen block 7. WT, wild type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 174 
 
 
Figure 4.7. TP53 mutations were found in all dysplastic areas and in infiltrated 
oesophageal ducts in patient 28. (A) A H&E of an entire section of oesophageal 
mucosa showing dysplasia, tissue from patient 28, specimen block 8. (B) Higher 
power of highlighted areas showing three areas of dysplasia. (C) Serial section 
showing post laser-capture microdissection (LCM). Yellow areas are TP53 WT 
whereas dark blue areas are positive for the TP53 mutation c.C493T. (D and E) Two 
representative traces showing the TP53 mutation c.C493T (D) and a TP53 WT trace 
(E). (F) Key for patient 28 on post LCM section. 
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Table 4.8. Association of the identified mutation with histology shows TP53 
mutations were found in all dysplastic areas and in infiltrated oesophageal ducts 
in patient 28. This table corresponds to the laser-capture microdissection data 
presented in Figure 4.7, tissue from patient 28, specimen block 8. WT, wild type. 
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Figure 4.8. TP53 mutations were found in all dysplastic areas and in focal areas of 
invasive oesophageal squamous cell carcinoma in patient 28. (A) A H&E of an 
entire section of oesophageal mucosa showing dysplasia and small areas of invasive 
oesophageal squamous cell carcinoma (OSCC), tissue from patient 28, specimen block 
9. (B) Higher power of highlighted areas showing from left to right an area of 
dysplasia and two areas of dysplasia and OSCC. (C) Serial section showing post laser-
capture microdissection (LCM). Yellow areas are TP53 WT whereas dark blue areas 
are positive for the TP53 mutation c.C493T. (D and E) Two representative traces 
showing the TP53 mutation c.C493T (D) and a TP53 WT trace (E). (F) Key for patient 
28 on post LCM section. 
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Table 4.9. Association of the identified mutation with histology shows TP53 
mutations were found in all dysplastic areas and in focal areas of oesophageal 
squamous cell carcinoma in patient 28. This table corresponds to the laser-capture 
microdissection data presented in Figure 4.8, tissue from patient 28, specimen block 9. 
WT, wild type. 
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Oesophageal squamous cell dysplasia and carcinoma demonstrate clonal 
expansion through tumour progression 
 
Three phylogenetic trees were used to summarise the data for patients 4 (A), 26 (B) 
and 28 (C) (Figure 4.9).  
 
In the case of patient 4 it can be inferred that at some point in the development of 
oesophageal squamous cell dysplasia both a TP53 and an NRF2 mutation must have 
occurred (Figure 4.9A). As seen in GA (Figure 3.19), one of the mutations occurred 
first, followed by a second mutation through clonal evolution as the tumour 
progressed. Because all OSCC areas presented the same TP53 and NRF2 mutations, 
this data indicates that OSCC is clonal, that this clone was likely to have evolved from 
an original dysplastic mutated clone and that a second mutation was likely to have 
caused the transition from dysplasia to OSCC.  
 
The phylogenetic tree of patient 26 demonstrated that all OSCC areas had a TP53 
mutation and that this mutation was probably also present in the dysplasia. However, 
this could not be confirmed experimentally due to a lack of available dysplastic tissue 
for this particular patient (Figure 4.9B). 
 
In the case of patient 28, a TP53 mutation arose during clonal expansion in the 
dysplasia or even at an earlier stage, which probably led to further progression of the 
carcinoma. The TP53 mutated clone was also found in the focal OSCC areas 
surrounding the dysplasia and also in the infiltrated oesophageal ducts. This shows 
that a mutation present in cells within a dysplastic area can clonally expand to form an 
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associated carcinoma and, in this case, the oesophageal squamous cell dysplasia and 
OSCC were therefore clonal (Figure 4.9C).  
 
 
Figure 4.9. Phylogenetic trees provide evidence for a monoclonal origin for 
oesophageal squamous cell carcinoma. (A-C) Phylogenetic trees representative of 
patients 4 (A), 26 (B) and 28 (C) presenting oesophageal squamous cell carcinoma 
(OSCC), the data has been interpreted from the experimental data found in Figures 4.2 
to 4.8. Tree branches represent phenotypic or genotypic changes. The wild type 
genotype is coloured in yellow (representing TP53) and/or green (representing NRF2). 
NRF2 mutations are coloured in pink and TP53 mutations are coloured in dark blue. 
Cumulative mutations are represented by different coloured lines and a “?” has been 
used to highlight likely but not proven genotypic and phenotypic events previous to 
OSCC development in the three patients. 
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4.3. Discussion 
 
All samples were screened for mutations in the three most frequently mutated genes in 
OSCC. These genes account for over 70% of all somatic mutations previously 
reported for OSCC in the COSMIC database (16/05/2013) (256). However, from the 
33 patients included in our study, 12 (36.36%) presented with a single identifiable 
functional mutation and only 2 (6.06%) presented two functional mutations. After 
using the Bonferroni adjustment for multiple testing, all mutation frequencies obtained 
were comparable to those from previous reports (260) (Figure 4.1).  The absence of 
mutations in a large proportion of our OSCC patients (63.64%) could indicate that 
other mutational events occur at a much higher frequency in OSCC than has been 
reported previously. These would include LOH at TP53 locus 17p13.1; LOH and 
promoter methylation of p15INK4b and CDKN2A respectively; reduced Rb expression 
and cyclin D1; mutations in the ras family and Notch1 signalling pathway; and EGFR 
and c-myc gene amplifications (162, 167, 230-233, 259, 261).  
 
This lack of mutations could also be explained by mutational events in genes not yet 
known to have an effect in sporadic OSCC, such as mutations in the TOC 
susceptibility gene RHBDF2.  Von Brevern et al have already reported high levels of 
LOH of microsatellite markers in the 17q region correspondent to RHBDF2 in 
sporadic OSCC; however, RHBDF2 somatic mutations have not yet been reported 
(262). Moreover, there are very few exome sequencing studies for OSCC. Agrawal 
and colleagues performed a study comparing genetic differences between OAC and 
OSCC in North American patients, suggesting that different genes are involved in 
carcinogenesis in both tumour types and that the ethnicity and geographic location of 
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OSCC patients considerably affects the genes involved in different subtypes of OSCC, 
as is the case for Notch1 (233). Further exome sequencing studies will hopefully 
reveal novel target genes pertinent to the development of OSCC.  
 
To study clonal expansion in OSCC, the tissue from 3 patients that had detectable 
mutations were studied by LCM of FFPE specimens with varied histology, including 
hyperplasia, dysplasia and carcinoma. The data suggested that during field 
cancerisation a mutation might arise in a pre-neoplastic area (for example in an area of 
oesophagitis (162)), followed by the development of dysplasia where subsequent 
mutations will occur via clonal evolution. Clonal expansion within the dysplasia will 
eventually lead to progression into a squamous cell carcinoma (Figure 4.9). In tissue 
from patients 4 and 26 OSCC areas contained mutated cells. Whilst, in tissue from 
patient 28 all dysplastic areas and associated focal OSCC and infiltrated oesophageal 
ducts were populated by mutated cells. In the case of patient 4 it is likely that a 
mutation in a gene not included in the screening was responsible for field 
cancerisation, since the microdissected dysplasia area appeared WT for both TP53 and 
NRF2. Overall, the LCM data of these patients suggested that OSCD and OSCC were 
clonal and that clonal expansion occurred as the tumour progressed.  
 
Therefore the results from this study are in agreement with those of Shima and 
colleagues (259): LOH analysis showed that single clones within OSCC fields 
acquired further loss of microsatellites as the carcinoma evolved. These results were 
also in agreement with the findings from Mandard et al (162), who observed a TP53 
mutated clone in an area of oesophagitis which clonally expanded into a squamous cell 
carcinoma. However, Mandard and colleagues had observed two areas of oesophagitis 
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containing two different TP53 mutations. This could be explained by a mutation in an 
unknown gene that through field cancerisation took over the oesophageal mucosa and 
then, via clonal evolution, led to genetic divergence in the oesophagitis and finally 
genetic progression into a carcinoma. Following on from previous work and using data 
from this study, it seems likely that OSCC is monoclonal in origin and that genetic 
heterogeneity arises through clonal evolution (88). This was observed in the study of 
clonal expansion in GA (Results Chapter 3), and not because of clonal competition as 
seen in BO (157) and colorectal microadenomas (16).  
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5. Clonal expansion in tylosis with oesophageal cancer 
 
 
5.1.  Introduction 
 
Tylosis with oesophageal cancer (TOC) is a rare familial syndrome inherited in an 
autosomal-dominant manner (163). Symptoms include palmoplantar keratoderma 
(PPK), oral keratosis and follicular papules and it can be associated with a high risk 
for oesophageal SCC development (up to a 95% by the age of 65) (237-239). 
Rhomboids are intramembrane serine proteases, which typically contain six or seven 
transmembrane domains (TMD) classified into four subgroups: Secretase A and B, 
Presenilin-Associated-Rhomboid-Like (PARL) and iRhoms (240). The gene 
responsible for TOC was recently identified as the inactive rhomboid protease 
RHBDF2, also known as iRhom2 (163). To date, heterozygous missense RHBDF2 
mutations have been found in four different families: from the UK, c.T557C 
p.Ile186Thr; US, c.T557C p.Ile186Thr; Germany, c.C566T p. Pro189Leu; and 
Finland, c.A562G p.Asp188Asn (163, 263). iRhoms are predicted to localise to the 
endoplasmic reticulum (ER) membrane (241) although in the epidermis and 
oesophagus RHBDF2 is also localised at the plasma membrane (163). The TOC 
mutations have been found clustered in the highly conserved extended N-terminal 
domain of RHBDF2, suggesting an important function for this region of the RHBDF2 
protein (see Introduction Figure 1.8) (242).  
 
The Secretase A type Rhomboid RHBDL2 is the active Rhomboid relative of iRhom1 
and RHBDF2 (240). RHBDL2 is known to be responsible for EGF cleavage 
independently of ADAM (A Desintegrin And Metalloprotease) family members: 
thrombomodulin (ThM) in wound healing; and ephrin B3, where cleavage may lead to 
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intercellular interactions between ephrinB3 and eph receptors (243, 264, 265). Both 
iRhom1 1 and RHBDF2 lack the catalytic residues present in active Rhomboid 
proteases and, instead, they present an invariant proline residue that is N terminal to 
the expected location of the catalytic serine (i.e., GPx replacing the GxS rhomboid 
catalytic motif) (Figure 1.8 A) (244, 245). Nevertheless, Zettl and colleagues showed 
that human iRhom1 and mouse RHBDF2 interact directly with the RHBDL2 ligand 
EGF in the ER using immunoprecipitation experiments; they were both found to target 
EGF for ER-associated degradation (ERAD) (245). Keratinocytes from TOC patients 
are unresponsive to exogenous EGF; but, in the absence of exogenous EGF cell 
migration and proliferation are maintained whereas both are significantly reduced in 
control keratinocytes (163). These results suggest that EGF levels might be higher in 
TOC patients and that human RHBDF2 also plays a physiological role in EGF 
signaling (163, 242).  
 
Both iRhom1 and RHBDF2 have been reported in the ER and Golgi in cultured cells 
(266, 267). Blaydon and colleagues observed strong plasma membrane expression and 
some cytoplasmic staining, probably representing the ER and the Golgi, in human 
stratified squamous epithelium such as the skin and the oesophagus (163, 242). These 
workers suggested that RHBDF2 trafficking or targeting is altered in TOC patients as 
they had observed that RHBDF2 immunohistochemistry staining was much more 
diffuse in human stratified skin biopsies from TOC patients compared to healthy 
controls. To date, no RHBDF2 mutations have been reported in sporadic OSCC, 
although Von Brevern and colleagues showed high levels of LOH of microsatellite 
markers in the 17q region correspondent to RHBDF2 in sporadic OSCC (262). In 
addition, Blaydon also showed a more cytoplasmic localisation of RHBDF2 in both 
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tylotic and sporadic OSCC patients suggesting that RHBDF2 also plays a role in the 
pathogenesis of sporadic OSCC development (163).  
 
Studies on RHBDF2 knock-out mice (RHBDF2-/-) revealed a severe reduction of 
TNFα levels in serum and in bone marrow derived macrophages (BMDMs), 
suggesting that RHBDF2 is critical for the TNF convertase (TACE) ADAM17 
maturation and trafficking from the endoplasmic reticulum (ER) (243, 246). Lack of 
activated ADAM17 in the cell membrane prevents the cleavage-mediated activation of 
TNFα leading to a severe reduction of TNFα levels in RHBDF2 -/- mice. In support of 
this suggestion, ADAM17, a member of the membrane-anchored ADAM family of 
proteases, is widely expressed in somatic tissues and is responsible for the proteolytic 
cleavage of the majority of known ectodomain shedding events (268), including TNFα 
and five of the seven known ligands of EGFR (269). Overall, these findings suggest 
that RHBDF2 binds to ADAM17 in the ER and is crucial for the trafficking of 
ADAM17 from the ER into the Golgi, where ADAM17 undergoes furin-mediated 
cleavage activation before trafficking to the cell surface (243). Unpublished data 
suggests that the RHBDF2 gain of function TOC mutations leads to an increased level 
of ADAM17-mediated shedding of EGF signalling molecules in TOC cells (242). This 
increased activation would account, in part, for the unresponsiveness of TOC 
keratinocytes to exogenous EGF and also for the hyperproliferative epidermal 
phenotype observed in tylotic patients (242). The epidermal hyperproliferation 
observed in the areas undergoing frequent wound healing might be due to the 
excessive ADAM17 activation, as observed in TOC, because wound healing is 
mediated, in part, via EGFR signalling in keratinocytes (247). 
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Hence, RHBDF2 appears capable of regulating EGFR signalling through two separate 
pathways by controlling the shedding of pro-EGF targeting for ERAD and also by 
controlling the rate of that shedding through the regulation of ADAM17 maturation 
and transit from the ER into the Golgi.  
 
5.1.1. Hypothesis and Aims 
 
The hypothesis for the project presented here is to investigate if TOC associated 
RHBDF2 mutations persist during tumour progression in TOC and that the localisation 
of RHBDF2 and ADAM17 plays a key role in oesophageal tumourigenesis.   
 
The aims of this project are: 
4. To characterise the mutational state of RHBDF2 in sporadic OSCC 
5. To determine if RHBDF2 germline gain of function mutations persist during tumour 
progression in TOC 
6. To assess the localisation of RHBDF2 and ADAM17 in sporadic OSCC and TOC 
 
6.3   Results 
 
TOC associated RHBDF2 mutations are not found in sporadic oesophageal 
squamous cell carcinomas but are present in oesophageal carcinomas from 
patients with tylosis 
 
To assess the mutational state of RHBDF2 in OSCC, areas of carcinoma or dysplasia 
in tumour tissue from 34 patients were needle macrodissected and screened for 
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mutations in the highly conserved extended N-terminal domain of RHBDF2 (exons 5 
and 6, for full methods see 2.1.4, 2.2 and 2.4). Patient 1 was removed from the 
screening due to insufficient DNA to obtain PCR results. From the 33 remaining 
patients, 30 presented with sporadic OSCC and 3 presented with TOC (these patients 
are also the ones from Results Chapter 4, see Table 4.1 and Table 7.6 in the appendix). 
The RHBDF2 mutations detected in this screening were exclusive to the 3 patients 
with TOC. Therefore, RHBDF2 does not appear to be mutated in sporadic OSCC at a 
high frequency, see Table 5.1.  
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Table 5.1. Summary of mutations in inactive rhomboid protein RHBDF2 in 
specimens from sporadic and tylosis associated oesophageal squamous cell 
carcinoma patients. Screening of 33 oesophageal squamous cell carcinomas (OSCC) 
for RHBDF2. Light grey, WT; dark blue, mutated samples; the mutations found are 
written in bold. Patient 1 was removed from the screening due to insufficient DNA to 
obtain PCR results. The red rectangles highlight the three samples analysed by laser-
capture microdissection and a “--“ has been used to highlight information that was not 
available. 
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RHBDF2 germline mutations can be lost in oesophageal carcinomas from 
patients with tylosis when carcinomas exhibit LOH in 17q 
 
To assess the clonality of TOC, the three tylotic patients (2, 33 and 34) who all carried 
the same germline RHBDF2 mutation (c.T557C p.Ile186Thr) were analysed by LCM 
for the muscle, dysplastic and carcinoma areas, when present in the available tissue for 
each patient (see Table 5.2). As TOC is caused by the germline mutation in RHBDF2, 
all laser-captured areas should present the c.T557C mutation unless LOH of the 
mutated allele had occurred during the clonal expansion of the carcinoma.  
 
 
Table 5.2. Oesophageal carcinoma from tylotic patients analysed by laser-capture 
microdissection. List of the blocks of oesophageal epithelium used for laser-capture 
microdissection from the three TOC patients.  
 
Patient	  
Gene	  
mutated	   Block	  	   Histopathological	  phenotypes	  and	  tissue	  
2	   RHBDF2	  	   2	   OSCC,	  Muscle	  
	  	   	  	   3	   OSCC,	  Muscle	  
33	   RHBDF2	   EE	   Dysplasia,	  OSCC,	  Muscle	  
34	   RHBDF2	   K	   Dysplasia,	  OSCC,	  Muscle	  
 
 
Two specimens of oesophageal epithelium from patient 2 had both muscle and 
OSCC areas available (Figures 5.1 and 5.2). As expected the muscle areas 
analysed showed the RHBDF2 mutation. However, there was a mixture of two 
populations in the carcinoma; one population of cells presenting the RHBDF2 
mutation and a WT population where the mutation appeared to be lost (see 
Table 5.3). 
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Dissected muscle, dysplasia and carcinoma areas from patient 33 all had the 
RHBDF2 mutation, indicating that there was no LOH of the mutated allele in 
this patient (Figures 5.3, Table 5.4). All muscle, dysplasia and carcinoma areas 
microdissected from patient 34 were WT for RHBDF2, which indicated there 
was LOH of the RHBDF2 mutated allele (Figures 5.4, Table 5.5). 
 
Retrospective studies using extracted DNA from two separate samples of frozen 
tumour tissue from patient 34 showed the T/C and T/T genotype respectively 
(163). In addition, studies using single-nucleotide polymorphism analysis on 
patients 33 and 34 revealed genetic instability in the tumour in patient 34 but 
not in patient 33. LOH data on chromosome 17q25 from the same DNA sample 
prepared from a frozen tumour resection from patient 34 showed evidence of: 
retention of heterozygosity (2 markers); loss of the WT allele (3 markers); and 
loss of the mutated allele  (2 markers) (Figure 5.5). These results are consistent 
with the findings presented here as we found the mutation in all muscle, 
dysplasia and carcinoma LCM areas of patient 33 (B) but not in those of patient 
34 (C). 
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Figure 5.1. The RHBDF2 germline mutation was absent from areas of 
oesophageal squamous cell carcinoma from patient 2 indicating loss of 
heterozygosity of the mutated allele. (A) A H&E of an entire section of 
oesophageal mucosa showing a poorly differentiated oesophageal squamous cell 
carcinoma (OSCC), tissue from patient 2, specimen block 2. (B) Higher power 
of highlighted areas showing three areas of OSCC. (C) Serial section showing 
post laser-capture microdissection (LCM). Yellow areas are RHBDF2 WT 
whereas dark blue areas are positive for the RHBDF2 mutation c.T557C. (D and 
E) Two representative traces showing the RHBDF2 mutation c.T557C (D), an 
RHBDF2 WT trace (E). (F) Key for patient 2 on post LCM section. 
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Figure 5.2. The RHBDF2 germline mutation was absent from areas of 
oesophageal squamous cell carcinoma from patient 2 indicating loss of 
heterozygosity of the mutated allele. (A) A H&E of an entire section of 
oesophageal mucosa showing a poorly differentiated oesophageal squamous cell 
carcinoma (OSCC), tissue from patient 2, specimen block 3. (B) Higher power 
of highlighted areas showing from left to right an area of OSCC, a muscle area 
and another area of OSCC. (C) Serial section showing post laser-capture 
microdissection (LCM). Yellow areas are RHBDF2 WT whereas dark blue 
areas are positive for the RHBDF2 mutation c.T557C. (D and E) Two 
representative traces showing the RHBDF2 mutation c.T557C (D), an RHBDF2 
WT trace (E). (F) Key for patient 2 on post LCM section. 
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Table 5.3. Association of the germline mutation with histology shows that 
the RHBDF2 mutation was absent from areas of oesophageal squamous 
cell carcinoma from patient 2 indicating loss of heterozygosity of the 
mutated allele. These tables correspond to the laser-capture microdissection 
data presented in Figure 5.1 (A) and 5.2 (B), tissue from patient 2, specimen 
blocks 2 and 3 respectively. WT, wild type. 
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Figure 5.3. The RHBDF2 germline mutation was present in all areas of 
oesophageal squamous cell carcinoma from patient 33 indicating there is 
no loss of heterozygosity of the mutated allele. (A) A H&E of an entire 
section of oesophageal mucosa showing a specimen with oesophageal 
squamous cell carcinoma (OSCC), tissue from patient 33. (B) Higher power of 
highlighted areas showing three areas of OSCC. (C) Serial section showing post 
laser-capture microdissection (LCM). Yellow areas are RHBDF2 WT whereas 
dark blue areas are positive for the RHBDF2 mutation c.T557C. (D and E) Two 
representative traces showing the RHBDF2 mutation c.T557C (D), an RHBDF2 
WT trace (E). (F) Key for patient 33 on post LCM section. 
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Table 5.4. Association of the germline mutation with histology shows that 
the RHBDF2 mutation was present in all areas of oesophageal squamous 
cell carcinoma from patient 33 indicating there is no loss of heterozygosity 
of the mutated allele. This table corresponds to the laser-capture 
microdissection data presented in Figure 5.3, tissue from patient 33. 
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Figure 5.4. The RHBDF2 germline mutation was absent from oesophageal 
squamous cell carcinoma, dysplasia or muscle epithelium obtained from 
patient 34 indicating loss of heterozygosity of the mutated allele. (A) A 
H&E of an entire section of oesophageal mucosa from patient 34 showing a 
poorly differentiated oesophageal squamous cell carcinoma (OSCC) and areas 
of dysplastic tissue. (B) Higher power of highlighted areas showing from left to 
right an area of dysplasia and two areas of OSCC. (C) Serial section showing 
post laser-capture microdissection (LCM). Yellow areas are RHBDF2 WT 
whereas dark blue areas are positive for the RHBDF2 mutation c.T557C. (D and 
E) Two representative traces showing the RHBDF2 mutation c.T557C (D), an 
RHBDF2 WT trace (E). (F) Key for patient 34 on post LCM section. 
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Table 5.5. Association of the germline mutation with histology shows that 
the RHBDF2 mutation was absent from oesophageal squamous cell 
carcinoma, dysplasia or muscle epithelium obtained from patient 34 
indicating loss of heterozygosity of the mutated allele. This table corresponds 
to the laser-capture microdissection data presented in Figure 5.4, tissue from 
patient 34. WT, wild type. 
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Figure 5.5. Single-nucleotide polymorphism analysis reveals genetic 
instability in patient 34 but not in patient 33. (A) Schematic representation of 
the location of the microsatellites used for single-nucleotide polymorphism 
(SNP) analysis for chromosome 17, seen in tables B and C. (B-C) These tables 
correspond to the SNP analysis performed on patients 33 (B) and 34 (C) using 
blood or adjacent normal tissue and frozen tumour tissue by pyrosequencing as 
given in (163). WT, wild type; MUT, mutated; +, both alleles are present in 
chromosome 17; Loss of mutated and WT allele analysed by SNP analysis. This 
work was carried out by Dr J. Risk, Dr A.Ellis and Dr J.K Field at the 
Department of Molecular & Clinical Cancer Medicine, Institute of Translational 
Medicine. 
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Investigating RHBDF2 and ADAM17 expression in sporadic and tylotic 
oesophageal squamous cell carcinoma. 
 
To study the role of RHBDF2 and ADAM17 in the pathogenesis of OSCC 
development, RHBDF2 and ADAM17 IHC was performed on patients 
presenting either sporadic oesophageal squamous cell dysplasia, OSCC or TOC. 
As no RHBDF2 mutations were found in any of the sporadic OSCC patients 
(Table 5.1) patients 26 and 28 only, from the LCM study on clonal expansion in 
sporadic OSCC, were selected for IHC (Results Chapter 4). IHC was also 
performed on tissue from patients 33 and 34 that were part of the LCM study on 
clonality in TOC. 
 
Even though RHBDF2 and ADAM17 primary antibodies were optimised 
several times in the pathology department, neither of the antibodies seemed very 
specific and they both showed a significant amount of background in all 
samples, which made the analysis extremely difficult. The staining revealed a 
cytoplasmic localisation of RHBDF2 and ADAM17 in both sporadic and tylotic 
OSCC, which could represent protein in the ER and the Golgi (Figure 5.6). Both 
RHBDF2 and ADAM17 showed a similar staining pattern in the OSCC from 
the different patients, being strong in the 2 to 3 basal cells along dysplastic areas 
and stronger in areas of OSCC. Nevertheless, the staining seemed much weaker 
and variable in tylotic associated OSCC (C, D, H and I) than in sporadic 
oesophageal squamous cell dysplasia and OSCC (M, N, R and S). Due to a lack 
of better antibodies, no final conclusions could be drawn on a higher expression 
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level of ADAM17 in TOC specimens, where there is an RHBDF2 gain of 
function mutation, compared to sporadic specimens.  
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6.3  Discussion 
 
Both sporadic and tylotic OSCC were screened for the RHBDF2 gain of function 
mutations that are known to be responsible for TOC (163). However, mutations were 
only found in the OSCCs from the three TOC patients in the screening, which are 
germline RHBDF2 mutations. The other 30 patients with sporadic OSCC were all WT 
for RHBDF2. Hence, there are still no RHBDF2 mutations reported in sporadic OSCC 
and mutation of the highly conserved N-terminal domain from RHBDF2 does not 
seem crucial for OSCC development in sporadic cases. It is, of course, possible that 
RHBDF2 mutations are present in the RHBDF2 exons that were not sequenced in 
sporadic OSCC. However, no RHBDF2 mutations have been reported from the exome 
sequencing studies published to date in a number of SCC tumour types (233, 270). 
 
To study clonal expansion in TOC and determine if RHBDF2 germline gain of 
function mutations persist during tumour progression in TOC, tissue from FFPE 
specimens provided by the three TOC patients were analysed by LCM. These 
specimens showed varied histology and included dysplasia and carcinoma. The data 
suggests that there is LOH of the mutated allele on chromosome 17q resulting in the 
loss of the germline mutation. We observed RHBDF2 mutated and WT populations of 
cells in very poorly differentiated OSCC specimens from patient 2. These two 
populations of cells are within the same carcinoma confirming that LOH can occur 
during clonal expansion in tumour progression in TOC. Retrospective single-
nucleotide polymorphism studies carried out on frozen surgical resections from 
OSCCs from patients 33 and 34 suggested that in the case of patient 34 LOH occurred 
on both chromosomes in regions of 17q25, including LOH of two markers in the 
 203 
mutated allele (Figure 5.5 C). Moreover, DNA from frozen tumour resections also 
revealed a loss of the RHBDF2 mutation. These findings were supported by the LCM 
study, as all patient 33 areas were RHBDF2 mutated whereas all areas from patient 34 
were WT. It can therefore be concluded from both previous studies and the LCM 
study presented here that, as Von Brevern and colleagues had observed in sporadic 
OSCC (262), OSCC from tylotic patients can also present high levels of LOH of 
microsatellite markers in the 17q region correspondent to RHBDF2 during tumour 
progression.  
 
To investigate the function of RHBDF2 and its relation to ADAM17 in both sporadic 
and tylotic OSCC, we performed IHC of both proteins in serial sections of two OSCC 
and two TOC patients. From the study of Blaydon and colleagues (163), we expected 
to find a cytoplasmic localisation of RHBDF2 in both sporadic and tylotic OSCC 
specimens. We also anticipated that if RHBDF2 facilitates the translocation of 
ADAM17 from the ER into the Golgi, then ADAM17 staining should be cytoplasmic, 
as per RHBDF2 (representing the ER and the Golgi), but would also be present in the 
cell membrane as ADAM17 is a cell surface membrane anchored protease (243). 
However, both primary antibodies stained blood vessels, blood cells, inflammatory 
cells and muscle even after two rounds of IHC optimisation in the pathology 
department. According to the analysis carried out with the help of the pathologists, it 
was concluded that due to the high background staining and the apparent unspecificity 
of the primary antibodies the staining could not be scored and quantified as previously 
planned. However, the best possible descriptive analysis of the staining given the 
circumstance suggested that both RHBDF2 and ADAM17 show a similar cytoplasmic 
staining pattern, which appeared weak and variable in the TOC samples; and stronger, 
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but still variable, in the sporadic OSCC samples. ADAM17 IHC did not appear 
membranous in any of the samples. The connection between a higher expression level 
of ADAM17 in TOC specimens, where there is an RHBDF2 gain of function 
mutation, compared to sporadic specimens, could not be established.  
 
Future work should consist of a quantifying study with new primary RHBDF2 and 
ADAM17 antibodies on tylotic and sporadic OSCC patients for which the mutation 
status of RHBDF2 needs to be previously established. New primary antibodies would 
be necessary in order to assess the role of the EGFR signalling pathway in wound 
healing in tylotic patients (163, 242, 247).   
 
In summary, it would appear that RHDBF2 mutations are not crucial for OSCC 
development in sporadic cases. Clonal analysis of OSCC in tylotic patients has 
revealed that clonal expansion can lead to LOH of microsatellites in the region of 
17q25, hence leading to a loss of the mutated allele of RHBDF2.  This would fit the 
data from the LCM study on sporadic OSCC (Results Chapter 4), which suggested that 
OSCC is monoclonal in origin and that genetic heterogeneity arises through clonal 
evolution (88), as was also observed in the study of clonal expansion in GA (Results 
Chapter 3). As the loss of the mutated allele of RHBDF2 does not seem to stop cancer 
progression, the RHBDF2 gain of function mutation might be required to initiate 
OSCC development in tylotic patients but may not be needed for cancer progression. 
Further studies on the molecular role of RHBDF2 in combination with ADAM17 will 
give more insight into the role of RHBDF2 in the pathogenesis of OSCC development 
(163, 242). 
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6. Discussion 
 
6.1 Summary of findings 
 
The somatic mutation theory of carcinogenesis has provided a framework for some of 
the most important advances in 20th century translational oncology. This theory 
proposes that tumour clonality is the result of sequential mutations of the progeny of a 
single stem cell (271). Previously, genetic studies have analysed large areas of tissue 
or biopsies, but could not rule out the presence of other clones or subclones, since the 
large number of cells used for DNA isolation could mask genetic heterogeneity. 
Recent improvements based on laser microdissection and isolation of pre-neoplastic 
and tumour tissue have permitted the work in this thesis and allowed an exploration of 
clonality and mutation burden, but at a much higher resolution than previously 
possible in the carcinomas studied here. Implementation of these new technologies has 
resulted in clonality studies becoming an essential tool for investigations in tumour 
biology. Here I present a study involving different carcinoma aetiologies and different 
areas of the gastrointestinal tract; this has afforded some comparison of carcinogenic 
processes in gastrointestinal malignancies. 
 
Previous publications had linked large fields of IM in the human stomach to a higher 
incidence of GA and had also observed the same genetic mutations in areas of IM and 
in the associated preneoplastic lesions present in follow-up biopsies (153, 187, 193). 
Moreover, findings from our laboratory proved that IM glands are clonal and expand 
by crypt fission (71). The results from this study on clonal origins of dysplasia from 
intestinal metaplasia show that dysplastic glands are also clonal as all glands within an 
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entire region of dysplasia contain a founder mutation (Figures 3.1, 3.2 and 3.4). 
Importantly the total percentage of mutated IM glands was very small (Table 3.2) (72), 
indicating that after the occurrence of a mutation in IM, cellular expansion can take 
place rapidly followed by the formation of dysplastic glands. Hence, large clonal 
lesions of dysplasia can arise from IM, which can be perceived as field cancerisation 
of the human stomach. 
 
In order to find dysplastic lesions with mutations in the first project, and subsequently 
to study clonal expansion in GA, 23 patients specimens and 51 GA tumours, 
respectively, were screened for genes accounting for approximately 75% of all somatic 
mutations reported previously for GA in the COSMIC database (16/05/2013) (256). 
Even though our mutation frequencies were comparable to those from previous reports 
(256) (Figure 3.5), the low percentage of mutations found in these specimens indicated 
that the specific genetic events described by Correa and colleagues (153) in the 
stepwise progression towards GA does not fit with either of the LCM studies in the 
human stomach presented here (Figure 3.30). 
 
The results from LCM of specimens from 6 patients presenting with GA suggested 
that during field cancerisation a mutation arises in IM followed by the development of 
dysplasia where subsequent mutations occur. Hence, clonal expansion within the 
dysplasia leads eventually to progression to an adenocarcinoma, and HGD and GA are 
clonal (Figure 3.19). Some of the GA specimens presented WT and mutated TP53 
populations with the same LOH pattern, indicating that a founder mutation in an 
unknown gene must have taken place previous to the LOH. Therefore, these two 
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populations are clonal and have evolved through clonal evolution, as suggested in 
Nowell’s model of clonal evolution (88). 
 
The observation of field cancerisation in the human stomach in GA suggests that a 
similar event may also occur in HDGC. However, no TP53 mutations were found in 
the LCM study carried out in 5 patients presenting with HDGC. This data suggested 
that field cancerisation might be due to events such as promoter methylation of the 
WT CDH1 allele in HDGC, as it is thought to be the second hit mutation in over 50% 
of diffuse gastric carcinoma cases (257). The immunohistochemistry results for E-
cadherin in these patients revealed some signet ring areas positive for E-cadherin, even 
though the AB-PAS production was the same as that of E-cadherin negative areas and 
the negative control showed no background staining. However, as normal 
membranous staining has been observed in CDH1 methylated cells, the faint positive 
staining is most likely due to the low sensitivity of the immunohistochemical staining 
in detecting subpopulations of cells with gene methylation and hence downregulation 
of E-cadherin. 
 
In order to carry out a similar study to that of GA on clonal expansion in OSCC, a 
mutation screen was performed on 33 sporadic and tylotic OSCC tumours for genes 
accounting for approximately over 70% of all somatic mutations previously reported 
for OSCC in the COSMIC database (16/05/2013) (256). After using the Bonferroni 
adjustment for multiple testing all mutation frequencies obtained were comparable to 
previous reports (256), a low number of tumours presented identifiable mutations. 
This absence of mutations in a large proportion of our OSCC cohort could indicate 
that other mutational events in genes not present in the screening occur at a much 
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higher frequency in OSCC than reported previously. However, when both sporadic 
and tylotic OSCC specimens were screened for the RHBDF2 gain of function 
mutations that are known to be responsible for TOC (163), mutations were only found 
in the OSCCs from the three TOC patients in the screening. Therefore, RHBDF2 
mutations do not seem to be crucial for OSCC development in sporadic cases.   
 
To study clonal expansion in OSCC, as done previously on GA specimens, LCM was 
carried out on tumour specimens from 3 patients presenting with OSCC. The results 
show that field cancerisation seems to have occurred in a pre-neoplastic area, followed 
by the development of OSCD where subsequent mutations occur and leading 
eventually to OSCC. The LCM data shows that this process occurs via clonal 
evolution (Figure 4.9), and therefore that OSCD and OSCC are clonal. Hence, these 
findings are in agreement with those on the clonal origins of GA. 
 
Finally, to study clonal expansion in TOC and determine if RHBDF2 germline gain of 
function mutations persist during tumour progression in TOC, three TOC patients 
were analysed by LCM. The data shows both WT and mutated RHBDF2 populations 
in some TOC specimens, suggesting that, during tumour progression and clonal 
evolution, OSCC from tylotic patients can also show high levels of LOH of 
microsatellite markers in the 17q region correspondent to RHBDF2 (262). Therefore, 
there is also a clonal evolution process in tylotic associated OSCC. After analysing the 
ADAM17 and RHBDF2 immunohistochemistry staining in tylotic and sporadic OSCC 
specimens, ADAM17 levels did not appear higher in tylotic specimens, where there is 
an RHBDF2 germline gain of function mutation.  
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6.2 Polyclonality, monoclonality and intratumour heterogeneity 
 
In 1976, Peter Nowell postulated the clonal evolution model of cancer where tumours 
were described to originate from a single cell (88). This model applied evolutionary 
theories to understand tumour growth and treatment failure, as well as the increased 
tumour aggressiveness that occurs during the advanced stages of most solid tumours. 
Nowell proposed that the originating mutated clone acquired further mutations as a 
result of genetic instability and eventually led to a tumour composed of subclones with 
a higher selective advantage to that of the original tumour-initiating clone.  
 
Tumour morphologic heterogeneity was first observed by David Von Hansemann, in 
1890, describing that the first change occurring in cancer is an alteration of the 
hereditary material of a normal cell at the site where the cancerous process begins 
(272). Recent publications using whole exome sequencing of clear cell renal tumours 
have revealed a striking inter-tumour heterogeneity in patients with kidney cancer as 
additional candidate cancer genes have now been identified (273-276). This represents 
an obvious limitation to a homogenous approach in systemic therapy in cancer 
patients. The recent use of whole-genome sequencing in tumour biopsies in spatial and 
temporal studies have provided increasing evidence for intratumour heterogeneity 
(ITH). Examples include studies in breast cancer by Navin and colleagues that used 
flow-sorted nuclei, whole genome amplification and next generation sequencing or 
Sector-Ploidy-Profiling. The acquired data indicated that tumours grow by punctuated 
clonal expansions with few persistent intermediates and it has been used to study new 
potential pathways of cancer progression. It has also provided information on the 
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differences in tumour growth organisation in monogenomic and polygenomic tumours 
(277, 278). 
 
Linear models of tumour evolution with sequentially ordered somatic mutations in 
driver genes followed by clonal sweeps of homogeneous tumour cell expansion seem 
insufficient to justify the presence of ITH within a primary tumour, and also within 
metastatic tumour sites (279). Therefore, it appears that branched evolutionary tumour 
growth contributes to ITH. In a tree structure of tumour evolution, an initiating 
mutation driving tumour growth would occur in the “trunk” of the tumour and most 
likely be present ubiquitously in all sites of the tumour. Subsequently, later somatic 
events would appear following the branched separation of subclones and would hereby 
provide ITH. 
 
The results presented in this thesis suggest that both GA and OSCC have a clonal 
origin and that they both acquire genetic heterogeneity as the tumours evolve. They 
also show that tylotic OSCC can present LOH of the chromosome 17q region, 
responsible for the tylosis RHBDF2 germline mutation, during tumour progression. 
Therefore, this data subscribes to the Nowell clonal evolution model of cancer and 
also supports the increasing evidence that tumours show ITH as the subclones emerge.  
 
Studies on Crohn’s disease patients by Galandiuk and colleagues produced similar 
findings to those reported here (64). They detected a mutation within non-tumour 
tissue that was also found in the presenting tumour, suggesting a clonal relationship 
between the tumour and the surrounding pre-neoplastic mucosa due to field 
cancerisation. Nevertheless, these results differ from those obtained from the clonal 
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origin of Barrett’s lesions (157), where Leedham and colleagues observed that 
Barrett’s glands were a mosaic of multiple genetically distinct independent clones. 
These observations are also in contrast to the findings in colorectal microadenomas 
(16), where clonal analysis on a crypt-by-crypt basis suggested that colorectal 
adenomas can be polyclonal and that clonal evolution takes place throughout adenoma 
development. 
 
Overall, it would appear that different underlying pre-neoplastic conditions, such as 
FAP (16) or Crohn’s (64), lead to different modes of clonal evolution. Nevertheless, it 
is evident that ITH is present throughout the carcinomas mentioned herein and that 
clonal studies will provide further insight into the dynamics of tumour growth.  
 
6.3 Limitations of the work presented in this thesis	  	  
The work presented here was all performed on formalin-fixed paraffin embedded 
(FFPE) archival tissue. FFPE was preferable in these studies because patient’s tissues 
needed to be collected retrospectively: germline mutations such as RHBDF2 and 
CDH1 needed to be assessed first in the case of TOC and HDGC patients; and the 
proper orientation in the specimens was necessary to assess the spatial distribution of 
IM, HGD, GA, HDGC, OSCD and OSCC by LCM for clonal ordering studies. 
However, the use of FFPE tissue presents major methodological disadvantages that 
contribute to the limitations of this work. The major limitations are as follows: 
 
1. The small amounts of partially degraded DNA obtained by LCM from FFPE required 
nested PCR in order to allow the identification of mutations via PCR-sequencing. The 
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risk of contamination from both unintentionally dissected tissue and artefactual was 
high, but these were significantly reduced by careful use of LCM and by the use of 
several negative controls in every PCR reaction. Therefore, whilst risk of 
contamination was reduced to a minimum, the small amount of available lysate for 
each sample was a great limitation for this work particularly when either duplication 
of sequencing or multiple mutated genes were sequenced to verify findings.  
 
2. Data showing genetic alterations encompassed with microsatellite marker analysis of 
LOH increase greatly the significance of the findings. However, the small amount of 
DNA obtained from LCM as well as the lack of informative markers in control tissue 
for some of the patients restricted considerably the application of MS markers and 
limited mainly the amount of duplication possible. 
 
3. In order to study the clonal origins of the different carcinomas presented here it was 
important to have identified the founding mutation in the tissue. Even though all HGD, 
GA, OSCD and sporadic and tylotic OSCC specimens were individually screened for 
genes accounting for 70-75% of all somatic mutations previously reported for these 
carcinomas, a low percentage of patients presented with single identifiable functional 
mutations and a very low percentage (1.96% in GA specimens and 6.06% in OSCC 
specimens) presented with two functional mutations. The lack of hotspots in other 
genes related to these carcinomas, such as ARID1A and FAT4 for GA, and LOH, 
methylation changes and reduced expression, in genes such as p15INK4b and CDKN2A, 
Rb, cyclin D1 and Notch1 amongst others for OSCC, means that other more advanced 
sequencing and expression techniques should be used in this type of study; a number 
were not available at the start of this project or were too expensive to be considered. 
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Moreover, the specific genetic events described by Correa and colleagues (153) in the 
stepwise progression towards GA did not fit with either of our LCM studies in the 
human stomach and the data showed mutated and WT TP53 populations presenting 
the same LOH signature in GA. Therefore, this data suggests that founding mutations 
occurring in IM in the human stomach and in gastritis or OSCD in the human 
oesophagus were possibly missed in this study. However the work of this thesis was a 
clonality assay, re-assessing previous publications but using a higher resolution of 
microdissection and a complete screening of most of the known mutated genes in the 
individual specimens that were collected.  
 
4. The limited number of antibodies available for RHBDF2 and ADAM17 meant that the 
data obtained from the immunohistochemistry studies performed in sporadic and 
tylotic OSCC was very poor. Unfortunately, no definite correlation will be established 
between sporadic and tylotic carcinomas and between the function of RHBDF2 and 
ADAM17 until better molecular tools are in the market.  
 
6.4. Future directions 
 
This work has raised a number of important questions providing the basis for a great 
deal of further investigation. This section will briefly explore potential future 
directions: 	  
1. The genes involved in the stepwise progression towards GA (Chapter 3) and towards 
OSCC (Chapter 4): The use of more advanced deep-sequencing technologies in these 
samples such as whole-genome sequencing in the dysplasia and carcinoma specimens 
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would provide further insight into the tree structure of tumour growth of GA and 
OSCC and would probably allow a re-evaluation of the work presented here. 
 
2. Clonal analysis of IM, HGD, GA, OSCD and sporadic and tylotic OSCC (Chapters 3, 
4 and 5):  Performing SNP arrays on the LCM samples of different histology 
following the progression to both carcinomas in the same patients would improve 
considerably the knowledge of clonal analysis in both GA and OSCC. The tree 
structure of the carcinoma specimens analysed in this thesis would be much more 
complete and the study of the clones and subclones present would provide more 
insight into ITH in the cancers of the gastrointestinal tract. 
 
3. Clonal analysis of HDGC (Chapter 3.3): Performing deep-sequencing in the LCM 
areas of HDGC and bisulfite sequencing of CDH1 would clarify if the methylation of 
CDH1 is the second hit mutation for the formation of signet ring cells in HDGC in 
only 50% of the cases and would also highlight the presence of clones and subclones 
in the progression of HDGC. 
 
4. The relationship between ADAM17 and RHBDF2 (Chapter 5): Further studies using 
cell cultures and western blotting are currently assessing the individual function of 
RHBDF2 and ADAM17. Moreover, studies using fresh-frozen tissue have been able 
to localise RHBDF2 in vivo in the oesophagus and in the skin (163). Therefore, once 
better antibodies are available we will be able to assess the relationship in vivo 
retrospectively using FFPE tissue. 
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6.5. Final conclusions 
 
The work presented in this thesis has improved the resolution of the study of clonality 
by using somatic gene mutations to analyse the clonality of gastrointestinal pre-
neoplastic and neoplastic lesions in the human oesophagus and human stomach. The 
data presented here has made evident that different underlying inflammatory and pre-
neoplastic conditions lead to different modes of clonal evolution, as seen in the colon 
in FAP (16) and Crohn’s (64) patients and as seen in the oesophagus in Barrett’s 
oesophagus (157) and here in OSCD and OSCC. This work has also highlighted that 
the different organs of origin and the aetiology of the carcinomas mean that different 
genes are involved in the progression to distinct tumours types. Moreover, the data 
from the screenings of GA and OSCC has proved that inter-tumour heterogeneity 
occurs in the gastrointestinal tract as the tumour specimens analysed did not show a 
cohesive genetic signature, as for example Correa and colleagues had suggested (153).    
 
The somatic mutation theory of carcinogenesis seems to hold true for both the 
progression to GA and OSCC, as both carcinomas seem to evolve from a single 
mutated stem cell and acquire genetic heterogeneity as the tumours evolve. The 
mechanism does not currently fit all clonality studies. However, it is possible that 
future deep-sequencing results will bring into light founder mutations in genes still not 
known to be involved in certain malignant pathways and that may be crucial during 
field cancerisation. It is also possible that clonal interaction, cooperation or 
competition may play an important role in the development of certain pre-malignant 
conditions and carcinomas, and promote the concept of carcinogenesis as an 
evolutionary process (280).  
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This study has approached many questions surrounding carcinomas of the human 
oesophagus and stomach and has contributed significantly to the debate on 
gastrointestinal carcinogenesis. Increasing evidence of ITH only highlights the need to 
investigate the primary tumour and metastatic subclones in order to provide a 
personalised treatment to each patient that would take into consideration the existing 
mutations and the subclones dynamics to avoid favouring treatment-resistant clones. 
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7.  Appendix 
 
 
Table 7.1. Primers and reaction conditions for Genomic PCR sequencing 
 
Primer Sequence 5' to 3' Conditions 
      
APC 1st 1F GGACAAAGCAGTAAAACCGAAC 55/1/0 
APC 1st 1R AACTACATCTTGAAAAACATATTGGA   
APC 1st 2F AAGTGGTCAGCCTCAAAAGG 60/3/5 
APC 1st 2R GCTATTTGCAGGGTATTAGCA   
APC 1st 3F GATACTCCAATATGTTTTTCAAGATG 55/1/0 
APC 1st 3R GCCTGGCTGATTCTGAAGAT   
APC 1st 4F CCCTGCAAATAGCAGAAATAAAA 55/2/5 
APC 1st 4R AACATGAGTGGGGTCTCCTG   
APC 1st 5F CAGACTGCAGGGTTCTAGTTTATC 60/2/0 
APC 1st 5R CATTCCACTGCATGGTTCAC   
APC 1st 6F CCAAAAGTGGTGCTCAGACA 60/2/0 
APC 1st 6R CATGGTTTGTCCAGGGCTAT   
APC 1st 7F TTTGAGAGTCGTTCGATTGC 60/1/0 
APC 1st 7R TCTCTTTTCAGCAGTAGGTGCTT   
APC 1st 8F CATGCAGTGGAATGGTAAGT 55/2/0 
APC 1st 8R GCAGCATTTACTGCAGCTT   
APC 1st 9F CAAGCGAGAAGTACCTAAAAA 55/2/0 
APC 1st 9R TTCTGTATAAATGGCTCATCG   
APC 1st 10F GGTTCTTCCAGATGCTGATA 55/1/5 
APC 1st 10R CTTGGTTTTCATTTGATTCTTT   
APC 1st 11F AATTAAGAATAATGCCTCCAGT 55/2/0 
APC 1st 11R TTTACGTGATGACTTTGTTGG   
APC 1st 12F CCAAGAGAAAGAGGCAGAAAAA 55/1/5 
APC 1st 12R TGATGGTAGAAGTTTGTACACAGG   
APC 2nd 1F CAAGCAGTGAGAATACGTCCA 55/1/0 
APC 2nd 1R TTTCTTGGTTAATAGAAGAAACTTTGC   
APC 2nd 2F GCCACTTGCAAAGTTTCTTCT 55/2/5 
APC 2nd 2R TGCTTCCTGTGTCGTCTGA   
APC 2nd 3F CAGACGACACAGGAAGCAGA 60/1/0 
APC 2nd 3R TGGAACTTCGCTCACAGGAT   
APC 2nd 4F GAAGATCCTGTGAGCGAAGTTCC 60/1/0 
APC 2nd 4R CAAGTCCTCTGGGGTGAGTA   
APC 2nd 5F AGAATCAGCCAGGCACAAAG 55/1/0 
APC 2nd 5R GCAATCGAACGACTCTCAAA   
APC 2nd 6F CACTATGTTCAGGAGACCCCA 60/1/0 
APC 2nd 6R TGGAAGATCACTGGGGCTTA   
APC 2nd 7F GTGAACCATGCAGTGGAATG 60/1/0 
APC 2nd 7R ACTTCTCGCTTGGTTTGAGC   
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Table 7.1. continued 
 
 
Primer Sequence 5' to 3' Conditions 
      
APC 2nd 8F GCTTAGGTCCACTCTCTCTCTT 60/1/0 
APC 2nd 8R GGCATTATAAGCCCCAGT   
APC 2nd 9F CCTAAAAATAAAGCACCTACTGCTG 60/3/5 
APC 2nd 9R CACTCAGGCTGGATGAACAA   
APC 2nd 10F ACATTTTGCCACGGAAAGTA 55/2/0 
APC 2nd 10R GGCTGCTCTGATTCTGTTTC   
APC 2nd 11F CAGGAAAATGACAATGGGAAT 55/2/0 
APC 2nd 11R TGGCATGGCAGAAATAATACA   
APC 2nd 12F GGACCTATTAGATGATTCAGATGATG 55/2/0 
APC 2nd 12R ACTTGGTTTCCTTGCCACAG   
p53-5 1st F CACTTGTGCCCTGACTTTCA 55/1/5 
p53-5 1st R GAGCAATCAGTGAGGAATCAGA   
p53-6 1st F AGAGACGACAGGGCTGGTT 60/2/5 
p53-6 1st R TGGAGGGCCACTGACAAC   
p53-7 1st F TGCTTGCCACAGGTCTCC 60/1/5 
p53-7 1st R GGTCAGAGGCAAGCAGAGG   
p53-8 1st F TTTTTAAATGGGACAGGTAGGA 60/2/5 
p53-8 1st R CACCCTTGGTCTCCTCCAC   
p53-5 2nd F TCTGTCTCCTTCCTCTTCCTACA 60/1/5 
p53-5 2nd R AACCAGCCCTGTCGTCTCT   
p53-6 2nd F CAGGCCTCTGATTCCTCACT 60/1/0 
p53-6 2nd R CTTAACCCCTCCTCCCAGAG   
p53-7 2nd F CTTGGGCCTGTGTTATCTCC 60/1/5 
p53-7 2nd R GTGTGCAGGGTGGCAAGT   
p53-8 2nd F GCCTCTTGCTTCTCTTTTCC 60/2/0 
p53-8 2nd R GCTTCTTGTCCTGCTTGCTT   
p16-2A 1st F GCTTCCTTTCCGTCATGC 60/2/5 
p16-2A 1st R CAGGTACCGTGCGACATC   
p16-2B 1st F CTGTTCTCTCTGGCAGGTCA 60/2/5 
p16-2B 1st R TGTGCTGGAAAATGAATGCT   
p16-2A 2nd F CCTGGCTCTGACCATTCTGT 60/2/5 
p16-2A 2nd R CAGCTCCTCAGCCAGGTC   
p16-2B 2nd F CTTCCTGGACACGCTGGT 60/2/5 
p16-2B 2nd R TGGAAGCTCTCAGGGTACAAA   
Kras 1st F GAGTTTGTATTAAAAGGTACTGGTGGA 60/2/5 
Kras 1st R ATCAAAGAATGGTCCTGCAC   
Kras 2nd F TTTGATAGTGTATTAACCTTAT 55/2/5 
Kras 2nd R TATTAAAACAAGATTTACCTC   
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Table 7.1. continued 
 
 
Primer Sequence 5' to 3' Conditions 
      
B-cat 1st F CTTTTTAGTTCTCAAAACTGCA 55/2.5/0 
B-cat 1st R CAATGGGTCATATCACAGATTC   
B-cat 2nd F CAATCTACTAATGCTAATACTG 55/2.5/5 
B-cat 2nd R GACTTTCAGTAAGGCAATGAAA   
NRF2 1F CCACCATCAACAGTGGCATA 60/2.5/5 
NRF2 1R TGGGAGAAATTCACCTGTCTC   
NRF2 2F CATGAGCTCTCTCCTTCCTTTT 60/2.5/5 
NRF2 2R TGGGAGAAATTCACCTGTCTC   
 
NOTE: Naming nomenclature is as follows: gene-exon, polymerase chain reaction 
round; primer direction. Large exons, consisting of more than 250 nucleotides, were 
subdivided into separate regions for amplification; a letter following the exon number 
denotes these regions (eg. p16-2A). For APC primers, the numbers do not refer to 
exons but identify regions of the mutation cluster region. Reaction condition 
nomenclature is annealing temperature/magnesium concentration (mmol/L)/addition 
of Q-solution. F: forward; R: reverse. 
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Table 7.2. Primers and reaction conditions for Microsatellite Loss of 
Heterozygosity Analysis 
 
 
Primer Sequence 5' to 3' Conditions 
      
Multiplex 2   57/0 
D17S250 F [FAM]GGAAGAATCAAATAGACAAT   
D17S250 R GCTGGCCATATATATATTTAAACC   
D17S1832 F [FAM]ACGCCTTGACATAGTTGC   
D17S1832 R TGTGTGACTGTTCAGCCTC   
D18S474 F [FAM]CTCCACCCACTAGATGTCAG   
D18S474 R ACTTGCTTAAGCCTTGGACT   
D3S1313 F [FAM]TACTTTCCTTCAGATCCTTGG   
D3S1313 R AACTAGGGGCCATGAATAAG   
      
Multiplex 3   57/0 
D17S1176 F [FAM]ACTTCATATACATATCACGTGC   
D17S1176 R TCAATGGAGAATTACGATAGTG   
D17S1678 F [FAM]TTTGGGTCTTTGAACCCTTG   
D17S1678 R CCACAACAAAACACCAGTGC   
D17S1881 F [FAM]CCCAGTTTAAGGAGTTTGGC   
D17S1881 R TAGGGCAGTCAGCCTTGTG   
      
Multiplex 4   57/5 
D9S942 F [FAM]GCAAGATTCCAAACAGTA   
D9S942 R CTCATCCTGCGGAAACCATT   
D5S2001 F [HEX]GCCAAGATGGTCTCGATCTC   
D5S2001 R TCTGAACAGGTGATGGCAAC   
D17S1506E F [FAM]TGTGGGATGGGGTGAGATTTC   
D17S1506E R CTGTTGGTCGGTGGGTTG   
D5S489 F [HEX]GGGCTTTTGTGTTGTTTCTA   
D5S489 R GAAAACCCATAACCAGACTTG   
 
 
NOTE: Reaction condition nomenclature is annealing temperate/Q-solution used in 
reaction. Other conditions were performed according to manufacturer’s instructions. 
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Table 7.3. Summary of clinicopathological features in screened samples. Gender, 
age and tumour site information from the screening of 51 gastric adenocarcinomas 
(GA) for mutations within genes accounting for 85% of known mutations (see 
COSMIC database) in GA (256). (--) stands for patient information not available. 
 
 
 
SAMPLE	   GENDER	   AGE	  
TUMOUR	  
SITE	  
1	   M	   52	   GOJ	  
2	   M	   79	   GOJ	  
3	   M	   67	   Pyloric	  
4	   F	   80	   Antrum	  
5	   F	   29	   Body	  
6	   F	   85	   Body	  
7	   F	   44	   Body	  
8	   M	   69	   Body	  
9	   M	   80	   Antrum	  
10	   M	   48	   Antrum	  
11	   M	   55	   GOJ	  
12	   M	   64	   Body	  
13	   M	   58	   Fundus	  
14	   M	   45	   Antral	  
15	   M	   81	   Antral	  
16	   F	   48	   Antral	  
17	   M	   76	   Antral	  
18	   M	   69	   Body	  
19	   M	   80	   Pyloric	  
20	   M	   65	   Body	  
21	   F	   72	   Pyoric	  
22	   F	   45	   Antrum	  
23	   M	   80	   Body	  
24	   F	   69	   GOJ	  
25	   M	   67	   Body	  
26	   M	   66	   GOJ	  
27	   M	   52	   Body	  
28	   F	   63	   GOJ	  
29	   M	   64	   GOJ	  
30	   M	   85	   GOJ	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Table 7.3. continued 
 
 
 
SAMPLE	   GENDER	   AGE	  
TUMOUR	  
SITE	  
31	   F	   61	   Antrum	  
32	   M	   48	   Antrum	  
33	   M	   78	   Body	  
34	   F	   77	   Pyloric	  
35	   M	   65	   GOJ	  
36	   M	   68	   GOJ	  
37	   M	   60	   Pyloric	  
38	   M	   71	   Antrum	  
39	   F	   69	   Body	  
40	   F	   84	   Antrum	  
41	   M	   56	   Body	  
42	   M	   56	   GOJ	  
43	   M	   61	   Body	  
44	   M	   77	   Antrum	  
45	   M	   64	   Antrum	  
46	   F	   45	   Pyloric	  
47	   M	   51	   Antrum	  
48	   M	   53	  
Distal	  
stomach	  
49	   M	   66	   Antrum	  
50	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  
51	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	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Figure 7.1. Loss of heterozygosity of microsatellite marker D17S1832 was 
observed in patient 8. Two traces (A and B) representative of 17p microsatellite 
marker D17S1832 from patient 8, specimen blocks 6, 7 and 8, corresponding to 
figures 3.6 to 3.9. (A) Representative trace of a control sample where both alleles are 
present; the values for the area under the control peaks are 1869.0 and 1611.6 
respectively. (B) Representative trace where loss of heterozygosity (LOH) has 
occurred for marker D17S1832 (180bp); the values for the area under the sample 
peaks this example are 1903.7 and 102.9 respectively. LOH was calculated by 
measuring the area under the curve of the samples compared to that of a normalized 
control (gastritis or muscle epithelium areas from the same patient). LOH was 
considered when the area under the curve was <0.5 or >2.0. 
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Figure 7.2. Loss of heterozygosity of microsatellite marker D17S1881 was 
observed in patient 8. Two traces (A and B) representative of 17p microsatellite 
marker D17S1881 from patient 8, specimen blocks 6, 7 and 8, corresponding to 
figures 3.6 to 3.9. (A) Representative trace of a control sample where both alleles are 
present; the values for the area under the control peaks are 109.4 and 80.6 respectively. 
(B) Representative trace where loss of heterozygosity (LOH) has occurred for marker 
D17S1881 (210bp) the values for the area under the sample peaks this example are 
67.2 and 0 respectively. LOH was calculated by measuring the area under the curve of 
the samples compared to that of a normalized control (gastritis or muscle epithelium 
areas from the same patient). LOH was considered when the area under the curve was 
<0.5 or >2.0. 
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Figure 7.3. Loss of heterozygosity of microsatellite marker D17S1506E was 
observed in patient 8. Two traces (A and B) representative of 17p microsatellite 
marker D17S1506E from patient 8, specimen blocks 6, 7 and 8, corresponding to 
figures 3.6 to 3.9. (A) Representative trace of a control sample where both alleles are 
present; the values for the area under the control peaks are 2151.1 and 2366.1 
respectively. (B) Representative trace where loss of heterozygosity (LOH) has 
occurred for marker D17S1506E (150bp); the values for the area under the sample 
peaks this example are 207.2 and 862.6 respectively. LOH was calculated by 
measuring the area under the curve of the samples compared to that of a normalized 
control (gastritis or muscle epithelium areas from the same patient). LOH was 
considered when the area under the curve was <0.5 or >2.0. 
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Figure 7.4. Loss of heterozygosity of microsatellite marker D17S1678 was 
observed in patient 8. Two traces (A and B) representative of 17p microsatellite 
marker D17S1678 from patient 8, specimen blocks 6, 7 and 8, corresponding to 
figures 3.6 to 3.9. (A) Representative trace of a control sample where both alleles are 
present; the values for the area under the control peaks are 4002.1 and 3825.2 
respectively. (B) Representative trace where loss of heterozygosity (LOH) has 
occurred for marker D17S1678 (120bp); the values for the area under the sample 
peaks this example are 371.7 and 1577.4 respectively. LOH was calculated by 
measuring the area under the curve of the samples compared to that of a normalized 
control (gastritis or muscle epithelium areas from the same patient). LOH was 
considered when the area under the curve was <0.5 or >2.0. 
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Figure 7.5. Loss of heterozygosity of microsatellite marker D17S1176 was 
observed in patient 8. Two traces (A and B) representative of 17p microsatellite 
marker D17S1176 from patient 8, specimen blocks 6, 7 and 8, corresponding to 
figures 3.6 to 3.9. (A) Representative trace of a control sample where both alleles are 
present; the values for the area under the control peaks are 727.0 and 615.8 
respectively. (B) Representative trace where loss of heterozygosity (LOH) has 
occurred for marker D17S1176 (80bp); the values for the area under the sample peaks 
this example are 167.4 and 0 respectively. LOH was calculated by measuring the area 
under the curve of the samples compared to that of a normalized control (gastritis or 
muscle epithelium areas from the same patient). LOH was considered when the area 
under the curve was <0.5 or >2.0. 
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Figure 7.6. Loss of heterozygosity of microsatellite marker D17S1881 was 
observed in patient 10. Two traces (A and B) representative of 17p microsatellite 
marker D17S1881 from patient 10 corresponding to figures 3.10 and 3.11. (A) 
Representative trace of a control sample where both alleles are present; the values for 
the area under the control peaks are 202.9 and 196.4 respectively. (B) Representative 
trace where loss of heterozygosity (LOH) has occurred for marker D17S1881 (210bp); 
the values for the area under the sample peaks this example are 1237.5 and 153.8 
respectively. LOH was calculated by measuring the area under the curve of the 
samples compared to that of a normalized control (gastritis or muscle epithelium areas 
from the same patient). LOH was considered when the area under the curve was <0.5 
or >2.0. 
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Figure 7.7. Loss of heterozygosity of microsatellite marker D17S250 was observed 
in patient 10. Two traces (A and B) representative of 17q microsatellite marker 
D17S250 from patient 10 corresponding to figures 3.10 and 3.11. (A) Representative 
trace of a control sample where both alleles are present; the values for the area under 
the control peaks are 202.9 and 196.4 respectively. (B) Representative trace where loss 
of heterozygosity (LOH) has occurred for marker D17S250 (140bp); the values for the 
area under the sample peaks this example are 1237.5 and 153.8 respectively. LOH was 
calculated by measuring the area under the curve of the samples compared to that of a 
normalized control (gastritis or muscle epithelium areas from the same patient). LOH 
was considered when the area under the curve was <0.5 or >2.0. 
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Figure 7.8. Loss of heterozygosity of microsatellite marker D17S1881 was 
observed in patient 22. Two traces (A and B) representative of 17p microsatellite 
marker D17S1881 from patient 22 corresponding to figures 3.12 and 3.13. (A) 
Representative trace of a control sample where both alleles are present; the values for 
the area under the control peaks are 167.5 and 153.0 respectively. (B) Representative 
trace where loss of heterozygosity (LOH) has occurred for marker D17S1881 (210bp); 
the values for the area under the sample peaks this example are 0 and 87.7 
respectively. LOH was calculated by measuring the area under the curve of the 
samples compared to that of a normalized control (gastritis or muscle epithelium areas 
from the same patient). LOH was considered when the area under the curve was <0.5 
or >2.0. 
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Figure 7.9. Loss of heterozygosity of microsatellite marker D17S1506E was 
observed in patient 22. Two traces (A and B) representative of 17p microsatellite 
marker D17S1506E from patient 22 corresponding to figures 3.12 and 3.13. (A) 
Representative trace of a control sample where both alleles are present; the values for 
the area under the control peaks are 364.8 and 329.9 respectively. (B) Representative 
trace where loss of heterozygosity (LOH) has occurred for marker D17S1506E 
(140bp); the values for the area under the sample peaks this example are 2603.6 and 
841.7 respectively. LOH was calculated by measuring the area under the curve of the 
samples compared to that of a normalized control (gastritis or muscle epithelium areas 
from the same patient). LOH was considered when the area under the curve was <0.5 
or >2.0. 
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Figure 7.10. Loss of heterozygosity of microsatellite marker D17S1176 was 
observed in patient 22. Two traces (A and B) representative of 17p microsatellite 
marker D17S1176 from patient 22 corresponding to figures 3.12 and 3.13. (A) 
Representative trace of a control sample where both alleles are present; the values for 
the area under the control peaks are 288.6 and 293.8 respectively. (B) Representative 
trace where loss of heterozygosity (LOH) has occurred for marker D17S1176 (80bp); 
the values for the area under the sample peaks this example are 279.7 and 0 
respectively. LOH was calculated by measuring the area under the curve of the 
samples compared to that of a normalized control (gastritis or muscle epithelium areas 
from the same patient). LOH was considered when the area under the curve was <0.5 
or >2.0. 
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Figure 7.11. Loss of heterozygosity of microsatellite marker D17S250 was 
observed in patient 22. Two traces (A and B) representative of 17q microsatellite 
marker D17S250 from patient 22 corresponding to figures 3.12 and 3.13. (A) 
Representative trace of a control sample where both alleles are present; the values for 
the area under the control peaks are 167.2 and 149.7 respectively. (B) Representative 
trace where loss of heterozygosity (LOH) has occurred for marker D17S250 (140bp); 
the values for the area under the sample peaks this example are 143.1 and 0 
respectively. LOH was calculated by measuring the area under the curve of the 
samples compared to that of a normalized control (gastritis or muscle epithelium areas 
from the same patient). LOH was considered when the area under the curve was <0.5 
or >2.0. 
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Figure 7.12. Loss of heterozygosity of microsatellite marker D17S1678 was 
observed in patient 33. Two traces (A and B) representative of 17p microsatellite 
marker D17S1678 from patient 33 corresponding to figures 3.14 to 3.16. (A) 
Representative trace of a control sample where both alleles are present; the values for 
the area under the control peaks are 10742.7 and 13074.1 respectively. (B) 
Representative trace where loss of heterozygosity (LOH) has occurred for marker 
D17S1678 (120bp); the values for the area under the sample peaks this example are 
2998.4 and 9641.4 respectively. The purple vertical line on the traces denotes a high 
concentration of PCR product. LOH was calculated by measuring the area under the 
curve of the samples compared to that of a normalized control (gastritis or muscle 
epithelium areas from the same patient). LOH was considered when the area under the 
curve was <0.5 or >2.0. 
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Figure 7.13. Loss of heterozygosity of microsatellite marker D17S1176 was 
observed in patient 33. Two traces (A and B) representative of 17p microsatellite 
marker D17S1176 from patient 33 corresponding to figures 3.14 to 3.16. (A) 
Representative trace of a control sample where both alleles are present; the values for 
the area under the control peaks are 401.0 and 428.9 respectively. (B) Representative 
trace where loss of heterozygosity (LOH) has occurred for marker D17S1176 (80bp); 
the values for the area under the sample peaks this example are 238.1 and 755.4 
respectively. LOH was calculated by measuring the area under the curve of the 
samples compared to that of a normalized control (gastritis or muscle epithelium areas 
from the same patient). LOH was considered when the area under the curve was <0.5 
or >2.0. 
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Figure 7.14. Loss of heterozygosity of microsatellite marker D17S1832 was 
observed in patient 51. Two traces (A and B) representative of 17p microsatellite 
marker D17S1832 from patient 51 corresponding to figures 3.17 and 3.18. (A) 
Representative trace of a control sample where both alleles are present; the values for 
the area under the control peaks are 6822.9 and 5558.9 respectively. (B) 
Representative trace where loss of heterozygosity (LOH) has occurred for marker 
D17S1832 (180bp); the values for the area under the sample peaks this example are 
8249.8 and 1238.3 respectively. The purple vertical line on the traces denotes a high 
concentration of PCR product. LOH was calculated by measuring the area under the 
curve of the samples compared to that of a normalized control (gastritis or muscle 
epithelium areas from the same patient). LOH was considered when the area under the 
curve was <0.5 or >2.0. 
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Figure 7.15. Loss of heterozygosity of microsatellite marker D17S1506E was 
observed in patient 51. Two traces (A and B) representative of 17p microsatellite 
marker D17S1506E from patient 51 corresponding to figures 3.17 and 3.18. (A) 
Representative trace of a control sample where both alleles are present; the values for 
the area under the control peaks are 8622.9 and 8960.0 respectively. (B) 
Representative trace where loss of heterozygosity (LOH) has occurred for marker 
D17S1506E (150bp); the values for the area under the sample peaks this example are 
10663.4 and 1141.9 respectively. The purple vertical line on the traces denotes a high 
concentration of PCR product. LOH was calculated by measuring the area under the 
curve of the samples compared to that of a normalized control (gastritis or muscle 
epithelium areas from the same patient). LOH was considered when the area under the 
curve was <0.5 or >2.0. 
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Figure 7.16. TP53 mutations found in gastric adenocarcinoma but not in benign 
areas in patient 27. (A) A H&E of an entire section of gastric mucosa showing 
benign areas underneath gastric adenocarcinoma (GA); tissue from patient 27, 
specimen block 5. (B) Higher power of highlighted areas, showing from left to right an 
area of GA, a muscle area, two areas of GA area and an area of gastritis. (C) Serial 
section, showing post laser-capture microdissection (LCM). Yellow areas are TP53 
WT whereas dark blue areas are positive for the TP53 mutation c.G818A. (D, E) Two 
representative traces showing the TP53 mutation c.G818A (D) and a TP53 WT trace 
(E). (F) Key for patient 27 on post LCM section. 
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Table 7.4. Association of identified mutations and histology shows TP53 mutations 
in gastric adenocarcinoma but not in benign areas in patient 27. This table 
corresponds to the laser-capture microdissection data presented in Supplementary 
Figure 7.16; tissue from patient 27, specimen block 5. WT, wild type. 
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Figure 7.17. TP53 mutations found in gastric adenocarcinoma but not in intestinal 
metaplastic glands in patient 27. (A) A H&E of an entire section of gastric mucosa 
showing oesophageal squamous epithelium, gastritis, intestinal metaplasia (IM) and 
areas of gastric adenocarcinoma (GA) from patient 27, specimen block 3. (B) Higher 
power of highlighted areas, showing from top to bottom two areas of IM, a muscle 
area and an area of GA. (C) Serial section showing post laser-capture microdissection 
(LCM). Yellow areas are TP53 WT whereas dark blue areas are positive for the TP53 
mutation c.G818A. (D, E) Two representative traces showing the TP53 mutation 
c.G818A (D) and a TP53 WT trace (E). (F) Key for patient 27 on post LCM section. 
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Table 7.5. Association of identified mutations and histology shows TP53 mutations 
in gastric adenocarcinoma but not in intestinal metaplastic areas in patient 27. 
This table corresponds to the laser-capture microdissection data presented in 
Supplementary Figure 7.17; tissue from patient 27, specimen block 3. WT, wild type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.18. Phylogenetic tree provides evidence for a monoclonal origin for 
gastric adenocarcinoma in patient 27. Phylogenetic tree representative of patient 27, 
the data has been interpreted from the experimental data found in figures 7.1 and 7.2. 
Tree branches represent either phenotypic or genotypic changes. The wild type 
genotype is coloured in green and TP53 mutation c.G818A has been coloured in dark 
blue. A “?” has been used to highlight likely genotypic and phenotypic events previous 
to GA development in patient 27. 
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Table 7.6. Summary of clinical features in screened samples. Gender and age 
information from the screening of 33 oesophageal squamous cell dysplasia and 
carcinoma (OSCC) specimens for the most commonly reported mutations (see 
COSMIC database) in OSCC (256). (--) stands for patient information not available. 
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